{
    "58a95c711978bbde22000001_000": [
        {
            "text": "Alzheimer's disease",
            "probability": 0.44631885629344586,
            "start_logit": 6.121676445007324,
            "end_logit": 6.01128625869751
        },
        {
            "text": "Alzheimer's disease. Alzheimer's disease",
            "probability": 0.2682675174970808,
            "start_logit": 5.6126275062561035,
            "end_logit": 6.01128625869751
        },
        {
            "text": "Alzheimer's disease (AD)",
            "probability": 0.10436399903510926,
            "start_logit": 6.121676445007324,
            "end_logit": 4.5581374168396
        },
        {
            "text": "Alzheimer's disease. Alzheimer's disease (AD)",
            "probability": 0.062729751482444,
            "start_logit": 5.6126275062561035,
            "end_logit": 4.5581374168396
        },
        {
            "text": "A\u03b2 plaques in Alzheimer's disease. Alzheimer's disease",
            "probability": 0.026628374252857336,
            "start_logit": 3.3026201725006104,
            "end_logit": 6.01128625869751
        },
        {
            "text": "Alzheimer's disease (AD) is characterized by deposition of amyloid-\u03b2",
            "probability": 0.022330381339969285,
            "start_logit": 6.121676445007324,
            "end_logit": 3.0162007808685303
        },
        {
            "text": "A\u03b2 plaques in Alzheimer's disease",
            "probability": 0.019688026937875188,
            "start_logit": 3.3026201725006104,
            "end_logit": 5.709319591522217
        },
        {
            "text": "Alzheimer's disease. Alzheimer's disease (AD) is characterized by deposition of amyloid-\u03b2",
            "probability": 0.013422054395340291,
            "start_logit": 5.6126275062561035,
            "end_logit": 3.0162007808685303
        },
        {
            "text": "Alzheimer's disease (AD) is characterized by deposition of amyloid-\u03b2 (A\u03b2",
            "probability": 0.009959890090030473,
            "start_logit": 6.121676445007324,
            "end_logit": 2.2088186740875244
        },
        {
            "text": "A\u03b2 plaques in Alzheimer's disease. Alzheimer's disease (AD)",
            "probability": 0.006226587977731698,
            "start_logit": 3.3026201725006104,
            "end_logit": 4.5581374168396
        },
        {
            "text": "Alzheimer's disease. Alzheimer's disease (AD) is characterized by deposition of amyloid-\u03b2 (A\u03b2",
            "probability": 0.005986560843935127,
            "start_logit": 5.6126275062561035,
            "end_logit": 2.2088186740875244
        },
        {
            "text": "A\u03b2",
            "probability": 0.005245999930360848,
            "start_logit": 4.413967609405518,
            "end_logit": 3.2754273414611816
        },
        {
            "text": "Alzheimer's disease.",
            "probability": 0.0016432889383849174,
            "start_logit": 5.6126275062561035,
            "end_logit": 0.9160012602806091
        },
        {
            "text": "Alzheimer",
            "probability": 0.0015061402799246557,
            "start_logit": 6.121676445007324,
            "end_logit": 0.3198029100894928
        },
        {
            "text": "A\u03b2 plaques in Alzheimer's disease. Alzheimer's disease (AD) is characterized by deposition of amyloid-\u03b2",
            "probability": 0.0013322801471304451,
            "start_logit": 3.3026201725006104,
            "end_logit": 3.0162007808685303
        },
        {
            "text": "AD)",
            "probability": 0.0011125006849935157,
            "start_logit": 1.5804020166397095,
            "end_logit": 4.5581374168396
        },
        {
            "text": "Alzheimer's disease. Alzheimer",
            "probability": 0.0009052911572082265,
            "start_logit": 5.6126275062561035,
            "end_logit": 0.3198029100894928
        },
        {
            "text": "Alzheimer's disease (AD",
            "probability": 0.0007886654814523735,
            "start_logit": 6.121676445007324,
            "end_logit": -0.32716038823127747
        },
        {
            "text": "Alzheimer's disease (AD) is characterized by deposition of amyloid-",
            "probability": 0.0007854386000771251,
            "start_logit": 6.121676445007324,
            "end_logit": -0.3312603533267975
        },
        {
            "text": "disease",
            "probability": 0.0007583946346482853,
            "start_logit": -0.2559085786342621,
            "end_logit": 6.01128625869751
        }
    ],
    "58a95c711978bbde22000001_001": [
        {
            "text": "amyloid-\u03b2",
            "probability": 0.5462861013474282,
            "start_logit": 5.924500942230225,
            "end_logit": 8.043437957763672
        },
        {
            "text": "Alzheimer's disease",
            "probability": 0.252198146094828,
            "start_logit": 6.745779514312744,
            "end_logit": 6.4492316246032715
        },
        {
            "text": "-amyloid-\u03b2",
            "probability": 0.1042277200326224,
            "start_logit": 4.2679362297058105,
            "end_logit": 8.043437957763672
        },
        {
            "text": "Aducanumab is an anti-amyloid-\u03b2",
            "probability": 0.025716580132579207,
            "start_logit": 2.8684940338134766,
            "end_logit": 8.043437957763672
        },
        {
            "text": "Alzheimer's disease compared with amyloid burden alone. SIGNIFICANCE STATEMENT: Alzheimer's disease",
            "probability": 0.023834788188117392,
            "start_logit": 4.3867106437683105,
            "end_logit": 6.4492316246032715
        },
        {
            "text": "Alzheimer's disease (AD)",
            "probability": 0.019347954222185187,
            "start_logit": 6.745779514312744,
            "end_logit": 3.881603240966797
        },
        {
            "text": "\u03b2",
            "probability": 0.011958125767600174,
            "start_logit": 2.102769136428833,
            "end_logit": 8.043437957763672
        },
        {
            "text": "Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is currently without a cure. Aducanumab",
            "probability": 0.006777996485939591,
            "start_logit": 6.745779514312744,
            "end_logit": 2.832698106765747
        },
        {
            "text": ") is a progressive neurodegenerative disorder that is currently without a cure. Aducanumab is an anti-amyloid-\u03b2",
            "probability": 0.0016813397268437018,
            "start_logit": 0.1409490406513214,
            "end_logit": 8.043437957763672
        },
        {
            "text": "yloid-\u03b2",
            "probability": 0.0013924548247703102,
            "start_logit": -0.04757364094257355,
            "end_logit": 8.043437957763672
        },
        {
            "text": "amyloid-",
            "probability": 0.001222454577646797,
            "start_logit": 5.924500942230225,
            "end_logit": 1.9411559104919434
        },
        {
            "text": "anti-amyloid-\u03b2",
            "probability": 0.0009513063719929663,
            "start_logit": -0.4285610020160675,
            "end_logit": 8.043437957763672
        },
        {
            "text": "Alzheimer",
            "probability": 0.0008693039340721791,
            "start_logit": 6.745779514312744,
            "end_logit": 0.7789540886878967
        },
        {
            "text": "-\u03b2",
            "probability": 0.0008439414629212573,
            "start_logit": -0.5483140349388123,
            "end_logit": 8.043437957763672
        },
        {
            "text": "Alzheimer's disease (AD",
            "probability": 0.0005484404476094096,
            "start_logit": 6.745779514312744,
            "end_logit": 0.3183399736881256
        },
        {
            "text": "amyloid",
            "probability": 0.0005478658532013211,
            "start_logit": 5.924500942230225,
            "end_logit": 1.1385703086853027
        },
        {
            "text": "progressive neurodegenerative disorder that is currently without a cure. Aducanumab is an anti-amyloid-\u03b2",
            "probability": 0.0005258109008689357,
            "start_logit": -1.0214555263519287,
            "end_logit": 8.043437957763672
        },
        {
            "text": "disease",
            "probability": 0.0003902126097193116,
            "start_logit": 0.27450090646743774,
            "end_logit": 6.4492316246032715
        },
        {
            "text": "AD)",
            "probability": 0.00034296423496582844,
            "start_logit": 2.7130637168884277,
            "end_logit": 3.881603240966797
        },
        {
            "text": "Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is currently without a cure.",
            "probability": 0.0003364927840877842,
            "start_logit": 6.745779514312744,
            "end_logit": -0.17016202211380005
        }
    ],
    "58a95c711978bbde22000001_002": [
        {
            "text": "Apolipoprotein E4",
            "probability": 0.792915300741567,
            "start_logit": 5.097533226013184,
            "end_logit": 5.187281131744385
        },
        {
            "text": "A\u03b2",
            "probability": 0.04616709392125616,
            "start_logit": 4.102949142456055,
            "end_logit": 3.33841609954834
        },
        {
            "text": "A\u03b242",
            "probability": 0.037516770750565316,
            "start_logit": 3.5214874744415283,
            "end_logit": 3.7123985290527344
        },
        {
            "text": "APP gene in Down's syndrome",
            "probability": 0.02185953936819995,
            "start_logit": 4.172706127166748,
            "end_logit": 2.521029233932495
        },
        {
            "text": "APP",
            "probability": 0.0155742301554864,
            "start_logit": 4.172706127166748,
            "end_logit": 2.18200945854187
        },
        {
            "text": "E4",
            "probability": 0.013881441107008848,
            "start_logit": 1.0523695945739746,
            "end_logit": 5.187281131744385
        },
        {
            "text": "Down's syndrome",
            "probability": 0.011930194959578994,
            "start_logit": 3.56714129447937,
            "end_logit": 2.521029233932495
        },
        {
            "text": "Apolipoprotein E4,",
            "probability": 0.009060756519594846,
            "start_logit": 5.097533226013184,
            "end_logit": 0.7155173420906067
        },
        {
            "text": "APP gene",
            "probability": 0.008728840474228977,
            "start_logit": 4.172706127166748,
            "end_logit": 1.6030243635177612
        },
        {
            "text": "Alzheimer's disease",
            "probability": 0.0067069328431576215,
            "start_logit": 3.547560930252075,
            "end_logit": 1.9646787643432617
        },
        {
            "text": "Apolipoprotein E",
            "probability": 0.006254419221268227,
            "start_logit": 5.097533226013184,
            "end_logit": 0.344853013753891
        },
        {
            "text": "polipoprotein E4",
            "probability": 0.005859953126373632,
            "start_logit": 0.18995842337608337,
            "end_logit": 5.187281131744385
        },
        {
            "text": "A\u03b2 antibodies (solanezumab, crenezumab,",
            "probability": 0.004407533502686077,
            "start_logit": 4.102949142456055,
            "end_logit": 0.9894640445709229
        },
        {
            "text": "A\u03b242 and related A\u03b2 peptides is a very early, often initiating factor in Alzheimer's disease",
            "probability": 0.00412141418568704,
            "start_logit": 3.5214874744415283,
            "end_logit": 1.5038068294525146
        },
        {
            "text": "A\u03b2 antibodies (solanezumab, crenezumab, and aducanumab)",
            "probability": 0.002895703647074068,
            "start_logit": 4.102949142456055,
            "end_logit": 0.5693769454956055
        },
        {
            "text": "A\u03b2 antibodies (solanezumab,",
            "probability": 0.002857855745309943,
            "start_logit": 4.102949142456055,
            "end_logit": 0.5562204122543335
        },
        {
            "text": "APP gene in Down's syndrome leads to A\u03b2 deposits in the teens",
            "probability": 0.0028491692085546904,
            "start_logit": 4.172706127166748,
            "end_logit": 0.483419269323349
        },
        {
            "text": "Apolipoprotein E4, which predisposes to AD in >\u00a040% of cases, has been found to impair A\u03b2",
            "probability": 0.002454863544438846,
            "start_logit": 5.097533226013184,
            "end_logit": -0.5903640985488892
        },
        {
            "text": "4",
            "probability": 0.0021312791474568395,
            "start_logit": -0.8214608430862427,
            "end_logit": 5.187281131744385
        },
        {
            "text": "Apolipoprotein",
            "probability": 0.0018267078305062357,
            "start_logit": 5.097533226013184,
            "end_logit": -0.8859199285507202
        }
    ],
    "58a95c711978bbde22000001_003": [
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease",
            "probability": 0.5097081858501991,
            "start_logit": 5.08236837387085,
            "end_logit": 4.524201393127441
        },
        {
            "text": "Alzheimer's disease",
            "probability": 0.4182722898837916,
            "start_logit": 4.884662628173828,
            "end_logit": 4.524201393127441
        },
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD)",
            "probability": 0.02227001474963259,
            "start_logit": 5.08236837387085,
            "end_logit": 1.3936041593551636
        },
        {
            "text": "Alzheimer's disease (AD)",
            "probability": 0.018275025443307776,
            "start_logit": 4.884662628173828,
            "end_logit": 1.3936041593551636
        },
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses, only five",
            "probability": 0.008638690778337095,
            "start_logit": 5.08236837387085,
            "end_logit": 0.4466140568256378
        },
        {
            "text": "five medical treatments have been approved for Alzheimer's disease",
            "probability": 0.00406695230215369,
            "start_logit": 0.2514238953590393,
            "end_logit": 4.524201393127441
        },
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer",
            "probability": 0.003321793069058298,
            "start_logit": 5.08236837387085,
            "end_logit": -0.5091322660446167
        },
        {
            "text": "Alzheimer",
            "probability": 0.0032844644769264805,
            "start_logit": 5.08236837387085,
            "end_logit": -0.5204333662986755
        },
        {
            "text": "Alzheimer's disease.",
            "probability": 0.00185639233007877,
            "start_logit": 5.08236837387085,
            "end_logit": -1.0910019874572754
        },
        {
            "text": "Alzheimer'",
            "probability": 0.001822811339696783,
            "start_logit": 5.08236837387085,
            "end_logit": -1.1092569828033447
        },
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses,",
            "probability": 0.0014517042056204949,
            "start_logit": 5.08236837387085,
            "end_logit": -1.3368988037109375
        },
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer'",
            "probability": 0.001184864237938107,
            "start_logit": 5.08236837387085,
            "end_logit": -1.540008783340454
        },
        {
            "text": "Alzheimer's disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease (AD",
            "probability": 0.0009334213052968573,
            "start_logit": 5.08236837387085,
            "end_logit": -1.7785356044769287
        },
        {
            "text": "Alzheimer's",
            "probability": 0.0007995679365648238,
            "start_logit": 5.08236837387085,
            "end_logit": -1.9333207607269287
        },
        {
            "text": "Alzheimer's disease (AD",
            "probability": 0.0007659760577350785,
            "start_logit": 4.884662628173828,
            "end_logit": -1.7785356044769287
        },
        {
            "text": "disease",
            "probability": 0.0007375303270615847,
            "start_logit": -1.4559180736541748,
            "end_logit": 4.524201393127441
        },
        {
            "text": "'s disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease",
            "probability": 0.0006673661825774596,
            "start_logit": -1.5558863878250122,
            "end_logit": 4.524201393127441
        },
        {
            "text": "Alzheimer's disease. Despite",
            "probability": 0.0006565781148268799,
            "start_logit": 5.08236837387085,
            "end_logit": -2.1303505897521973
        },
        {
            "text": "disease. Despite the significant public health issue that it poses, only five medical treatments have been approved for Alzheimer's disease",
            "probability": 0.0006549818589354825,
            "start_logit": -1.5746177434921265,
            "end_logit": 4.524201393127441
        },
        {
            "text": "'s disease",
            "probability": 0.0006313895502611895,
            "start_logit": -1.6113022565841675,
            "end_logit": 4.524201393127441
        }
    ],
    "587f760792a5b8ad44000005_000": [
        {
            "text": "JAMM",
            "probability": 0.4311313270089417,
            "start_logit": 1.576690673828125,
            "end_logit": 1.9188333749771118
        },
        {
            "text": "JAMM is a universal peak finder that is applicable to different types of datasets. We show that JAMM",
            "probability": 0.12012524887770125,
            "start_logit": 1.5729233026504517,
            "end_logit": 0.6447229385375977
        },
        {
            "text": "JAMM is available for free and can run on Linux",
            "probability": 0.06785301199343188,
            "start_logit": 1.1764131784439087,
            "end_logit": 0.4700419008731842
        },
        {
            "text": "Linux",
            "probability": 0.048354213336002,
            "start_logit": 0.8376227617263794,
            "end_logit": 0.4700419008731842
        },
        {
            "text": "JAMM: a peak finder",
            "probability": 0.046285004659367183,
            "start_logit": 1.576690673828125,
            "end_logit": -0.3127613365650177
        },
        {
            "text": "JAMM is a universal peak finder",
            "probability": 0.034966851176573895,
            "start_logit": 1.5729233026504517,
            "end_logit": -0.5894114971160889
        },
        {
            "text": "JAMM: a peak finder for joint analysis of NGS",
            "probability": 0.028650186082256394,
            "start_logit": 1.576690673828125,
            "end_logit": -0.79241943359375
        },
        {
            "text": "JAMM:",
            "probability": 0.0252993512618192,
            "start_logit": 1.576690673828125,
            "end_logit": -0.9168006181716919
        },
        {
            "text": "JAMM is among the best performing peak finders",
            "probability": 0.024081430115762362,
            "start_logit": 1.531707763671875,
            "end_logit": -0.9211554527282715
        },
        {
            "text": "JAMM is among the best performing peak finders in terms of site detection accuracy",
            "probability": 0.02212086845567792,
            "start_logit": 1.531707763671875,
            "end_logit": -1.0060750246047974
        },
        {
            "text": "peak finder that is applicable to different types of datasets. We show that JAMM",
            "probability": 0.021115655225572075,
            "start_logit": -0.16559691727161407,
            "end_logit": 0.6447229385375977
        },
        {
            "text": "JAMM: a peak finder for joint analysis of NGS replicates.",
            "probability": 0.019570802350232896,
            "start_logit": 1.576690673828125,
            "end_logit": -1.1735405921936035
        },
        {
            "text": "peak finder that can integrate information from biological replicates, determine enrichment site widths accurately and resolve neighboring narrow peaks. JAMM",
            "probability": 0.018989392390665653,
            "start_logit": -0.48357197642326355,
            "end_logit": 0.8565638065338135
        },
        {
            "text": "JAMM is a universal peak finder that is applicable to different types of datasets.",
            "probability": 0.016386249993350213,
            "start_logit": 1.5729233026504517,
            "end_logit": -1.3473694324493408
        },
        {
            "text": "enrichment site widths accurately and resolve neighboring narrow peaks. JAMM",
            "probability": 0.014777663880515888,
            "start_logit": -0.7343356609344482,
            "end_logit": 0.8565638065338135
        },
        {
            "text": "JAMM: a peak",
            "probability": 0.012466587139956433,
            "start_logit": 1.576690673828125,
            "end_logit": -1.6245273351669312
        },
        {
            "text": "enrichment site widths and are not widely applicable to different types of datasets. RESULTS: We developed JAMM",
            "probability": 0.01215766375698006,
            "start_logit": -0.4007324278354645,
            "end_logit": 0.32780346274375916
        },
        {
            "text": "peak finder",
            "probability": 0.012114088381252833,
            "start_logit": 0.23624174296855927,
            "end_logit": -0.3127613365650177
        },
        {
            "text": "Linux machines through the command line: http://code.google.com/p/jamm",
            "probability": 0.011946903072553503,
            "start_logit": 0.8376227617263794,
            "end_logit": -0.9280393719673157
        },
        {
            "text": "JAMM: a peak finder for joint analysis of NGS replicates. MOTIVATION: Although peak finding",
            "probability": 0.01160750084138685,
            "start_logit": 1.576690673828125,
            "end_logit": -1.6959278583526611
        }
    ],
    "58a9bbe81978bbde22000007_000": [
        {
            "text": "crypt base",
            "probability": 0.180387230652325,
            "start_logit": -0.01166903879493475,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "Paneth cell",
            "probability": 0.07555457238296784,
            "start_logit": 0.37032002210617065,
            "end_logit": -0.4569370448589325
        },
        {
            "text": "stem cells. These stem cells reside at the crypt base",
            "probability": 0.06975718451060293,
            "start_logit": -0.9617544412612915,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "the crypt base",
            "probability": 0.06790848680216158,
            "start_logit": -0.9886138439178467,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "crypt",
            "probability": 0.06589851619870557,
            "start_logit": -0.01166903879493475,
            "end_logit": -0.21168726682662964
        },
        {
            "text": "Paneth cell,",
            "probability": 0.05394917094869581,
            "start_logit": 0.37032002210617065,
            "end_logit": -0.7937499284744263
        },
        {
            "text": "dedicated resident stem cells. These stem cells reside at the crypt base",
            "probability": 0.05323567386932245,
            "start_logit": -1.232046127319336,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "self-renewing tissue fueled by dedicated resident stem cells. These stem cells reside at the crypt base",
            "probability": 0.05322524810534319,
            "start_logit": -1.2322419881820679,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "rapidly self-renewing tissue fueled by dedicated resident stem cells. These stem cells reside at the crypt base",
            "probability": 0.044014709034627016,
            "start_logit": -1.4222509860992432,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "classic example of a rapidly self-renewing tissue fueled by dedicated resident stem cells. These stem cells reside at the crypt base",
            "probability": 0.03963189105446047,
            "start_logit": -1.527140736579895,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "Paneth",
            "probability": 0.034751326481409904,
            "start_logit": 0.37032002210617065,
            "end_logit": -1.2335745096206665
        },
        {
            "text": "villi",
            "probability": 0.03388115406069425,
            "start_logit": -0.13877804577350616,
            "end_logit": -0.7498352527618408
        },
        {
            "text": "Intestinal stem cells and their defining niche. The intestinal epithelium",
            "probability": 0.03367042768689328,
            "start_logit": -1.084795594215393,
            "end_logit": 0.18994329869747162
        },
        {
            "text": "intestinal epithelium",
            "probability": 0.03337639764067483,
            "start_logit": -1.0935665369033813,
            "end_logit": 0.18994329869747162
        },
        {
            "text": "stem cells reside at the crypt base",
            "probability": 0.03260120207504466,
            "start_logit": -1.7224256992340088,
            "end_logit": 0.7953026294708252
        },
        {
            "text": "crypt base,",
            "probability": 0.02783417025883485,
            "start_logit": -0.01166903879493475,
            "end_logit": -1.0735387802124023
        },
        {
            "text": "stem cells. These stem cells reside at the crypt",
            "probability": 0.025483483153572174,
            "start_logit": -0.9617544412612915,
            "end_logit": -0.21168726682662964
        },
        {
            "text": "Paneth cell, and the stromal compartment, where cell-associated ligands and soluble factors regulate stem cell behavior.",
            "probability": 0.025317284982590154,
            "start_logit": 0.37032002210617065,
            "end_logit": -1.550304889678955
        },
        {
            "text": "the crypt",
            "probability": 0.02480812251165933,
            "start_logit": -0.9886138439178467,
            "end_logit": -0.21168726682662964
        },
        {
            "text": "intestinal stem cell niche comprises both epithelial cells, in particular the Paneth cell",
            "probability": 0.024713747589414747,
            "start_logit": -0.7471755146980286,
            "end_logit": -0.4569370448589325
        }
    ],
    "58a9bbe81978bbde22000007_001": [
        {
            "text": "male",
            "probability": 0.29950912723835826,
            "start_logit": 2.9592525959014893,
            "end_logit": 2.893653392791748
        },
        {
            "text": "Paneth cell-containing adenomas, as 23 of 26 (88.5%) of these adenomas occurred in male",
            "probability": 0.1937497735449318,
            "start_logit": 2.5236752033233643,
            "end_logit": 2.893653392791748
        },
        {
            "text": "male sex and Paneth cell-containing adenomas, as 23 of 26 (88.5%) of these adenomas occurred in male",
            "probability": 0.14395171382895794,
            "start_logit": 2.226585626602173,
            "end_logit": 2.893653392791748
        },
        {
            "text": "Paneth cells",
            "probability": 0.1271806180143326,
            "start_logit": 3.483356237411499,
            "end_logit": 1.5130131244659424
        },
        {
            "text": "male sex",
            "probability": 0.05460943229508241,
            "start_logit": 2.226585626602173,
            "end_logit": 1.9243820905685425
        },
        {
            "text": "Paneth cell",
            "probability": 0.021545997599227196,
            "start_logit": 2.7248427867889404,
            "end_logit": 0.49610838294029236
        },
        {
            "text": "Paneth",
            "probability": 0.01938924713161016,
            "start_logit": 3.483356237411499,
            "end_logit": -0.36787649989128113
        },
        {
            "text": "Paneth cells,",
            "probability": 0.01862933657969106,
            "start_logit": 3.483356237411499,
            "end_logit": -0.4078575670719147
        },
        {
            "text": "Paneth cells, which were not limited to the base of the crypts but aberrantly located throughout the crypts",
            "probability": 0.01583387684647134,
            "start_logit": 3.483356237411499,
            "end_logit": -0.5704433917999268
        },
        {
            "text": "Paneth cells, which were not limited to the base of the crypts",
            "probability": 0.015594099448730232,
            "start_logit": 3.483356237411499,
            "end_logit": -0.5857025384902954
        },
        {
            "text": "sex and Paneth cell-containing adenomas, as 23 of 26 (88.5%) of these adenomas occurred in male",
            "probability": 0.014570853637796507,
            "start_logit": -0.06386908888816833,
            "end_logit": 2.893653392791748
        },
        {
            "text": "Paneth cell-containing adenomas were more likely to occur in the proximal colon",
            "probability": 0.012756874525299595,
            "start_logit": 2.7248427867889404,
            "end_logit": -0.02801138535141945
        },
        {
            "text": "male individuals compared with 71",
            "probability": 0.008730275209004427,
            "start_logit": 2.9592525959014893,
            "end_logit": -0.6416946053504944
        },
        {
            "text": "Paneth cells in colonic adenomas: association with male sex",
            "probability": 0.008240585807446296,
            "start_logit": 2.519731283187866,
            "end_logit": -0.25989875197410583
        },
        {
            "text": "Paneth cells have been reported in colorectal adenomas",
            "probability": 0.008022685976903803,
            "start_logit": 2.9423024654388428,
            "end_logit": -0.7092680931091309
        },
        {
            "text": "Paneth cells have been reported in colorectal adenomas and adenocarcinomas;",
            "probability": 0.007914023159571258,
            "start_logit": 2.9423024654388428,
            "end_logit": -0.7229050993919373
        },
        {
            "text": "Paneth cell-",
            "probability": 0.007738159186917959,
            "start_logit": 2.7248427867889404,
            "end_logit": -0.5279178619384766
        },
        {
            "text": "Paneth cells in colonic adenomas: association with male",
            "probability": 0.007473778099744228,
            "start_logit": 2.519731283187866,
            "end_logit": -0.35756954550743103
        },
        {
            "text": "male individuals compared with 71 of 126 (56.3%) non-Paneth cell",
            "probability": 0.007392725953261869,
            "start_logit": 2.9592525959014893,
            "end_logit": -0.8079949617385864
        },
        {
            "text": "Paneth cells, which were not limited to the base",
            "probability": 0.0071668159166610665,
            "start_logit": 3.483356237411499,
            "end_logit": -1.3631336688995361
        }
    ],
    "58a9bbe81978bbde22000007_002": [
        {
            "text": "Lgr5",
            "probability": 0.615372727319912,
            "start_logit": 1.8673518896102905,
            "end_logit": 2.6283178329467773
        },
        {
            "text": "Paneth cell zone",
            "probability": 0.04737149659915269,
            "start_logit": 1.062512755393982,
            "end_logit": 0.8689495325088501
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated",
            "probability": 0.035879827811090045,
            "start_logit": 1.8673518896102905,
            "end_logit": -0.21373507380485535
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth",
            "probability": 0.03509437651218075,
            "start_logit": 1.8673518896102905,
            "end_logit": -0.2358694076538086
        },
        {
            "text": "Wip-1 phosphatase",
            "probability": 0.02917626380278499,
            "start_logit": 0.6795059442520142,
            "end_logit": 0.7672911286354065
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells",
            "probability": 0.025778189161829064,
            "start_logit": 1.8673518896102905,
            "end_logit": -0.5443815588951111
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells (crypt base columnar",
            "probability": 0.024973644505297814,
            "start_logit": 1.8673518896102905,
            "end_logit": -0.5760892629623413
        },
        {
            "text": "Paneth",
            "probability": 0.01867867087097268,
            "start_logit": 1.236693263053894,
            "end_logit": -0.2358694076538086
        },
        {
            "text": "Lgr5 expression)",
            "probability": 0.017637360771747847,
            "start_logit": 1.8673518896102905,
            "end_logit": -0.9238908886909485
        },
        {
            "text": "gr5",
            "probability": 0.017412438631670857,
            "start_logit": -1.6976914405822754,
            "end_logit": 2.6283178329467773
        },
        {
            "text": "5",
            "probability": 0.01633577777103141,
            "start_logit": -1.7615185976028442,
            "end_logit": 2.6283178329467773
        },
        {
            "text": "Paneth cell",
            "probability": 0.014554885877338915,
            "start_logit": 1.062512755393982,
            "end_logit": -0.3111444413661957
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells (crypt base columnar cells",
            "probability": 0.014214132573133914,
            "start_logit": 1.8673518896102905,
            "end_logit": -1.1396735906600952
        },
        {
            "text": "Paneth cells",
            "probability": 0.01372021271944688,
            "start_logit": 1.236693263053894,
            "end_logit": -0.5443815588951111
        },
        {
            "text": "Paneth cells (crypt base columnar",
            "probability": 0.013292000956370509,
            "start_logit": 1.236693263053894,
            "end_logit": -0.5760892629623413
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells (crypt base",
            "probability": 0.013265932512839116,
            "start_logit": 1.8673518896102905,
            "end_logit": -1.20871102809906
        },
        {
            "text": "Lgr",
            "probability": 0.013187833876197088,
            "start_logit": 1.8673518896102905,
            "end_logit": -1.2146155834197998
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells (crypt base columnar cells (CBCCs))",
            "probability": 0.012219866274037252,
            "start_logit": 1.8673518896102905,
            "end_logit": -1.2908473014831543
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells (crypt base columnar cells (CBCCs",
            "probability": 0.011495293974483322,
            "start_logit": 1.8673518896102905,
            "end_logit": -1.3519725799560547
        },
        {
            "text": "Lgr5 expression) suggest a location intercalated between the Paneth cells (crypt base columnar cells (CBCCs)",
            "probability": 0.010339067478483059,
            "start_logit": 1.8673518896102905,
            "end_logit": -1.4579806327819824
        }
    ],
    "58a9bbe81978bbde22000007_003": [
        {
            "text": "pneumatosis intestinalis",
            "probability": 0.3041718394312634,
            "start_logit": 1.8198126554489136,
            "end_logit": 2.7189013957977295
        },
        {
            "text": "Paneth cells",
            "probability": 0.20577567206522399,
            "start_logit": 3.089007616043091,
            "end_logit": 1.058900237083435
        },
        {
            "text": "Paneth cells (PCs) in the intestinal crypts",
            "probability": 0.13996438236262987,
            "start_logit": 3.089007616043091,
            "end_logit": 0.6735016107559204
        },
        {
            "text": "Paneth",
            "probability": 0.07484176644040538,
            "start_logit": 3.089007616043091,
            "end_logit": 0.04748973622918129
        },
        {
            "text": "Paneth cells and necrotizing enterocolitis",
            "probability": 0.04417355939799071,
            "start_logit": 2.899714708328247,
            "end_logit": -0.2904670536518097
        },
        {
            "text": "PCs in crypt-related homeostasis, the anatomic location of pneumatosis intestinalis",
            "probability": 0.03772177736865728,
            "start_logit": -0.2675425708293915,
            "end_logit": 2.7189013957977295
        },
        {
            "text": "tumor necrosis factor-\u03b1",
            "probability": 0.024967483681703154,
            "start_logit": 1.3123611211776733,
            "end_logit": 0.7263344526290894
        },
        {
            "text": "Paneth cells (PCs) in the intestinal crypts. PCs",
            "probability": 0.023664398583898138,
            "start_logit": 3.089007616043091,
            "end_logit": -1.1039146184921265
        },
        {
            "text": "Paneth cells and necrotizing enterocolitis:",
            "probability": 0.017481214850801754,
            "start_logit": 2.899714708328247,
            "end_logit": -1.2174665927886963
        },
        {
            "text": "Paneth cells (PCs) in the intestinal crypts.",
            "probability": 0.016224494680511486,
            "start_logit": 3.089007616043091,
            "end_logit": -1.4813642501831055
        },
        {
            "text": "Paneth cells (PCs)",
            "probability": 0.01579081165859784,
            "start_logit": 3.089007616043091,
            "end_logit": -1.508458137512207
        },
        {
            "text": "crypt-related homeostasis, the anatomic location of pneumatosis intestinalis",
            "probability": 0.015122522361707821,
            "start_logit": -1.181594967842102,
            "end_logit": 2.7189013957977295
        },
        {
            "text": "Paneth cells and necrotizing enterocolitis: a novel hypothesis for disease pathogenesis.",
            "probability": 0.014589173307082131,
            "start_logit": 2.899714708328247,
            "end_logit": -1.3983137607574463
        },
        {
            "text": "neumatosis intestinalis",
            "probability": 0.013012485937490251,
            "start_logit": -1.3318707942962646,
            "end_logit": 2.7189013957977295
        },
        {
            "text": "tumor necrosis factor-",
            "probability": 0.01296718203334143,
            "start_logit": 1.3123611211776733,
            "end_logit": 0.07118183374404907
        },
        {
            "text": "pneumatosis intestinalis close to the crypts",
            "probability": 0.011241056754739812,
            "start_logit": 1.8198126554489136,
            "end_logit": -0.579118549823761
        },
        {
            "text": "necrosis. We suggest an alternate hypothesis wherein NEC is caused by injury to Paneth cells",
            "probability": 0.011114376675888334,
            "start_logit": 0.17046047747135162,
            "end_logit": 1.058900237083435
        },
        {
            "text": "pneumatosis intestinalis close to the crypts,",
            "probability": 0.006904010872309299,
            "start_logit": 1.8198126554489136,
            "end_logit": -1.0665888786315918
        },
        {
            "text": "NEC is caused by injury to Paneth cells",
            "probability": 0.005314754892763204,
            "start_logit": -0.5672920942306519,
            "end_logit": 1.058900237083435
        },
        {
            "text": "intestinalis",
            "probability": 0.004957036642994457,
            "start_logit": -2.2969720363616943,
            "end_logit": 2.7189013957977295
        }
    ],
    "58a9bbe81978bbde22000007_004": [
        {
            "text": "Wnt",
            "probability": 0.3025978866611378,
            "start_logit": 5.2310662269592285,
            "end_logit": 3.1121582984924316
        },
        {
            "text": "Crohn's disease",
            "probability": 0.22309594438309596,
            "start_logit": 5.322659969329834,
            "end_logit": 2.715761661529541
        },
        {
            "text": "Wnt pathway",
            "probability": 0.177030253604045,
            "start_logit": 5.2310662269592285,
            "end_logit": 2.5760741233825684
        },
        {
            "text": "Wnt pathway transcription factor TCF7L2",
            "probability": 0.07031191139203644,
            "start_logit": 5.2310662269592285,
            "end_logit": 1.6526947021484375
        },
        {
            "text": "Wnt pathway transcription factor TCF7L",
            "probability": 0.03621883380667925,
            "start_logit": 5.2310662269592285,
            "end_logit": 0.9893327355384827
        },
        {
            "text": "\u03b1-defensins",
            "probability": 0.02613593630271721,
            "start_logit": 3.7559263706207275,
            "end_logit": 2.138204574584961
        },
        {
            "text": "Wnt pathway transcription factor TCF7L2 (also known as TCF4",
            "probability": 0.021199548907664303,
            "start_logit": 5.2310662269592285,
            "end_logit": 0.4537333846092224
        },
        {
            "text": "transcription factor TCF7L2",
            "probability": 0.020595579775603015,
            "start_logit": 4.003201484680176,
            "end_logit": 1.6526947021484375
        },
        {
            "text": "Wnt pathway transcription factor TCF7L2 (also known as TCF4)",
            "probability": 0.02034070508974608,
            "start_logit": 5.2310662269592285,
            "end_logit": 0.4123775362968445
        },
        {
            "text": "Paneth cells",
            "probability": 0.018351581240353,
            "start_logit": 3.9686315059661865,
            "end_logit": 1.571903944015503
        },
        {
            "text": "Crohn's disease is most likely a complex disease of the Paneth cell",
            "probability": 0.014552106732690362,
            "start_logit": 4.138891696929932,
            "end_logit": 1.1696637868881226
        },
        {
            "text": "Crohn's disease (CD) affects the small intestine",
            "probability": 0.014540201270990035,
            "start_logit": 5.322659969329834,
            "end_logit": -0.014922946691513062
        },
        {
            "text": "transcription factor TCF7L",
            "probability": 0.010609125342726159,
            "start_logit": 4.003201484680176,
            "end_logit": 0.9893327355384827
        },
        {
            "text": "Paneth",
            "probability": 0.010178115456073923,
            "start_logit": 3.9686315059661865,
            "end_logit": 0.9824280738830566
        },
        {
            "text": "transcription factor TCF7L2 (also known as TCF4",
            "probability": 0.0062097159939254526,
            "start_logit": 4.003201484680176,
            "end_logit": 0.4537333846092224
        },
        {
            "text": "transcription factor TCF7L2 (also known as TCF4)",
            "probability": 0.005958145726291943,
            "start_logit": 4.003201484680176,
            "end_logit": 0.4123775362968445
        },
        {
            "text": "Wnt pathway transcription factor TCF7L2 (",
            "probability": 0.0058417294823942655,
            "start_logit": 5.2310662269592285,
            "end_logit": -0.8352196216583252
        },
        {
            "text": "Paneth's disease. In about 70% of patients Crohn's disease",
            "probability": 0.00583311663839066,
            "start_logit": 1.6786094903945923,
            "end_logit": 2.715761661529541
        },
        {
            "text": "Crohn's disease is most likely a complex disease of the Paneth cell: Paneth's disease",
            "probability": 0.00537445767893027,
            "start_logit": 4.138891696929932,
            "end_logit": 0.1735856831073761
        },
        {
            "text": "Wnt pathway transcription factor TCF7L2 (also known as TCF4),",
            "probability": 0.0050251045145091235,
            "start_logit": 5.2310662269592285,
            "end_logit": -0.9858002662658691
        }
    ],
    "58a9bbe81978bbde22000007_005": [
        {
            "text": "the",
            "probability": 0.941668163918588,
            "start_logit": 6.627172946929932,
            "end_logit": 6.704421520233154
        },
        {
            "text": "Trichinella spiralis",
            "probability": 0.01999838015233144,
            "start_logit": 4.339015960693359,
            "end_logit": 5.1405768394470215
        },
        {
            "text": "TGF-beta",
            "probability": 0.013874658453886772,
            "start_logit": 3.996595859527588,
            "end_logit": 5.117409706115723
        },
        {
            "text": "Math1, a transcription factor required for secretory cell differentiation in the",
            "probability": 0.011514461727143264,
            "start_logit": 2.223123788833618,
            "end_logit": 6.704421520233154
        },
        {
            "text": "(TGF-beta",
            "probability": 0.00230512360693772,
            "start_logit": 2.2016661167144775,
            "end_logit": 5.117409706115723
        },
        {
            "text": "transforming growth factor-beta (TGF-beta",
            "probability": 0.002155044923612341,
            "start_logit": 2.134343385696411,
            "end_logit": 5.117409706115723
        },
        {
            "text": "TGF-beta)",
            "probability": 0.0019277982341740255,
            "start_logit": 3.996595859527588,
            "end_logit": 3.143724203109741
        },
        {
            "text": "transforming growth factor-beta",
            "probability": 0.0016096523486389981,
            "start_logit": 2.134343385696411,
            "end_logit": 4.825616359710693
        },
        {
            "text": "secretory cell differentiation in the",
            "probability": 0.0007794258512305829,
            "start_logit": -0.46967771649360657,
            "end_logit": 6.704421520233154
        },
        {
            "text": "TGF-beta).",
            "probability": 0.0006501476502275884,
            "start_logit": 3.996595859527588,
            "end_logit": 2.0567898750305176
        },
        {
            "text": ". Transcription of Math1, a transcription factor required for secretory cell differentiation in the",
            "probability": 0.0006264836398491806,
            "start_logit": -0.6881126165390015,
            "end_logit": 6.704421520233154
        },
        {
            "text": "parasite Trichinella spiralis",
            "probability": 0.00041471668729385917,
            "start_logit": 0.4632050096988678,
            "end_logit": 5.1405768394470215
        },
        {
            "text": "spiralis",
            "probability": 0.0003981261788022159,
            "start_logit": 0.42237839102745056,
            "end_logit": 5.1405768394470215
        },
        {
            "text": "Transcription of Math1, a transcription factor required for secretory cell differentiation in the",
            "probability": 0.00036706304139679495,
            "start_logit": -1.2227016687393188,
            "end_logit": 6.704421520233154
        },
        {
            "text": "-infection. Transcription of Math1, a transcription factor required for secretory cell differentiation in the",
            "probability": 0.00033606843003713526,
            "start_logit": -1.3109204769134521,
            "end_logit": 6.704421520233154
        },
        {
            "text": "(TGF-beta)",
            "probability": 0.00032028271065386347,
            "start_logit": 2.2016661167144775,
            "end_logit": 3.143724203109741
        },
        {
            "text": "transcription factor required for secretory cell differentiation in the",
            "probability": 0.0003079272215195029,
            "start_logit": -1.3983718156814575,
            "end_logit": 6.704421520233154
        },
        {
            "text": "transforming growth factor-beta (TGF-beta)",
            "probability": 0.00029943020306505294,
            "start_logit": 2.134343385696411,
            "end_logit": 3.143724203109741
        },
        {
            "text": "crypt on day 2 post-infection. Transcription of Math1, a transcription factor required for secretory cell differentiation in the",
            "probability": 0.0002672678366603014,
            "start_logit": -1.5399839878082275,
            "end_logit": 6.704421520233154
        },
        {
            "text": "mice with the parasite Trichinella spiralis",
            "probability": 0.00017977718395121876,
            "start_logit": -0.3726723790168762,
            "end_logit": 5.1405768394470215
        }
    ],
    "58a2df9c60087bc10a000006_000": [
        {
            "text": "beta-thalassaemia",
            "probability": 0.5038472887656786,
            "start_logit": 2.8122141361236572,
            "end_logit": 3.5398967266082764
        },
        {
            "text": "beta-thalassaemia trait carriers. The frequency of beta-thalassaemia",
            "probability": 0.24450569556603646,
            "start_logit": 3.145615339279175,
            "end_logit": 2.4834609031677246
        },
        {
            "text": "heterozygosity for beta-thalassaemia",
            "probability": 0.027142445091925396,
            "start_logit": -0.1089603453874588,
            "end_logit": 3.5398967266082764
        },
        {
            "text": "beta-thalassaemia trait carriers. The frequency of beta-thalassaemia trait was estimated in 209",
            "probability": 0.026178754825103696,
            "start_logit": 3.145615339279175,
            "end_logit": 0.24917049705982208
        },
        {
            "text": "beta-thalassaemia trait",
            "probability": 0.024771033122833342,
            "start_logit": 3.3831920623779297,
            "end_logit": -0.04367947205901146
        },
        {
            "text": "beta-thalassaemia trait carriers. The frequency of beta-thalassaemia trait",
            "probability": 0.022069955832791553,
            "start_logit": 3.145615339279175,
            "end_logit": 0.07843951880931854
        },
        {
            "text": "beta-thalassaemia trait was estimated in 209",
            "probability": 0.021861182444244516,
            "start_logit": 2.9653797149658203,
            "end_logit": 0.24917049705982208
        },
        {
            "text": "beta-thalassaemia trait (4.31%), as compared with the mean incidence of heterozygosity",
            "probability": 0.019159440833379397,
            "start_logit": 3.3831920623779297,
            "end_logit": -0.30055883526802063
        },
        {
            "text": "beta-",
            "probability": 0.013165911008449748,
            "start_logit": 3.3831920623779297,
            "end_logit": -0.6757234334945679
        },
        {
            "text": "beta-thalassaemia trait (4.31%), as compared with the mean incidence of heterozygosity for beta-",
            "probability": 0.012075570038209499,
            "start_logit": 3.3831920623779297,
            "end_logit": -0.7621700167655945
        },
        {
            "text": "thalassaemia",
            "probability": 0.0103545317216222,
            "start_logit": -1.0726348161697388,
            "end_logit": 3.5398967266082764
        },
        {
            "text": "(4.31%), as compared with the mean incidence of heterozygosity for beta-thalassaemia",
            "probability": 0.009429858577991284,
            "start_logit": -1.1661779880523682,
            "end_logit": 3.5398967266082764
        },
        {
            "text": "beta-thalassaemia trait carriers. The frequency of beta-",
            "probability": 0.009356990155498264,
            "start_logit": 3.145615339279175,
            "end_logit": -0.7796540260314941
        },
        {
            "text": "beta-thalassaemia trait carriers",
            "probability": 0.008694491109891218,
            "start_logit": 3.145615339279175,
            "end_logit": -0.8530880808830261
        },
        {
            "text": "acute myocardial infarction in beta-thalassaemia",
            "probability": 0.008524753192975075,
            "start_logit": -0.22485393285751343,
            "end_logit": 2.4976656436920166
        },
        {
            "text": "acute myocardial infarction in beta-thalassaemia trait carriers. The frequency of beta-thalassaemia",
            "probability": 0.008404517267602754,
            "start_logit": -0.22485393285751343,
            "end_logit": 2.4834609031677246
        },
        {
            "text": "beta-thalassaemia trait (4.31%)",
            "probability": 0.008292394715963422,
            "start_logit": 3.3831920623779297,
            "end_logit": -1.138015627861023
        },
        {
            "text": "beta-thalassaemia trait was estimated in 209 consecutive patients hospitalized for acute myocardial infarction",
            "probability": 0.008055615678103527,
            "start_logit": 2.9653797149658203,
            "end_logit": -0.7491726279258728
        },
        {
            "text": "-thalassaemia",
            "probability": 0.007863266372290961,
            "start_logit": -1.1130247116088867,
            "end_logit": 3.3050644397735596
        },
        {
            "text": "beta-thalassaemia trait (4.31%",
            "probability": 0.006246303679409016,
            "start_logit": 3.3831920623779297,
            "end_logit": -1.4213645458221436
        }
    ],
    "58a2df9c60087bc10a000006_001": [
        {
            "text": "S-beta thalassemia.",
            "probability": 0.3370851893356821,
            "start_logit": 5.797169208526611,
            "end_logit": 3.165513038635254
        },
        {
            "text": "S-beta thalassemia",
            "probability": 0.22871650230226095,
            "start_logit": 5.797169208526611,
            "end_logit": 2.777660608291626
        },
        {
            "text": "beta thalassemia.",
            "probability": 0.12388023526441125,
            "start_logit": 4.796148777008057,
            "end_logit": 3.165513038635254
        },
        {
            "text": "beta thalassemia",
            "probability": 0.08405428363641876,
            "start_logit": 4.796148777008057,
            "end_logit": 2.777660608291626
        },
        {
            "text": "beta-thalassemia trait being 8",
            "probability": 0.06306517241698913,
            "start_logit": 5.146933078765869,
            "end_logit": 2.1395821571350098
        },
        {
            "text": "beta-thalassemia trait",
            "probability": 0.051286397103754516,
            "start_logit": 5.146933078765869,
            "end_logit": 1.932839035987854
        },
        {
            "text": "beta-thalassemia",
            "probability": 0.027231678677023988,
            "start_logit": 5.146933078765869,
            "end_logit": 1.2997944355010986
        },
        {
            "text": "beta-thalassemia trait being 8% and that of sickle cell trait ranging from 1",
            "probability": 0.013258492587404089,
            "start_logit": 5.146933078765869,
            "end_logit": 0.5800517797470093
        },
        {
            "text": "sickle cell disease (SCD) is mainly represented by S-beta thalassemia.",
            "probability": 0.012940789928389382,
            "start_logit": 2.537217855453491,
            "end_logit": 3.165513038635254
        },
        {
            "text": "beta-thalassemia trait being 8%",
            "probability": 0.011461135994136878,
            "start_logit": 5.146933078765869,
            "end_logit": 0.4343753159046173
        },
        {
            "text": "sickle cell disease (SCD) is mainly represented by S-beta thalassemia",
            "probability": 0.008780487256893668,
            "start_logit": 2.537217855453491,
            "end_logit": 2.777660608291626
        },
        {
            "text": "beta-thalassemia trait being 8% and that of sickle cell trait ranging from 1 to 32",
            "probability": 0.007798259598487539,
            "start_logit": 5.146933078765869,
            "end_logit": 0.04931406304240227
        },
        {
            "text": "beta-thalassemia trait being 8% and that of sickle cell trait",
            "probability": 0.0061754390141134695,
            "start_logit": 5.146933078765869,
            "end_logit": -0.18400654196739197
        },
        {
            "text": "S-",
            "probability": 0.004701874665532729,
            "start_logit": 5.797169208526611,
            "end_logit": -1.1068613529205322
        },
        {
            "text": "8",
            "probability": 0.004122162243070336,
            "start_logit": 2.419142246246338,
            "end_logit": 2.1395821571350098
        },
        {
            "text": "beta-thalassemia trait being 8% and that of sickle cell trait ranging from 1 to 32%",
            "probability": 0.0039061285448815796,
            "start_logit": 5.146933078765869,
            "end_logit": -0.6420397758483887
        },
        {
            "text": "sickle cell disease in Greece. Hemoglobinopathies are very common in Greece, the incidence of beta-thalassemia trait",
            "probability": 0.003524122868609406,
            "start_logit": 2.4691390991210938,
            "end_logit": 1.932839035987854
        },
        {
            "text": "-beta thalassemia.",
            "probability": 0.0030259049944317495,
            "start_logit": 1.0840437412261963,
            "end_logit": 3.165513038635254
        },
        {
            "text": "thalassemia.",
            "probability": 0.002903194185154017,
            "start_logit": 1.0426450967788696,
            "end_logit": 3.165513038635254
        },
        {
            "text": "beta-thalassemia trait being 8% and that of sickle cell",
            "probability": 0.0020825493823544558,
            "start_logit": 5.146933078765869,
            "end_logit": -1.270993709564209
        }
    ],
    "58a32edd60087bc10a000012_000": [
        {
            "text": "Naltrexone",
            "probability": 0.2549183817858682,
            "start_logit": 5.339801788330078,
            "end_logit": 5.200431823730469
        },
        {
            "text": "naltrexone",
            "probability": 0.2538147527857003,
            "start_logit": 5.213605880737305,
            "end_logit": 5.322288990020752
        },
        {
            "text": "Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes",
            "probability": 0.19141857432894527,
            "start_logit": 5.339801788330078,
            "end_logit": 4.9139509201049805
        },
        {
            "text": "Type 2 diabetes. Contrave(\u00ae) is a combination of naltrexone",
            "probability": 0.04491920351777963,
            "start_logit": 3.4818665981292725,
            "end_logit": 5.322288990020752
        },
        {
            "text": "Naltrexone/bupropion",
            "probability": 0.03018386961992067,
            "start_logit": 5.339801788330078,
            "end_logit": 3.066796064376831
        },
        {
            "text": "Type 2 diabetes",
            "probability": 0.02986022504250955,
            "start_logit": 3.4818665981292725,
            "end_logit": 4.9139509201049805
        },
        {
            "text": "naltrexone hydrochloride extended release and bupropion",
            "probability": 0.02822959601858021,
            "start_logit": 5.213605880737305,
            "end_logit": 3.1260552406311035
        },
        {
            "text": "obesity and obesity with Type 2 diabetes. Contrave(\u00ae) is a combination of naltrexone",
            "probability": 0.026528876126312814,
            "start_logit": 2.955235004425049,
            "end_logit": 5.322288990020752
        },
        {
            "text": "Naltrexone/bupropion for the treatment of obesity",
            "probability": 0.021774063402603787,
            "start_logit": 5.339801788330078,
            "end_logit": 2.7402079105377197
        },
        {
            "text": "naltrexone hydrochloride",
            "probability": 0.017918501431228705,
            "start_logit": 5.213605880737305,
            "end_logit": 2.671518087387085
        },
        {
            "text": "obesity and obesity with Type 2 diabetes",
            "probability": 0.017635179371402094,
            "start_logit": 2.955235004425049,
            "end_logit": 4.9139509201049805
        },
        {
            "text": "naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity",
            "probability": 0.016485661250237676,
            "start_logit": 5.213605880737305,
            "end_logit": 2.5881752967834473
        },
        {
            "text": "naltrexone hydrochloride extended release and bupropion hydrochloride",
            "probability": 0.01555714822156497,
            "start_logit": 5.213605880737305,
            "end_logit": 2.5302045345306396
        },
        {
            "text": "bupropion for the treatment of obesity and obesity with Type 2 diabetes",
            "probability": 0.014062361020112414,
            "start_logit": 2.7288410663604736,
            "end_logit": 4.9139509201049805
        },
        {
            "text": "diabetes. Contrave(\u00ae) is a combination of naltrexone",
            "probability": 0.008409500052599203,
            "start_logit": 1.8063632249832153,
            "end_logit": 5.322288990020752
        },
        {
            "text": "obesity with Type 2 diabetes. Contrave(\u00ae) is a combination of naltrexone",
            "probability": 0.006283884969606243,
            "start_logit": 1.5149896144866943,
            "end_logit": 5.322288990020752
        },
        {
            "text": "bupropion",
            "probability": 0.005826862135841102,
            "start_logit": 3.635713577270508,
            "end_logit": 3.1260552406311035
        },
        {
            "text": "diabetes",
            "probability": 0.005590249701694187,
            "start_logit": 1.8063632249832153,
            "end_logit": 4.9139509201049805
        },
        {
            "text": "naltrexone hydrochloride extended release",
            "probability": 0.005324318070117172,
            "start_logit": 5.213605880737305,
            "end_logit": 1.4579689502716064
        },
        {
            "text": "Naltrexone/bupropion for the treatment of obesity and obesity",
            "probability": 0.005258791147376046,
            "start_logit": 5.339801788330078,
            "end_logit": 1.3193895816802979
        }
    ],
    "5880a8ec0a76a87357000001_000": [
        {
            "text": "CAFE",
            "probability": 0.7537654207464218,
            "start_logit": 3.3971424102783203,
            "end_logit": 2.9690616130828857
        },
        {
            "text": "CAFE: an R package for the detection of gross chromosomal abnormalities",
            "probability": 0.03717419250930716,
            "start_logit": 3.3971424102783203,
            "end_logit": -0.040404822677373886
        },
        {
            "text": "CAFE has been developed to alleviate these issues. It is implemented as an R package that analyzes Affymetrix",
            "probability": 0.03417391503498061,
            "start_logit": 2.677455186843872,
            "end_logit": 0.5951302647590637
        },
        {
            "text": "CAFE: an R package for the detection of gross chromosomal abnormalities from gene expression microarray",
            "probability": 0.03153052803870517,
            "start_logit": 3.3971424102783203,
            "end_logit": -0.2050633728504181
        },
        {
            "text": "CAFE: an R",
            "probability": 0.0219309629469426,
            "start_logit": 3.3971424102783203,
            "end_logit": -0.5681201219558716
        },
        {
            "text": "chromosomal abnormalities from DNA microarray expression data are cumbersome and inflexible. CAFE",
            "probability": 0.021573436699196084,
            "start_logit": 1.290351390838623,
            "end_logit": 1.5222342014312744
        },
        {
            "text": "CAFE: an R package for the detection of gross chromosomal",
            "probability": 0.012346331514932609,
            "start_logit": 3.3971424102783203,
            "end_logit": -1.1426606178283691
        },
        {
            "text": "Linux",
            "probability": 0.011480938043307522,
            "start_logit": 0.5532107949256897,
            "end_logit": 1.6286001205444336
        },
        {
            "text": "Affymetrix",
            "probability": 0.010434530165058551,
            "start_logit": 1.4911130666732788,
            "end_logit": 0.5951302647590637
        },
        {
            "text": "chromosomal abnormalities from gene expression microarray data. SUMMARY",
            "probability": 0.009306842390163939,
            "start_logit": 1.3373373746871948,
            "end_logit": 0.6345353126525879
        },
        {
            "text": "CAFE has been developed to alleviate these issues. It is implemented as an R package that analyzes Affymetrix *.CEL",
            "probability": 0.008743312219590323,
            "start_logit": 2.677455186843872,
            "end_logit": -0.7680432796478271
        },
        {
            "text": "CAFE: an R package for the detection of gross chromosomal abnormalities from gene expression microarray data.",
            "probability": 0.008334469423544096,
            "start_logit": 3.3971424102783203,
            "end_logit": -1.5356197357177734
        },
        {
            "text": "CAFE has been developed to alleviate these issues. It is implemented as an R",
            "probability": 0.007291391173524365,
            "start_logit": 2.677455186843872,
            "end_logit": -0.9496380090713501
        },
        {
            "text": "E",
            "probability": 0.006355783967732641,
            "start_logit": -1.3785735368728638,
            "end_logit": 2.9690616130828857
        },
        {
            "text": "CAFE has been developed to alleviate these issues.",
            "probability": 0.005869498623092697,
            "start_logit": 2.677455186843872,
            "end_logit": -1.1665631532669067
        },
        {
            "text": "chromosomal abnormalities",
            "probability": 0.004738922244059501,
            "start_logit": 1.3373373746871948,
            "end_logit": -0.040404822677373886
        },
        {
            "text": "chromosomal abnormalities from gene expression microarray",
            "probability": 0.004019474549505059,
            "start_logit": 1.3373373746871948,
            "end_logit": -0.2050633728504181
        },
        {
            "text": "CAFE has been developed to alleviate these issues. It is implemented as an R package that analyzes Affymetrix *.CEL files",
            "probability": 0.003827094010771776,
            "start_logit": 2.677455186843872,
            "end_logit": -1.594226598739624
        },
        {
            "text": "cob87icW6z/cafe/ as both source and compiled packages for Linux",
            "probability": 0.0036970299182387564,
            "start_logit": -0.5799475312232971,
            "end_logit": 1.6286001205444336
        },
        {
            "text": "Linux and Windows",
            "probability": 0.003405925780924565,
            "start_logit": 0.5532107949256897,
            "end_logit": 0.41342881321907043
        }
    ],
    "58a877cf38c171fb5b000004_000": [
        {
            "text": "black",
            "probability": 0.3173420268965856,
            "start_logit": 4.552479267120361,
            "end_logit": 4.297486782073975
        },
        {
            "text": "Biston betularia): the replacement, during the Industrial Revolution, of the common pale typica form by a previously unknown black",
            "probability": 0.2112141000877824,
            "start_logit": 4.145371437072754,
            "end_logit": 4.297486782073975
        },
        {
            "text": "pale typica form by a previously unknown black",
            "probability": 0.13970178544541761,
            "start_logit": 3.732009172439575,
            "end_logit": 4.297486782073975
        },
        {
            "text": "black (carbonaria) form, driven by the interaction between bird predation and coal",
            "probability": 0.08557916461582259,
            "start_logit": 4.552479267120361,
            "end_logit": 2.9869484901428223
        },
        {
            "text": "Biston betularia)",
            "probability": 0.04077443115192224,
            "start_logit": 4.145371437072754,
            "end_logit": 2.652669668197632
        },
        {
            "text": "pale typica form by a previously unknown black (carbonaria) form, driven by the interaction between bird predation and coal",
            "probability": 0.037674058525042964,
            "start_logit": 3.732009172439575,
            "end_logit": 2.9869484901428223
        },
        {
            "text": "coal",
            "probability": 0.027097229823698023,
            "start_logit": 3.4024689197540283,
            "end_logit": 2.9869484901428223
        },
        {
            "text": "peppered moth",
            "probability": 0.02427132154451796,
            "start_logit": 2.645104169845581,
            "end_logit": 3.6341772079467773
        },
        {
            "text": "black (carbonaria",
            "probability": 0.019031908840817964,
            "start_logit": 4.552479267120361,
            "end_logit": 1.4836236238479614
        },
        {
            "text": "industrial melanism in the peppered moth",
            "probability": 0.015991250634823193,
            "start_logit": 2.2278504371643066,
            "end_logit": 3.6341772079467773
        },
        {
            "text": "melanism in the peppered moth",
            "probability": 0.010825398912255368,
            "start_logit": 1.837703824043274,
            "end_logit": 3.6341772079467773
        },
        {
            "text": "Biston betularia): the replacement, during the Industrial Revolution, of the common pale",
            "probability": 0.009987476285055556,
            "start_logit": 4.145371437072754,
            "end_logit": 1.2459464073181152
        },
        {
            "text": "Biston betularia",
            "probability": 0.009849139511424784,
            "start_logit": 4.145371437072754,
            "end_logit": 1.2319985628128052
        },
        {
            "text": "peppered moth (Biston betularia)",
            "probability": 0.009095574079140434,
            "start_logit": 2.645104169845581,
            "end_logit": 2.652669668197632
        },
        {
            "text": "pale typica form by a previously unknown black (carbonaria",
            "probability": 0.008378315571681706,
            "start_logit": 3.732009172439575,
            "end_logit": 1.4836236238479614
        },
        {
            "text": "moth",
            "probability": 0.007692642155271224,
            "start_logit": 1.4960730075836182,
            "end_logit": 3.6341772079467773
        },
        {
            "text": "pale",
            "probability": 0.006605942825484388,
            "start_logit": 3.732009172439575,
            "end_logit": 1.2459464073181152
        },
        {
            "text": "typica form by a previously unknown black",
            "probability": 0.006569639264768421,
            "start_logit": 0.6749580502510071,
            "end_logit": 4.297486782073975
        },
        {
            "text": "Biston betularia): the replacement, during the Industrial Revolution, of the common pale typica",
            "probability": 0.006325940956234481,
            "start_logit": 4.145371437072754,
            "end_logit": 0.7892732620239258
        },
        {
            "text": "industrial melanism in the peppered moth (Biston betularia)",
            "probability": 0.005992652872253171,
            "start_logit": 2.2278504371643066,
            "end_logit": 2.652669668197632
        }
    ],
    "5880aef4c872c95565000001_000": [
        {
            "text": "CD38",
            "probability": 0.9975124315837035,
            "start_logit": 9.504859924316406,
            "end_logit": 9.377897262573242
        },
        {
            "text": "38",
            "probability": 0.0008932250514296514,
            "start_logit": 2.4866786003112793,
            "end_logit": 9.377897262573242
        },
        {
            "text": "CD",
            "probability": 0.0006030057754864559,
            "start_logit": 9.504859924316406,
            "end_logit": 1.9668041467666626
        },
        {
            "text": "CD38 and SLAMF7,",
            "probability": 0.00018722154923016398,
            "start_logit": 9.504859924316406,
            "end_logit": 0.7971700429916382
        },
        {
            "text": "elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.000177674237309428,
            "start_logit": 0.8717917799949646,
            "end_logit": 9.377897262573242
        },
        {
            "text": "daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 0.00016345749493495813,
            "start_logit": 0.7883930206298828,
            "end_logit": 9.377897262573242
        },
        {
            "text": "CD38 and SLAMF7",
            "probability": 0.0001597441335040014,
            "start_logit": 9.504859924316406,
            "end_logit": 0.6384507417678833
        },
        {
            "text": "oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 5.848294923506829e-05,
            "start_logit": -0.2394247204065323,
            "end_logit": 9.377897262573242
        },
        {
            "text": "proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 5.748752458944096e-05,
            "start_logit": -0.2565920054912567,
            "end_logit": 9.377897262573242
        },
        {
            "text": "CD38 and SLAMF",
            "probability": 5.0232506355243606e-05,
            "start_logit": 9.504859924316406,
            "end_logit": -0.5184602737426758
        },
        {
            "text": "multiple myeloma",
            "probability": 4.855259543160573e-05,
            "start_logit": 4.605618000030518,
            "end_logit": 4.346766948699951
        },
        {
            "text": "CD38 and SLAM",
            "probability": 4.519295618264092e-05,
            "start_logit": 9.504859924316406,
            "end_logit": -0.6241813898086548
        },
        {
            "text": "; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38",
            "probability": 2.521425178022316e-05,
            "start_logit": -1.080750584602356,
            "end_logit": 9.377897262573242
        },
        {
            "text": "monoclonal antibodies that target CD38",
            "probability": 1.2046151499046355e-05,
            "start_logit": -1.819414734840393,
            "end_logit": 9.377897262573242
        },
        {
            "text": "Multiple Myeloma Gets Three New Drugs. In the last few weeks, the FDA approved three new therapies for multiple myeloma",
            "probability": 2.2307384148383334e-06,
            "start_logit": 1.5253030061721802,
            "end_logit": 4.346766948699951
        },
        {
            "text": "Multiple Myeloma",
            "probability": 1.174584746850515e-06,
            "start_logit": 1.5253030061721802,
            "end_logit": 3.7053489685058594
        },
        {
            "text": "multiple myeloma: ixazomib, the first oral proteasome",
            "probability": 8.45671992890472e-07,
            "start_logit": 4.605618000030518,
            "end_logit": 0.29649558663368225
        },
        {
            "text": "multiple myeloma: ixazomib, the first oral proteasome inhibitor;",
            "probability": 7.926855293112453e-07,
            "start_logit": 4.605618000030518,
            "end_logit": 0.23179060220718384
        },
        {
            "text": "multiple myeloma: ixazomib",
            "probability": 5.373553836538588e-07,
            "start_logit": 4.605618000030518,
            "end_logit": -0.15697631239891052
        },
        {
            "text": "SLAMF7,",
            "probability": 4.5020326106520435e-07,
            "start_logit": 3.47451114654541,
            "end_logit": 0.7971700429916382
        }
    ],
    "5880aef4c872c95565000001_001": [
        {
            "text": "CD38",
            "probability": 0.9626767187707407,
            "start_logit": 7.644521713256836,
            "end_logit": 7.537341594696045
        },
        {
            "text": "CD38 antibody or CD38",
            "probability": 0.015321983593270139,
            "start_logit": 5.843603134155273,
            "end_logit": 5.197831153869629
        },
        {
            "text": "CD38 and SLAMF7 in multiple myeloma",
            "probability": 0.011350106974950704,
            "start_logit": 8.069084167480469,
            "end_logit": 2.672288656234741
        },
        {
            "text": "multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical development. Of these agents, CD38",
            "probability": 0.005233303398199154,
            "start_logit": 2.42984676361084,
            "end_logit": 7.537341594696045
        },
        {
            "text": "CD38-",
            "probability": 0.001146890719140061,
            "start_logit": 7.644521713256836,
            "end_logit": 0.8046784996986389
        },
        {
            "text": "CD",
            "probability": 0.0009397107107057127,
            "start_logit": 8.069084167480469,
            "end_logit": 0.18087828159332275
        },
        {
            "text": "SLAMF7",
            "probability": 0.0009090805271464794,
            "start_logit": 4.345941066741943,
            "end_logit": 3.870882987976074
        },
        {
            "text": "CD38 and SLAMF7",
            "probability": 0.0004921475445537044,
            "start_logit": 8.069084167480469,
            "end_logit": -0.4659152328968048
        },
        {
            "text": "38",
            "probability": 0.0004293851430780892,
            "start_logit": -0.07059693336486816,
            "end_logit": 7.537341594696045
        },
        {
            "text": "CD38 and",
            "probability": 0.0002438915382808768,
            "start_logit": 8.069084167480469,
            "end_logit": -1.1679701805114746
        },
        {
            "text": ", CD38",
            "probability": 0.00023092077248345306,
            "start_logit": -0.6908765435218811,
            "end_logit": 7.537341594696045
        },
        {
            "text": "SLAMF",
            "probability": 0.00016783746673168108,
            "start_logit": 4.345941066741943,
            "end_logit": 2.181445360183716
        },
        {
            "text": "CD38-targeting",
            "probability": 0.0001447073121640594,
            "start_logit": 7.644521713256836,
            "end_logit": -1.2654181718826294
        },
        {
            "text": "SLAMF7)",
            "probability": 0.00014332370328191577,
            "start_logit": 4.345941066741943,
            "end_logit": 2.023555040359497
        },
        {
            "text": "Neutralization of the therapeutic CD38",
            "probability": 0.00012906534143686816,
            "start_logit": 0.5148794054985046,
            "end_logit": 5.7498297691345215
        },
        {
            "text": "multiple myeloma",
            "probability": 0.00010200644122387974,
            "start_logit": 3.357137680053711,
            "end_logit": 2.672288656234741
        },
        {
            "text": "CD38 and SLAMF7 in multiple myeloma.",
            "probability": 9.175487807446512e-05,
            "start_logit": 8.069084167480469,
            "end_logit": -2.145573139190674
        },
        {
            "text": "CD38-targeting antibodies have marked single agent activity in extensively pretreated MM,",
            "probability": 8.664245387670421e-05,
            "start_logit": 7.644521713256836,
            "end_logit": -1.7783414125442505
        },
        {
            "text": "CD38-targeting antibodies, interfere with blood compatibility testing and thereby complicate the safe release of blood products. Neutralization of the therapeutic CD",
            "probability": 8.620716310474948e-05,
            "start_logit": 6.686230182647705,
            "end_logit": -0.8250865340232849
        },
        {
            "text": "Neutralization of the therapeutic CD38 antibody or CD38",
            "probability": 7.431554755664549e-05,
            "start_logit": 0.5148794054985046,
            "end_logit": 5.197831153869629
        }
    ],
    "5880aef4c872c95565000001_002": [
        {
            "text": "CD38",
            "probability": 0.9718094954339526,
            "start_logit": 9.679611206054688,
            "end_logit": 9.388829231262207
        },
        {
            "text": "RANKL",
            "probability": 0.024736383689802514,
            "start_logit": 7.55550479888916,
            "end_logit": 7.842051029205322
        },
        {
            "text": "CD38) and elotuzumab (anti-CS1",
            "probability": 0.0009404556634495048,
            "start_logit": 9.679611206054688,
            "end_logit": 2.4482786655426025
        },
        {
            "text": "denosumab (anti-RANKL",
            "probability": 0.0006959790541110774,
            "start_logit": 3.9847939014434814,
            "end_logit": 7.842051029205322
        },
        {
            "text": "CD",
            "probability": 0.000561311572837356,
            "start_logit": 9.679611206054688,
            "end_logit": 1.9321902990341187
        },
        {
            "text": "38",
            "probability": 0.0005343801268302626,
            "start_logit": 2.1738035678863525,
            "end_logit": 9.388829231262207
        },
        {
            "text": "daratumumab (anti-CD38",
            "probability": 0.00019785689564018078,
            "start_logit": 1.1802401542663574,
            "end_logit": 9.388829231262207
        },
        {
            "text": "CD38)",
            "probability": 0.00011925700655607285,
            "start_logit": 9.679611206054688,
            "end_logit": 0.38319504261016846
        },
        {
            "text": "CD38) and elotuzumab (anti-CS1)",
            "probability": 5.263222517951589e-05,
            "start_logit": 9.679611206054688,
            "end_logit": -0.434757262468338
        },
        {
            "text": "anti-CD38",
            "probability": 5.005976826697922e-05,
            "start_logit": -0.1940862089395523,
            "end_logit": 9.388829231262207
        },
        {
            "text": "-CD38",
            "probability": 4.9637388491256166e-05,
            "start_logit": -0.20255951583385468,
            "end_logit": 9.388829231262207
        },
        {
            "text": "RANKL) or BHQ880 (anti-DKK-",
            "probability": 4.449536431786212e-05,
            "start_logit": 7.55550479888916,
            "end_logit": 1.521405577659607
        },
        {
            "text": "RANKL) or BHQ880 (anti-DKK",
            "probability": 3.563979929480582e-05,
            "start_logit": 7.55550479888916,
            "end_logit": 1.2994835376739502
        },
        {
            "text": "RANKL) or BHQ880 (anti-DKK-1",
            "probability": 3.5516087234182893e-05,
            "start_logit": 7.55550479888916,
            "end_logit": 1.2960063219070435
        },
        {
            "text": "NKL",
            "probability": 3.090524325459089e-05,
            "start_logit": 0.8704001903533936,
            "end_logit": 7.842051029205322
        },
        {
            "text": "CD38) and elotuzumab (anti-CS",
            "probability": 3.0625342753387696e-05,
            "start_logit": 9.679611206054688,
            "end_logit": -0.9762579798698425
        },
        {
            "text": "RANKL)",
            "probability": 2.580277311376926e-05,
            "start_logit": 7.55550479888916,
            "end_logit": 0.976502537727356
        },
        {
            "text": "RANK",
            "probability": 2.2397798282965344e-05,
            "start_logit": 7.55550479888916,
            "end_logit": 0.834983229637146
        },
        {
            "text": "RANKL) or BHQ880 (anti-DKK-1)",
            "probability": 1.388421773221845e-05,
            "start_logit": 7.55550479888916,
            "end_logit": 0.35677334666252136
        },
        {
            "text": "CD38) and elotuzumab",
            "probability": 1.328454889906287e-05,
            "start_logit": 9.679611206054688,
            "end_logit": -1.8114842176437378
        }
    ],
    "5880aef4c872c95565000001_003": [
        {
            "text": "CD38",
            "probability": 0.984919404364308,
            "start_logit": 9.51258659362793,
            "end_logit": 9.222898483276367
        },
        {
            "text": "CD38 IgG1-\u03ba",
            "probability": 0.008848868121695325,
            "start_logit": 9.51258659362793,
            "end_logit": 4.5106282234191895
        },
        {
            "text": "-CD38",
            "probability": 0.0019352834688333815,
            "start_logit": 3.280280590057373,
            "end_logit": 9.222898483276367
        },
        {
            "text": "CD38 IgG1",
            "probability": 0.0016427047770075209,
            "start_logit": 9.51258659362793,
            "end_logit": 2.8266828060150146
        },
        {
            "text": "CD",
            "probability": 0.000933225699890991,
            "start_logit": 9.51258659362793,
            "end_logit": 2.26123046875
        },
        {
            "text": "38",
            "probability": 0.0008100288266539091,
            "start_logit": 2.409341335296631,
            "end_logit": 9.222898483276367
        },
        {
            "text": "CD38 IgG1-",
            "probability": 0.00025591686001251907,
            "start_logit": 9.51258659362793,
            "end_logit": 0.9674360156059265
        },
        {
            "text": "anti-CD38",
            "probability": 0.00016169448019531167,
            "start_logit": 0.7979801297187805,
            "end_logit": 9.222898483276367
        },
        {
            "text": "Daratumumab is a fully human anti-CD38",
            "probability": 8.601457044677561e-05,
            "start_logit": 0.16678820550441742,
            "end_logit": 9.222898483276367
        },
        {
            "text": "daratumumab IFE reflex assay (DIRA). Daratumumab is a fully human anti-CD38",
            "probability": 8.503696842240998e-05,
            "start_logit": 0.15535758435726166,
            "end_logit": 9.222898483276367
        },
        {
            "text": "CD38 IgG1-\u03ba monoclonal",
            "probability": 5.661436898502256e-05,
            "start_logit": 9.51258659362793,
            "end_logit": -0.5411537885665894
        },
        {
            "text": "human anti-CD38",
            "probability": 5.592774828553172e-05,
            "start_logit": -0.26366785168647766,
            "end_logit": 9.222898483276367
        },
        {
            "text": "CD38 IgG1-\u03ba monoclonal antibody (mAb)",
            "probability": 4.5346758464922727e-05,
            "start_logit": 9.51258659362793,
            "end_logit": -0.7630779147148132
        },
        {
            "text": "IgG1-\u03ba",
            "probability": 3.989693542689247e-05,
            "start_logit": 4.110841274261475,
            "end_logit": 4.5106282234191895
        },
        {
            "text": "CD38 IgG1-\u03ba monoclonal antibody",
            "probability": 3.708487040074512e-05,
            "start_logit": 9.51258659362793,
            "end_logit": -0.9642075300216675
        },
        {
            "text": "fully human anti-CD38",
            "probability": 2.1862959928194006e-05,
            "start_logit": -1.2029346227645874,
            "end_logit": 9.222898483276367
        },
        {
            "text": "CD38 IgG",
            "probability": 2.0865761549954592e-05,
            "start_logit": 9.51258659362793,
            "end_logit": -1.5393069982528687
        },
        {
            "text": "CD38 IgG1-\u03ba monoclonal antibody (mAb",
            "probability": 1.9188665896894367e-05,
            "start_logit": 9.51258659362793,
            "end_logit": -1.6230968236923218
        },
        {
            "text": "-CD38 IgG1-\u03ba",
            "probability": 1.7387278713283767e-05,
            "start_logit": 3.280280590057373,
            "end_logit": 4.5106282234191895
        },
        {
            "text": "multiple myeloma",
            "probability": 7.646514882573935e-06,
            "start_logit": 3.4820973873138428,
            "end_logit": 3.4873225688934326
        }
    ],
    "5884c72fe56acf517600000f_000": [
        {
            "text": "PD-1",
            "probability": 0.5581384732393893,
            "start_logit": 5.616813659667969,
            "end_logit": 5.887386798858643
        },
        {
            "text": "PD-1/PD-L1",
            "probability": 0.22230611192592947,
            "start_logit": 5.616813659667969,
            "end_logit": 4.966835021972656
        },
        {
            "text": "Avelumab (MSB0010718C) on Human Tumor Cells. Several anti-PD-1",
            "probability": 0.0953978758210194,
            "start_logit": 3.8502628803253174,
            "end_logit": 5.887386798858643
        },
        {
            "text": "Avelumab (MSB0010718C) on Human Tumor Cells. Several anti-PD-1/PD-L1",
            "probability": 0.03799689839812819,
            "start_logit": 3.8502628803253174,
            "end_logit": 4.966835021972656
        },
        {
            "text": "PD-L1",
            "probability": 0.02767905654992898,
            "start_logit": 3.5334343910217285,
            "end_logit": 4.966835021972656
        },
        {
            "text": "IgG1",
            "probability": 0.017298037360773576,
            "start_logit": 4.413082599639893,
            "end_logit": 3.6171038150787354
        },
        {
            "text": "PD-1/PD-L",
            "probability": 0.009755973770814918,
            "start_logit": 5.616813659667969,
            "end_logit": 1.840659499168396
        },
        {
            "text": "PD-L1 Antibody Avelumab",
            "probability": 0.0049346134106315175,
            "start_logit": 4.357166290283203,
            "end_logit": 2.418701410293579
        },
        {
            "text": "MSB0010718C) on Human Tumor Cells. Several anti-PD-1",
            "probability": 0.004514674347637862,
            "start_logit": 0.7995396256446838,
            "end_logit": 5.887386798858643
        },
        {
            "text": "IgG1 anti-PD-L1",
            "probability": 0.003417112727911928,
            "start_logit": 4.413082599639893,
            "end_logit": 1.9953067302703857
        },
        {
            "text": "Avelumab",
            "probability": 0.002972403615371133,
            "start_logit": 3.8502628803253174,
            "end_logit": 2.418701410293579
        },
        {
            "text": "PD-1 on immune cells interacting with PD-L1",
            "probability": 0.002416430937338483,
            "start_logit": 4.348169326782227,
            "end_logit": 1.713715672492981
        },
        {
            "text": "PD-L",
            "probability": 0.0021615704109952533,
            "start_logit": 4.357166290283203,
            "end_logit": 1.5932620763778687
        },
        {
            "text": "PD-",
            "probability": 0.0020471380637215814,
            "start_logit": 5.616813659667969,
            "end_logit": 0.2792224586009979
        },
        {
            "text": "MSB0010718C) on Human Tumor Cells. Several anti-PD-1/PD-L1",
            "probability": 0.0017981912176920252,
            "start_logit": 0.7995396256446838,
            "end_logit": 4.966835021972656
        },
        {
            "text": "PD-1/PD-L1 monoclonal antibodies (mAb) are currently providing evidence of clinical benefit in subsets of cancer",
            "probability": 0.001706579851096338,
            "start_logit": 5.616813659667969,
            "end_logit": 0.09727098792791367
        },
        {
            "text": "1",
            "probability": 0.0016823934728522573,
            "start_logit": -0.18757596611976624,
            "end_logit": 5.887386798858643
        },
        {
            "text": "Avelumab (MSB0010718C) on Human Tumor Cells. Several anti-PD-1/PD-L",
            "probability": 0.0016675058590740455,
            "start_logit": 3.8502628803253174,
            "end_logit": 1.840659499168396
        },
        {
            "text": "anti-PD-1",
            "probability": 0.0010935353905917667,
            "start_logit": -0.6183775067329407,
            "end_logit": 5.887386798858643
        },
        {
            "text": "-PD-1",
            "probability": 0.0010154236291019974,
            "start_logit": -0.6924875378608704,
            "end_logit": 5.887386798858643
        }
    ],
    "5884c72fe56acf517600000f_001": [
        {
            "text": "programmed death-ligand 1",
            "probability": 0.5709816675362868,
            "start_logit": 8.839573860168457,
            "end_logit": 7.3610148429870605
        },
        {
            "text": "programmed death-ligand 1 (PD-L1",
            "probability": 0.22885554434367578,
            "start_logit": 8.839573860168457,
            "end_logit": 6.446748733520508
        },
        {
            "text": "PD-L1",
            "probability": 0.07867581259988662,
            "start_logit": 7.7718186378479,
            "end_logit": 6.446748733520508
        },
        {
            "text": "programmed death-ligand 1 (PD-L1)",
            "probability": 0.04099760626886332,
            "start_logit": 8.839573860168457,
            "end_logit": 4.727171421051025
        },
        {
            "text": "Programmed cell death protein-1",
            "probability": 0.015050113866950461,
            "start_logit": 5.484615802764893,
            "end_logit": 7.080001354217529
        },
        {
            "text": "PD-L1)",
            "probability": 0.014094130850547438,
            "start_logit": 7.7718186378479,
            "end_logit": 4.727171421051025
        },
        {
            "text": "programmed death-ligand",
            "probability": 0.010493659916356493,
            "start_logit": 8.839573860168457,
            "end_logit": 3.364428997039795
        },
        {
            "text": "programmed death-ligand 1 (PD-L",
            "probability": 0.00816795915202284,
            "start_logit": 8.839573860168457,
            "end_logit": 3.1138768196105957
        },
        {
            "text": "(PD-L1",
            "probability": 0.007419421628840424,
            "start_logit": 5.410583972930908,
            "end_logit": 6.446748733520508
        },
        {
            "text": "programmed death-",
            "probability": 0.007162199053445702,
            "start_logit": 8.839573860168457,
            "end_logit": 2.9824748039245605
        },
        {
            "text": "Programmed cell death protein-1 ligand (PD-L1",
            "probability": 0.004628604782045688,
            "start_logit": 5.484615802764893,
            "end_logit": 5.900871276855469
        },
        {
            "text": "PD-L",
            "probability": 0.002807975770965132,
            "start_logit": 7.7718186378479,
            "end_logit": 3.1138768196105957
        },
        {
            "text": "-programmed death-ligand 1",
            "probability": 0.00257641107187291,
            "start_logit": 3.4386141300201416,
            "end_logit": 7.3610148429870605
        },
        {
            "text": "programmed",
            "probability": 0.001972293858920622,
            "start_logit": 8.839573860168457,
            "end_logit": 1.6928550004959106
        },
        {
            "text": "programmed death",
            "probability": 0.0013552863016976897,
            "start_logit": 8.839573860168457,
            "end_logit": 1.317670464515686
        },
        {
            "text": "(PD-L1)",
            "probability": 0.0013291289383188325,
            "start_logit": 5.410583972930908,
            "end_logit": 4.727171421051025
        },
        {
            "text": "-programmed death-ligand 1 (PD-L1",
            "probability": 0.0010326530462014814,
            "start_logit": 3.4386141300201416,
            "end_logit": 6.446748733520508
        },
        {
            "text": "Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1",
            "probability": 0.0008711126565864826,
            "start_logit": 2.3542327880859375,
            "end_logit": 7.3610148429870605
        },
        {
            "text": "Programmed cell death protein-1 ligand (PD-L1)",
            "probability": 0.000801804701573022,
            "start_logit": 5.484615802764893,
            "end_logit": 4.147725582122803
        },
        {
            "text": "programmed death-ligand 1 (",
            "probability": 0.0007266136549422688,
            "start_logit": 8.839573860168457,
            "end_logit": 0.6942973732948303
        }
    ],
    "5884c72fe56acf517600000f_002": [
        {
            "text": "programmed death receptor 1",
            "probability": 0.23226050138975976,
            "start_logit": 8.27741813659668,
            "end_logit": 6.887941360473633
        },
        {
            "text": "programmed death receptor 1 (PD-1",
            "probability": 0.12971225882645288,
            "start_logit": 8.27741813659668,
            "end_logit": 6.305400371551514
        },
        {
            "text": "programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1",
            "probability": 0.11345410692942375,
            "start_logit": 8.27741813659668,
            "end_logit": 6.171480178833008
        },
        {
            "text": "programmed death ligand 1 (PD-L1",
            "probability": 0.10908423484543768,
            "start_logit": 8.238140106201172,
            "end_logit": 6.171480178833008
        },
        {
            "text": "programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1",
            "probability": 0.08840846778551864,
            "start_logit": 8.27741813659668,
            "end_logit": 5.922049522399902
        },
        {
            "text": "programmed death ligand 1",
            "probability": 0.08500326980882271,
            "start_logit": 8.238140106201172,
            "end_logit": 5.922049522399902
        },
        {
            "text": "programmed death ligand 1 (PD-L1). Several drugs targeting PD-1",
            "probability": 0.05919423785440128,
            "start_logit": 8.238140106201172,
            "end_logit": 5.560184001922607
        },
        {
            "text": "PD-1",
            "probability": 0.03448338387289341,
            "start_logit": 6.952577114105225,
            "end_logit": 6.305400371551514
        },
        {
            "text": "PD-1) and its ligand programmed death ligand 1 (PD-L1",
            "probability": 0.030161231919012453,
            "start_logit": 6.952577114105225,
            "end_logit": 6.171480178833008
        },
        {
            "text": "PD-1) and its ligand programmed death ligand 1",
            "probability": 0.023502968492293722,
            "start_logit": 6.952577114105225,
            "end_logit": 5.922049522399902
        },
        {
            "text": "programmed death receptor 1 (PD-1)",
            "probability": 0.02256454892726646,
            "start_logit": 8.27741813659668,
            "end_logit": 4.556461811065674
        },
        {
            "text": "PD-1) and its ligand programmed death ligand 1 (PD-L1). Several drugs targeting PD-1",
            "probability": 0.016366903418495712,
            "start_logit": 6.952577114105225,
            "end_logit": 5.560184001922607
        },
        {
            "text": "PD-L1",
            "probability": 0.016262263074382444,
            "start_logit": 6.334867000579834,
            "end_logit": 6.171480178833008
        },
        {
            "text": "PD-L1). Several drugs targeting PD-1",
            "probability": 0.008824669026095317,
            "start_logit": 6.334867000579834,
            "end_logit": 5.560184001922607
        },
        {
            "text": "programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1)",
            "probability": 0.006337281676572958,
            "start_logit": 8.27741813659668,
            "end_logit": 3.286531686782837
        },
        {
            "text": "programmed death ligand 1 (PD-L1)",
            "probability": 0.006093190818724687,
            "start_logit": 8.238140106201172,
            "end_logit": 3.286531686782837
        },
        {
            "text": "PD-1)",
            "probability": 0.005998677454369734,
            "start_logit": 6.952577114105225,
            "end_logit": 4.556461811065674
        },
        {
            "text": "programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L",
            "probability": 0.00444171169853089,
            "start_logit": 8.27741813659668,
            "end_logit": 2.931121587753296
        },
        {
            "text": "programmed death ligand 1 (PD-L",
            "probability": 0.004270631845347624,
            "start_logit": 8.238140106201172,
            "end_logit": 2.931121587753296
        },
        {
            "text": "programmed death receptor",
            "probability": 0.0035754603361979652,
            "start_logit": 8.27741813659668,
            "end_logit": 2.7141757011413574
        }
    ],
    "5884c72fe56acf517600000f_003": [
        {
            "text": "PD-L1",
            "probability": 0.6926343430589919,
            "start_logit": 5.634555339813232,
            "end_logit": 6.219412803649902
        },
        {
            "text": "PD-L1/PD-1 pathway. We assessed treatment with avelumab, an anti-PD-L1",
            "probability": 0.16451664544252878,
            "start_logit": 4.1970648765563965,
            "end_logit": 6.219412803649902
        },
        {
            "text": "PD-1 pathway. We assessed treatment with avelumab, an anti-PD-L1",
            "probability": 0.02765869749376846,
            "start_logit": 2.4139933586120605,
            "end_logit": 6.219412803649902
        },
        {
            "text": "Merkel cell carcinoma",
            "probability": 0.025856504423814385,
            "start_logit": 4.9275383949279785,
            "end_logit": 3.6384897232055664
        },
        {
            "text": "PD-L1/PD-1",
            "probability": 0.020187520824171107,
            "start_logit": 4.1970648765563965,
            "end_logit": 4.121465682983398
        },
        {
            "text": "PD-L1 monoclonal antibody, in patients with stage IV Merkel cell carcinoma",
            "probability": 0.01791945604833469,
            "start_logit": 5.634555339813232,
            "end_logit": 2.5647976398468018
        },
        {
            "text": "PD-L",
            "probability": 0.014655228905103321,
            "start_logit": 5.634555339813232,
            "end_logit": 2.3637077808380127
        },
        {
            "text": "/PD-1 pathway. We assessed treatment with avelumab, an anti-PD-L1",
            "probability": 0.009706610489206114,
            "start_logit": 1.366860270500183,
            "end_logit": 6.219412803649902
        },
        {
            "text": "-PD-L1",
            "probability": 0.003719962236729203,
            "start_logit": 0.4077666401863098,
            "end_logit": 6.219412803649902
        },
        {
            "text": "PD-L1/PD-1 pathway. We assessed treatment with avelumab, an anti-PD-L",
            "probability": 0.003480955170388705,
            "start_logit": 4.1970648765563965,
            "end_logit": 2.3637077808380127
        },
        {
            "text": "PD-1",
            "probability": 0.003393945519147813,
            "start_logit": 2.4139933586120605,
            "end_logit": 4.121465682983398
        },
        {
            "text": "anti-PD-L1",
            "probability": 0.0022494953031464266,
            "start_logit": -0.0952409952878952,
            "end_logit": 6.219412803649902
        },
        {
            "text": "avelumab, an anti-PD-L1",
            "probability": 0.002191059676226833,
            "start_logit": -0.12156157940626144,
            "end_logit": 6.219412803649902
        },
        {
            "text": "PD-L1 monoclonal antibody, in patients with stage IV",
            "probability": 0.001945870378576903,
            "start_logit": 5.634555339813232,
            "end_logit": 0.3446199595928192
        },
        {
            "text": "L1/PD-1 pathway. We assessed treatment with avelumab, an anti-PD-L1",
            "probability": 0.001748449936126301,
            "start_logit": -0.34721723198890686,
            "end_logit": 6.219412803649902
        },
        {
            "text": "L1",
            "probability": 0.001747224163633058,
            "start_logit": -0.3479185402393341,
            "end_logit": 6.219412803649902
        },
        {
            "text": "Merkel cell polyomavirus",
            "probability": 0.0017083359105630653,
            "start_logit": 4.164722442626953,
            "end_logit": 1.6842632293701172
        },
        {
            "text": "1",
            "probability": 0.0016802923120405162,
            "start_logit": -0.3869791030883789,
            "end_logit": 6.219412803649902
        },
        {
            "text": "the PD-L1/PD-1 pathway. We assessed treatment with avelumab, an anti-PD-L1",
            "probability": 0.0015809956971384476,
            "start_logit": -0.44789204001426697,
            "end_logit": 6.219412803649902
        },
        {
            "text": "1 pathway. We assessed treatment with avelumab, an anti-PD-L1",
            "probability": 0.001418407010363834,
            "start_logit": -0.5564124584197998,
            "end_logit": 6.219412803649902
        }
    ],
    "5884c72fe56acf517600000f_004": [
        {
            "text": "programed death-1",
            "probability": 0.16885824923994247,
            "start_logit": 6.469979286193848,
            "end_logit": 5.8025383949279785
        },
        {
            "text": "programed death-ligand 1",
            "probability": 0.15934032875759235,
            "start_logit": 5.758567810058594,
            "end_logit": 6.4559326171875
        },
        {
            "text": "death-ligand 1",
            "probability": 0.12364965950106142,
            "start_logit": 5.504977703094482,
            "end_logit": 6.4559326171875
        },
        {
            "text": "Programed death-1",
            "probability": 0.10961953216671959,
            "start_logit": 6.217440605163574,
            "end_logit": 5.623033046722412
        },
        {
            "text": "programed death-ligand 1 (Avelumab). OBJECTIVE: The programed death-1",
            "probability": 0.08290108291279186,
            "start_logit": 5.758567810058594,
            "end_logit": 5.8025383949279785
        },
        {
            "text": "programed death-1 (PD1)",
            "probability": 0.06458636811436624,
            "start_logit": 6.469979286193848,
            "end_logit": 4.841482162475586
        },
        {
            "text": "death-ligand 1 (Avelumab). OBJECTIVE: The programed death-1",
            "probability": 0.06433205425370092,
            "start_logit": 5.504977703094482,
            "end_logit": 5.8025383949279785
        },
        {
            "text": "Programed death-1/programed death-ligand 1",
            "probability": 0.0584148708841798,
            "start_logit": 6.217440605163574,
            "end_logit": 4.993587970733643
        },
        {
            "text": "programed death-1 (PD1)/programed death-ligand 1",
            "probability": 0.05509714293665828,
            "start_logit": 6.469979286193848,
            "end_logit": 4.682576656341553
        },
        {
            "text": "death-ligand 1 (Avelumab). OBJECTIVE: The programed death-1 (PD1)",
            "probability": 0.02460628222953334,
            "start_logit": 5.504977703094482,
            "end_logit": 4.841482162475586
        },
        {
            "text": "programed death-1 (PD1",
            "probability": 0.01610117238330362,
            "start_logit": 6.469979286193848,
            "end_logit": 3.4523708820343018
        },
        {
            "text": "programed death-ligand 1 (PD-L1",
            "probability": 0.013201493180700864,
            "start_logit": 6.659389495849609,
            "end_logit": 3.0643985271453857
        },
        {
            "text": "programed death-1 (PD1)/programed death-ligand 1 (PD-L1",
            "probability": 0.010923536064050077,
            "start_logit": 6.469979286193848,
            "end_logit": 3.0643985271453857
        },
        {
            "text": "anti-programed death-ligand 1",
            "probability": 0.008061069131566742,
            "start_logit": 2.774571657180786,
            "end_logit": 6.4559326171875
        },
        {
            "text": "programed death-ligand 1 (Avelumab). OBJECTIVE: The programed death-1 (PD1",
            "probability": 0.007904882543491793,
            "start_logit": 5.758567810058594,
            "end_logit": 3.4523708820343018
        },
        {
            "text": "programed death-ligand 1 (PD-L1)",
            "probability": 0.0077456791789627015,
            "start_logit": 6.659389495849609,
            "end_logit": 2.5312037467956543
        },
        {
            "text": "programed death-ligand 1 (Avelumab",
            "probability": 0.006467336502821649,
            "start_logit": 5.758567810058594,
            "end_logit": 3.251654624938965
        },
        {
            "text": "programed death-1 (PD1)/programed death-ligand 1 (PD-L1)",
            "probability": 0.006409139079483199,
            "start_logit": 6.469979286193848,
            "end_logit": 2.5312037467956543
        },
        {
            "text": "death-ligand 1 (Avelumab). OBJECTIVE: The programed death-1 (PD1",
            "probability": 0.006134266462984633,
            "start_logit": 5.504977703094482,
            "end_logit": 3.4523708820343018
        },
        {
            "text": "death-1",
            "probability": 0.00564585447608836,
            "start_logit": 3.071841239929199,
            "end_logit": 5.8025383949279785
        }
    ],
    "5884c72fe56acf517600000f_005": [
        {
            "text": "PD-1",
            "probability": 0.6531886262877432,
            "start_logit": 4.267839431762695,
            "end_logit": 3.9553279876708984
        },
        {
            "text": "PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Antibody-based PD-1",
            "probability": 0.14193944637780795,
            "start_logit": 3.942904472351074,
            "end_logit": 2.7537975311279297
        },
        {
            "text": "PD-1/PD-L1",
            "probability": 0.0801877779023014,
            "start_logit": 3.7322070598602295,
            "end_logit": 2.393465518951416
        },
        {
            "text": "PD-L1 blockade therapies have taken center stage in immunotherapies for cancer, with multiple clinical successes. PD-1",
            "probability": 0.024202262885236674,
            "start_logit": 0.9724196195602417,
            "end_logit": 3.9553279876708984
        },
        {
            "text": "PD-",
            "probability": 0.01468590768523925,
            "start_logit": 4.267839431762695,
            "end_logit": 0.16035041213035583
        },
        {
            "text": "PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Antibody-based PD-1",
            "probability": 0.01305077609413217,
            "start_logit": 1.5563515424728394,
            "end_logit": 2.7537975311279297
        },
        {
            "text": "PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Antibody-based PD-1/PD-L1",
            "probability": 0.009102194976432105,
            "start_logit": 1.5563515424728394,
            "end_logit": 2.393465518951416
        },
        {
            "text": "PD-1 and avelumab targeting PD-L1",
            "probability": 0.00861885244764762,
            "start_logit": 2.0290703773498535,
            "end_logit": 1.8661830425262451
        },
        {
            "text": "PD-1 signaling",
            "probability": 0.007165879005555362,
            "start_logit": 4.267839431762695,
            "end_logit": -0.5572072267532349
        },
        {
            "text": "PD-L1",
            "probability": 0.007061272772751993,
            "start_logit": 1.82974374294281,
            "end_logit": 1.8661830425262451
        },
        {
            "text": "PD-1/PD-L",
            "probability": 0.005933611169110542,
            "start_logit": 3.3771941661834717,
            "end_logit": 0.1447402983903885
        },
        {
            "text": "PD-1/PD-Ls interaction and how therapeutic antibodies, pembrolizumab targeting PD-1",
            "probability": 0.005745311804282821,
            "start_logit": 1.2412856817245483,
            "end_logit": 2.2483999729156494
        },
        {
            "text": "PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Antibody-based PD-1/PD-L",
            "probability": 0.0053691637755800175,
            "start_logit": 3.942904472351074,
            "end_logit": -0.520930826663971
        },
        {
            "text": "PD-1 signaling plays pivotal roles in tumor-driven T-cell dysfunction.",
            "probability": 0.004187106329826272,
            "start_logit": 4.267839431762695,
            "end_logit": -1.094528079032898
        },
        {
            "text": "PD-L1 blockade therapies are briefly summarized. We then focus on the recent breakthrough work concerning the structural basis of the PD-1",
            "probability": 0.003956883642799469,
            "start_logit": 1.5144619941711426,
            "end_logit": 1.602296233177185
        },
        {
            "text": "cancer, with multiple clinical successes. PD-1",
            "probability": 0.0037978180605927007,
            "start_logit": -0.8795998096466064,
            "end_logit": 3.9553279876708984
        },
        {
            "text": "1",
            "probability": 0.002996449326823145,
            "start_logit": -1.1165984869003296,
            "end_logit": 3.9553279876708984
        },
        {
            "text": "PD-1/PD-L1 interaction by two cancer",
            "probability": 0.002982814153683508,
            "start_logit": 3.942904472351074,
            "end_logit": -1.1087357997894287
        },
        {
            "text": "PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Antibody-based PD-",
            "probability": 0.002937466563498028,
            "start_logit": 3.942904472351074,
            "end_logit": -1.1240555047988892
        },
        {
            "text": "PD-1 and the present understanding of antibody-based PD-1/PD-L1",
            "probability": 0.002890378738955885,
            "start_logit": 0.9460129141807556,
            "end_logit": 1.8566761016845703
        }
    ],
    "5891f9e549702f2e01000002_000": [
        {
            "text": "restless legs syndrome",
            "probability": 0.4983825984016836,
            "start_logit": 2.167839288711548,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "Willis-Ekbom disease/restless legs syndrome",
            "probability": 0.28179400096034196,
            "start_logit": 1.5976475477218628,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "restless legs",
            "probability": 0.04480729109618238,
            "start_logit": 2.167839288711548,
            "end_logit": 0.6335707902908325
        },
        {
            "text": "Willis-Ekbom disease",
            "probability": 0.028017465189326043,
            "start_logit": 1.5976475477218628,
            "end_logit": 0.7342197299003601
        },
        {
            "text": "Willis-Ekbom disease/restless legs",
            "probability": 0.025334804767824903,
            "start_logit": 1.5976475477218628,
            "end_logit": 0.6335707902908325
        },
        {
            "text": "Ekbom disease/restless legs syndrome",
            "probability": 0.023226085862105235,
            "start_logit": -0.8982527256011963,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "legs syndrome",
            "probability": 0.02208383819943784,
            "start_logit": -0.9486827254295349,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "BACKGROUND: Willis-Ekbom disease/restless legs syndrome",
            "probability": 0.014135100549215062,
            "start_logit": -1.3948676586151123,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "tactile",
            "probability": 0.009960986976826718,
            "start_logit": 1.4099522829055786,
            "end_logit": -0.11223691701889038
        },
        {
            "text": "restless legs syndrome (WED/RLS) seems to be a frequent cause of intractable chronic insomnia",
            "probability": 0.009390291386370608,
            "start_logit": 2.167839288711548,
            "end_logit": -0.9291237592697144
        },
        {
            "text": "restless legs syndrome (WED/RLS)",
            "probability": 0.006987129615508127,
            "start_logit": 2.167839288711548,
            "end_logit": -1.2247302532196045
        },
        {
            "text": "-Ekbom disease/restless legs syndrome",
            "probability": 0.0057763403192661,
            "start_logit": -2.2897584438323975,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "syndrome",
            "probability": 0.005030119164054395,
            "start_logit": -2.4280850887298584,
            "end_logit": 3.0425679683685303
        },
        {
            "text": ": Willis-Ekbom disease/restless legs syndrome",
            "probability": 0.004504069166302717,
            "start_logit": -2.5385475158691406,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "Willis-Ekbom Disease",
            "probability": 0.003984008006734247,
            "start_logit": 0.607717752456665,
            "end_logit": -0.22639019787311554
        },
        {
            "text": "Willis-Ekbom disease/restless legs syndrome (WED/RLS)",
            "probability": 0.003950641968433301,
            "start_logit": 1.5976475477218628,
            "end_logit": -1.2247302532196045
        },
        {
            "text": "kbom disease/restless legs syndrome",
            "probability": 0.003856365711383739,
            "start_logit": -2.693803548812866,
            "end_logit": 3.0425679683685303
        },
        {
            "text": "Willis-Ekbom",
            "probability": 0.0037114417339299505,
            "start_logit": 1.5976475477218628,
            "end_logit": -1.287187933921814
        },
        {
            "text": "tactile sensitivities",
            "probability": 0.0025718450445634676,
            "start_logit": 1.4099522829055786,
            "end_logit": -1.4662895202636719
        },
        {
            "text": "restless",
            "probability": 0.0024955758805096546,
            "start_logit": 2.167839288711548,
            "end_logit": -2.2542805671691895
        }
    ],
    "5891f9e549702f2e01000002_001": [
        {
            "text": "restless legs syndrome",
            "probability": 0.26792942749837906,
            "start_logit": 2.364184856414795,
            "end_logit": 1.9643205404281616
        },
        {
            "text": "genetic",
            "probability": 0.26163297781981265,
            "start_logit": 1.6189565658569336,
            "end_logit": 2.685767889022827
        },
        {
            "text": "restless legs syndrome/Willis-Ekbom disease",
            "probability": 0.1646621640748434,
            "start_logit": 2.364184856414795,
            "end_logit": 1.4774928092956543
        },
        {
            "text": "Willis-Ekbom disease",
            "probability": 0.09606258631696121,
            "start_logit": 1.8252888917922974,
            "end_logit": 1.4774928092956543
        },
        {
            "text": "restless legs syndrome/Willis-Ekbom",
            "probability": 0.05394402684022577,
            "start_logit": 2.364184856414795,
            "end_logit": 0.3615438938140869
        },
        {
            "text": "Willis-Ekbom",
            "probability": 0.03147051275403073,
            "start_logit": 1.8252888917922974,
            "end_logit": 0.3615438938140869
        },
        {
            "text": "restless legs",
            "probability": 0.016147241503481694,
            "start_logit": 2.364184856414795,
            "end_logit": -0.844653844833374
        },
        {
            "text": "Ekbom disease",
            "probability": 0.015925766574104643,
            "start_logit": 0.02822730876505375,
            "end_logit": 1.4774928092956543
        },
        {
            "text": "sleep",
            "probability": 0.014758662516829491,
            "start_logit": 1.1809788942337036,
            "end_logit": 0.24863308668136597
        },
        {
            "text": "dopamine agonist therapy. Our analyses support the hypothesis that patients with a familial history of RLS/WED may have a genetic",
            "probability": 0.013945012582917702,
            "start_logit": -1.3128641843795776,
            "end_logit": 2.685767889022827
        },
        {
            "text": "restless legs syndrome/Willis-Ekbom disease (RLS/WED)",
            "probability": 0.011062535247500225,
            "start_logit": 2.364184856414795,
            "end_logit": -1.2228388786315918
        },
        {
            "text": "restless legs syndrome/",
            "probability": 0.007623130854000437,
            "start_logit": 2.364184856414795,
            "end_logit": -1.595215916633606
        },
        {
            "text": "genetic component",
            "probability": 0.007466892353276132,
            "start_logit": 1.6189565658569336,
            "end_logit": -0.8706958889961243
        },
        {
            "text": "Willis-Ekbom disease (RLS/WED)",
            "probability": 0.0064537943678087,
            "start_logit": 1.8252888917922974,
            "end_logit": -1.2228388786315918
        },
        {
            "text": "legs syndrome",
            "probability": 0.005461414128367738,
            "start_logit": -1.5288310050964355,
            "end_logit": 1.9643205404281616
        },
        {
            "text": "familial history of RLS/WED may have a genetic",
            "probability": 0.005455558459173652,
            "start_logit": -2.2513511180877686,
            "end_logit": 2.685767889022827
        },
        {
            "text": "Ekbom",
            "probability": 0.005217349014884725,
            "start_logit": 0.02822730876505375,
            "end_logit": 0.3615438938140869
        },
        {
            "text": "sleep specialist, as revealed by the partial absence of daytime symptoms, the high comorbidity with insomnia and other sleep",
            "probability": 0.004988961858440646,
            "start_logit": 1.1809788942337036,
            "end_logit": -0.8359692692756653
        },
        {
            "text": "sleep onset",
            "probability": 0.004953627364084583,
            "start_logit": 0.8034495711326599,
            "end_logit": -0.46554768085479736
        },
        {
            "text": "Willis-Ekbom disease (RLS/WED): a clinical and polysomnographic study. Clinical features variability",
            "probability": 0.004838357870876804,
            "start_logit": 1.8252888917922974,
            "end_logit": -1.5109317302703857
        }
    ],
    "5891f9e549702f2e01000002_002": [
        {
            "text": "iron",
            "probability": 0.9890956163876882,
            "start_logit": 4.964384078979492,
            "end_logit": 5.880871295928955
        },
        {
            "text": "brain iron",
            "probability": 0.00254800542321937,
            "start_logit": -0.997096061706543,
            "end_logit": 5.880871295928955
        },
        {
            "text": "Restless legs syndrome",
            "probability": 0.0014283915915578285,
            "start_logit": 1.9356043338775635,
            "end_logit": 2.3694090843200684
        },
        {
            "text": "The pathophysiology is only partially known and a genetic component together with dopaminergic and brain iron",
            "probability": 0.0012588811163970822,
            "start_logit": -1.7021836042404175,
            "end_logit": 5.880871295928955
        },
        {
            "text": "iron dysregulation",
            "probability": 0.001076592998522153,
            "start_logit": 4.964384078979492,
            "end_logit": -0.9421182870864868
        },
        {
            "text": "genetic component together with dopaminergic and brain iron",
            "probability": 0.0010690810286922878,
            "start_logit": -1.865607500076294,
            "end_logit": 5.880871295928955
        },
        {
            "text": "dopaminergic and brain iron",
            "probability": 0.0010539125242382608,
            "start_logit": -1.8798974752426147,
            "end_logit": 5.880871295928955
        },
        {
            "text": "Restless legs syndrome. Restless legs syndrome",
            "probability": 0.0008644460901872942,
            "start_logit": 1.4333889484405518,
            "end_logit": 2.3694090843200684
        },
        {
            "text": "Willis-Ekbom disease",
            "probability": 0.000264319741715254,
            "start_logit": 2.0962276458740234,
            "end_logit": 0.521640956401825
        },
        {
            "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease",
            "probability": 0.00022509807613617475,
            "start_logit": 1.9356043338775635,
            "end_logit": 0.521640956401825
        },
        {
            "text": "alpha-2-delta calcium channel ligands, opioids) and relieves symptoms only. Augmentation",
            "probability": 0.00015436047686659754,
            "start_logit": 1.633506178855896,
            "end_logit": 0.446493536233902
        },
        {
            "text": "legs",
            "probability": 0.00014460549700374511,
            "start_logit": 1.3270611763000488,
            "end_logit": 0.6876572370529175
        },
        {
            "text": "Willis-Ekbom",
            "probability": 0.00013740770800965569,
            "start_logit": 2.0962276458740234,
            "end_logit": -0.13256607949733734
        },
        {
            "text": "Restless legs syndrome. Restless legs syndrome (RLS), also known as Willis-Ekbom disease",
            "probability": 0.00013622675530621138,
            "start_logit": 1.4333889484405518,
            "end_logit": 0.521640956401825
        },
        {
            "text": "Willis-Ekbom disease (WED)",
            "probability": 0.00012274470072906046,
            "start_logit": 2.0962276458740234,
            "end_logit": -0.2454119622707367
        },
        {
            "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom",
            "probability": 0.00011701816337492945,
            "start_logit": 1.9356043338775635,
            "end_logit": -0.13256607949733734
        },
        {
            "text": "Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED)",
            "probability": 0.00010453095864396997,
            "start_logit": 1.9356043338775635,
            "end_logit": -0.2454119622707367
        },
        {
            "text": "Restless legs syndrome. Restless legs syndrome (RLS), also known as Willis-Ekbom",
            "probability": 7.081804066070805e-05,
            "start_logit": 1.4333889484405518,
            "end_logit": -0.13256607949733734
        },
        {
            "text": "Augmentation",
            "probability": 6.468179243957113e-05,
            "start_logit": 0.7636952996253967,
            "end_logit": 0.446493536233902
        },
        {
            "text": "Restless legs syndrome. Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED)",
            "probability": 6.326092861185209e-05,
            "start_logit": 1.4333889484405518,
            "end_logit": -0.2454119622707367
        }
    ],
    "5880be1dc872c95565000007_000": [
        {
            "text": "PARP",
            "probability": 0.4005968511335971,
            "start_logit": 5.98675012588501,
            "end_logit": 6.447422981262207
        },
        {
            "text": "ADP-ribose) polymerase",
            "probability": 0.2763413137395618,
            "start_logit": 5.158269882202148,
            "end_logit": 6.9045844078063965
        },
        {
            "text": "ADP-ribose) polymerase (PARP",
            "probability": 0.174945643856761,
            "start_logit": 5.158269882202148,
            "end_logit": 6.447422981262207
        },
        {
            "text": "(ADP-ribose) polymerase",
            "probability": 0.05034674577449355,
            "start_logit": 3.4555671215057373,
            "end_logit": 6.9045844078063965
        },
        {
            "text": "(ADP-ribose) polymerase (PARP",
            "probability": 0.03187342397855318,
            "start_logit": 3.4555671215057373,
            "end_logit": 6.447422981262207
        },
        {
            "text": "PARP)",
            "probability": 0.013291791140515439,
            "start_logit": 5.98675012588501,
            "end_logit": 3.041614055633545
        },
        {
            "text": "PARP inhibitors (rucaparib",
            "probability": 0.00802749103738534,
            "start_logit": 5.829289436340332,
            "end_logit": 2.6948001384735107
        },
        {
            "text": "Poly(ADP-ribose) polymerase",
            "probability": 0.006791504806733839,
            "start_logit": 1.4523056745529175,
            "end_logit": 6.9045844078063965
        },
        {
            "text": "ADP-ribose) polymerase (PARP)",
            "probability": 0.005804691056624344,
            "start_logit": 5.158269882202148,
            "end_logit": 3.041614055633545
        },
        {
            "text": "PARP inhibitors (rucaparib,",
            "probability": 0.004862698983047909,
            "start_logit": 5.829289436340332,
            "end_logit": 2.193521738052368
        },
        {
            "text": ". Poly(ADP-ribose) polymerase",
            "probability": 0.004565278788376402,
            "start_logit": 1.0551127195358276,
            "end_logit": 6.9045844078063965
        },
        {
            "text": "Poly(ADP-ribose) polymerase (PARP",
            "probability": 0.004299553205027123,
            "start_logit": 1.4523056745529175,
            "end_logit": 6.447422981262207
        },
        {
            "text": "PARP inhibitors with anti-angiogenic drugs. CONCLUSIONS: PARP",
            "probability": 0.0037875496386433854,
            "start_logit": 3.671762466430664,
            "end_logit": 4.101174354553223
        },
        {
            "text": ". Poly(ADP-ribose) polymerase (PARP",
            "probability": 0.002890178186569802,
            "start_logit": 1.0551127195358276,
            "end_logit": 6.447422981262207
        },
        {
            "text": "PARP) inhibitors target DNA repair",
            "probability": 0.0025950258294484,
            "start_logit": 5.98675012588501,
            "end_logit": 1.4080638885498047
        },
        {
            "text": "olaparib, the first and most-investigated oral PARP",
            "probability": 0.0025250631480754912,
            "start_logit": 1.889880657196045,
            "end_logit": 5.477602958679199
        },
        {
            "text": "PARP inhibitors represent a step change in the management of ovarian cancer. BRCA",
            "probability": 0.002106237550160548,
            "start_logit": 4.487114906311035,
            "end_logit": 2.6990058422088623
        },
        {
            "text": "P-ribose) polymerase",
            "probability": 0.0017273107577531178,
            "start_logit": 0.08319886028766632,
            "end_logit": 6.9045844078063965
        },
        {
            "text": "PARP inhibitors (rucaparib, niraparib and veliparib) are in progress and include non-BRCA-",
            "probability": 0.001440897010522476,
            "start_logit": 5.829289436340332,
            "end_logit": 0.9771939516067505
        },
        {
            "text": "polymerase",
            "probability": 0.001180750378149386,
            "start_logit": -0.2972167134284973,
            "end_logit": 6.9045844078063965
        }
    ],
    "5880be1dc872c95565000007_001": [
        {
            "text": "PARP",
            "probability": 0.5171026503795004,
            "start_logit": 5.803295612335205,
            "end_logit": 6.622974872589111
        },
        {
            "text": "poly (ADP) ribose polymerase (PARP",
            "probability": 0.3248860240657543,
            "start_logit": 5.338528633117676,
            "end_logit": 6.622974872589111
        },
        {
            "text": "poly (ADP) ribose polymerase",
            "probability": 0.12485102644010262,
            "start_logit": 5.338528633117676,
            "end_logit": 5.666621685028076
        },
        {
            "text": "PARP inhibitors will certainly emerge as the next challenge. While olaparib is the first PARP",
            "probability": 0.009908305319705478,
            "start_logit": 3.6584174633026123,
            "end_logit": 4.812984943389893
        },
        {
            "text": "homologous recombination",
            "probability": 0.0031421033565658,
            "start_logit": 3.959249496459961,
            "end_logit": 3.3636720180511475
        },
        {
            "text": "PARP), selectively kill HRD cells through a process known as tumour-selective synthetic lethality",
            "probability": 0.002753007585444495,
            "start_logit": 5.803295612335205,
            "end_logit": 1.3874274492263794
        },
        {
            "text": "BRCA 1/2 genes",
            "probability": 0.002641972739225953,
            "start_logit": 4.518509387969971,
            "end_logit": 2.6310455799102783
        },
        {
            "text": "PARP)",
            "probability": 0.0023418133029369593,
            "start_logit": 5.803295612335205,
            "end_logit": 1.2256590127944946
        },
        {
            "text": "PARP), selectively kill HRD cells through a process known as tumour-selective synthetic lethality. Olaparib",
            "probability": 0.0015344574413886608,
            "start_logit": 5.803295612335205,
            "end_logit": 0.802910327911377
        },
        {
            "text": "poly (ADP) ribose polymerase (PARP)",
            "probability": 0.0014713179530932876,
            "start_logit": 5.338528633117676,
            "end_logit": 1.2256590127944946
        },
        {
            "text": "P13K/AKT pathway and others are likely to merit assessment since resistance to PARP",
            "probability": 0.0014466610047307918,
            "start_logit": 3.116579055786133,
            "end_logit": 3.430708169937134
        },
        {
            "text": "RP",
            "probability": 0.001363461721871197,
            "start_logit": -0.1349189430475235,
            "end_logit": 6.622974872589111
        },
        {
            "text": "(PARP",
            "probability": 0.0009906479980399693,
            "start_logit": -0.4543417990207672,
            "end_logit": 6.622974872589111
        },
        {
            "text": "Olaparib is the first such agent, now approved for the treatment of ovarian cancer",
            "probability": 0.0009903194252274988,
            "start_logit": 3.234027862548828,
            "end_logit": 2.9342734813690186
        },
        {
            "text": "BRCA",
            "probability": 0.0009475686264289887,
            "start_logit": 4.518509387969971,
            "end_logit": 1.605663776397705
        },
        {
            "text": "PARP), selectively kill HRD cells through a process known as tumour-selective synthetic lethality.",
            "probability": 0.0008728347270158263,
            "start_logit": 5.803295612335205,
            "end_logit": 0.23872441053390503
        },
        {
            "text": "PARP inhibitor to receive approval for ovarian cancer treatment, others including rucaparib",
            "probability": 0.0008039980911484411,
            "start_logit": 5.385544776916504,
            "end_logit": 0.5743259191513062
        },
        {
            "text": "olaparib is the first PARP",
            "probability": 0.0007272583660508305,
            "start_logit": 1.0465706586837769,
            "end_logit": 4.812984943389893
        },
        {
            "text": "homologous recombination (HRD)",
            "probability": 0.0006225842136744301,
            "start_logit": 3.959249496459961,
            "end_logit": 1.7449032068252563
        },
        {
            "text": "BRCA 1",
            "probability": 0.000601987242094077,
            "start_logit": 4.518509387969971,
            "end_logit": 1.1520006656646729
        }
    ],
    "5880be1dc872c95565000007_002": [
        {
            "text": "PARP",
            "probability": 0.8551356473188688,
            "start_logit": 5.880311012268066,
            "end_logit": 6.335646152496338
        },
        {
            "text": "PARP)",
            "probability": 0.07077655128166561,
            "start_logit": 5.880311012268066,
            "end_logit": 3.8439137935638428
        },
        {
            "text": "Poly(ADP-ribose) Polymerase (PARP",
            "probability": 0.022425662596791775,
            "start_logit": 2.2392568588256836,
            "end_logit": 6.335646152496338
        },
        {
            "text": "(ADP-ribose) Polymerase (PARP",
            "probability": 0.009054084869618912,
            "start_logit": 1.332266926765442,
            "end_logit": 6.335646152496338
        },
        {
            "text": "PARP) Inhibitor",
            "probability": 0.006421308726687502,
            "start_logit": 5.880311012268066,
            "end_logit": 1.4440079927444458
        },
        {
            "text": "PARP-",
            "probability": 0.005828273233202904,
            "start_logit": 5.964988708496094,
            "end_logit": 1.262429118156433
        },
        {
            "text": "PARPs",
            "probability": 0.004026396964927847,
            "start_logit": 4.802619934082031,
            "end_logit": 2.0549490451812744
        },
        {
            "text": "PARP-1",
            "probability": 0.003837859313667621,
            "start_logit": 5.964988708496094,
            "end_logit": 0.8446230888366699
        },
        {
            "text": "ADP-ribose) Polymerase (PARP",
            "probability": 0.0034036075350744304,
            "start_logit": 0.35388681292533875,
            "end_logit": 6.335646152496338
        },
        {
            "text": "PARP-1/2",
            "probability": 0.003202219536659372,
            "start_logit": 5.964988708496094,
            "end_logit": 0.6635525226593018
        },
        {
            "text": "Poly(ADP-ribose) Polymerase",
            "probability": 0.002342907251895677,
            "start_logit": 2.2392568588256836,
            "end_logit": 4.0768327713012695
        },
        {
            "text": "(PARP",
            "probability": 0.0022236503790971644,
            "start_logit": -0.07179893553256989,
            "end_logit": 6.335646152496338
        },
        {
            "text": "Poly(ADP-ribose) Polymerase (PARP)",
            "probability": 0.0018560927307656884,
            "start_logit": 2.2392568588256836,
            "end_logit": 3.8439137935638428
        },
        {
            "text": "Poly(ADP-ribose) polymerases (PARP",
            "probability": 0.0018385310187546357,
            "start_logit": 1.9311034679412842,
            "end_logit": 4.1425604820251465
        },
        {
            "text": "PARPs)",
            "probability": 0.0017864632230512373,
            "start_logit": 4.802619934082031,
            "end_logit": 1.2423149347305298
        },
        {
            "text": "Polymerase (PARP",
            "probability": 0.0016799390760452056,
            "start_logit": -0.3521915674209595,
            "end_logit": 6.335646152496338
        },
        {
            "text": "PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination",
            "probability": 0.0014235981549440642,
            "start_logit": 5.880311012268066,
            "end_logit": -0.0624263770878315
        },
        {
            "text": "RP",
            "probability": 0.0009691803818289591,
            "start_logit": -0.9022536277770996,
            "end_logit": 6.335646152496338
        },
        {
            "text": "(ADP-ribose) Polymerase",
            "probability": 0.000945919925832818,
            "start_logit": 1.332266926765442,
            "end_logit": 4.0768327713012695
        },
        {
            "text": "PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.",
            "probability": 0.0008221064806198987,
            "start_logit": 5.880311012268066,
            "end_logit": -0.6114993095397949
        }
    ],
    "5880be1dc872c95565000007_003": [
        {
            "text": "PARP",
            "probability": 0.9415870128966729,
            "start_logit": 6.804709434509277,
            "end_logit": 6.9560980796813965
        },
        {
            "text": "ADP-ribose) polymerase (PARP",
            "probability": 0.02188837728710038,
            "start_logit": 3.135045051574707,
            "end_logit": 6.864151477813721
        },
        {
            "text": "ADP-ribose) polymerase",
            "probability": 0.020117612109894604,
            "start_logit": 3.135045051574707,
            "end_logit": 6.779791355133057
        },
        {
            "text": "PARP)",
            "probability": 0.0021945757066392083,
            "start_logit": 5.851141929626465,
            "end_logit": 1.8480875492095947
        },
        {
            "text": "Poly(ADP-ribose) polymerase (PARP",
            "probability": 0.0018252549160005433,
            "start_logit": 0.6508089303970337,
            "end_logit": 6.864151477813721
        },
        {
            "text": "Poly(ADP-ribose) polymerase",
            "probability": 0.0016775921723268857,
            "start_logit": 0.6508089303970337,
            "end_logit": 6.779791355133057
        },
        {
            "text": "(ADP-ribose) polymerase (PARP",
            "probability": 0.0015840454994443583,
            "start_logit": 0.5090712904930115,
            "end_logit": 6.864151477813721
        },
        {
            "text": "(ADP-ribose) polymerase",
            "probability": 0.0014558965474807666,
            "start_logit": 0.5090712904930115,
            "end_logit": 6.779791355133057
        },
        {
            "text": "ovarian carcinoma. OBJECTIVE: Poly(ADP-ribose) polymerase (PARP",
            "probability": 0.0012242577128593975,
            "start_logit": 0.25142398476600647,
            "end_logit": 6.864151477813721
        },
        {
            "text": "ovarian carcinoma. OBJECTIVE: Poly(ADP-ribose) polymerase",
            "probability": 0.0011252155181173222,
            "start_logit": 0.25142398476600647,
            "end_logit": 6.779791355133057
        },
        {
            "text": "RP",
            "probability": 0.0010065270506678062,
            "start_logit": -0.036351487040519714,
            "end_logit": 6.9560980796813965
        },
        {
            "text": "PARP inhibitor therapy, design future clinical trials and identify ovarian cancer patients most likely to benefit from PARP",
            "probability": 0.0008023926308789348,
            "start_logit": 3.566071033477783,
            "end_logit": 3.1270124912261963
        },
        {
            "text": "PA",
            "probability": 0.0005449205260697362,
            "start_logit": 6.804709434509277,
            "end_logit": -0.49858400225639343
        },
        {
            "text": "polymerase (PARP",
            "probability": 0.0005220851423497901,
            "start_logit": -0.6008353233337402,
            "end_logit": 6.864151477813721
        },
        {
            "text": "polymerase",
            "probability": 0.00047984856274942085,
            "start_logit": -0.6008353233337402,
            "end_logit": 6.779791355133057
        },
        {
            "text": "PARP inhibitor",
            "probability": 0.0004614403010802769,
            "start_logit": 6.804709434509277,
            "end_logit": -0.6648712754249573
        },
        {
            "text": "P-ribose) polymerase (PARP",
            "probability": 0.0004055867071443453,
            "start_logit": -0.8533313274383545,
            "end_logit": 6.864151477813721
        },
        {
            "text": "(PARP",
            "probability": 0.0003907600762729979,
            "start_logit": -0.8905722498893738,
            "end_logit": 6.864151477813721
        },
        {
            "text": "P-ribose) polymerase",
            "probability": 0.00037277482676013684,
            "start_logit": -0.8533313274383545,
            "end_logit": 6.779791355133057
        },
        {
            "text": "the PARP",
            "probability": 0.00033382380949004153,
            "start_logit": -1.139999270439148,
            "end_logit": 6.9560980796813965
        }
    ],
    "5880be1dc872c95565000007_004": [
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose) polymerase",
            "probability": 0.8219361699460119,
            "start_logit": 7.586005210876465,
            "end_logit": 8.031237602233887
        },
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP",
            "probability": 0.09935123436399226,
            "start_logit": 7.586005210876465,
            "end_logit": 5.918236255645752
        },
        {
            "text": "adenosine diphosphate [ADP]-ribose) polymerase",
            "probability": 0.023187786749031422,
            "start_logit": 4.01796817779541,
            "end_logit": 8.031237602233887
        },
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2",
            "probability": 0.019642806135382464,
            "start_logit": 7.586005210876465,
            "end_logit": 4.297286033630371
        },
        {
            "text": "Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase",
            "probability": 0.012232615386771497,
            "start_logit": 3.378448247909546,
            "end_logit": 8.031237602233887
        },
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1",
            "probability": 0.005620243967701849,
            "start_logit": 7.586005210876465,
            "end_logit": 3.045949935913086
        },
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose) polymer",
            "probability": 0.0031510720203154516,
            "start_logit": 7.586005210876465,
            "end_logit": 2.467317581176758
        },
        {
            "text": "adenosine diphosphate [ADP]-ribose) polymerase (PARP",
            "probability": 0.0028028152549079495,
            "start_logit": 4.01796817779541,
            "end_logit": 5.918236255645752
        },
        {
            "text": "PARP",
            "probability": 0.0017814584176985729,
            "start_logit": 3.5647761821746826,
            "end_logit": 5.918236255645752
        },
        {
            "text": "poly(adenosine diphosphate",
            "probability": 0.0016260655896521347,
            "start_logit": 7.586005210876465,
            "end_logit": 1.8057382106781006
        },
        {
            "text": "Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP",
            "probability": 0.0014786129174185637,
            "start_logit": 3.378448247909546,
            "end_logit": 5.918236255645752
        },
        {
            "text": "(adenosine diphosphate [ADP]-ribose) polymerase",
            "probability": 0.0013839186480619312,
            "start_logit": 1.1992615461349487,
            "end_logit": 8.031237602233887
        },
        {
            "text": "ovarian cancer",
            "probability": 0.001309195681387759,
            "start_logit": 4.09270715713501,
            "end_logit": 5.0822858810424805
        },
        {
            "text": "oral poly(adenosine diphosphate [ADP]-ribose) polymerase",
            "probability": 0.0012276082011540874,
            "start_logit": 1.079410195350647,
            "end_logit": 8.031237602233887
        },
        {
            "text": "PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer",
            "probability": 0.0007721951237006621,
            "start_logit": 3.5647761821746826,
            "end_logit": 5.0822858810424805
        },
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose",
            "probability": 0.000610369723743916,
            "start_logit": 7.586005210876465,
            "end_logit": 0.8258844614028931
        },
        {
            "text": "adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2",
            "probability": 0.0005541466800879829,
            "start_logit": 4.01796817779541,
            "end_logit": 4.297286033630371
        },
        {
            "text": "oly(adenosine diphosphate [ADP]-ribose) polymerase",
            "probability": 0.0004930224484954112,
            "start_logit": 0.1671418994665146,
            "end_logit": 8.031237602233887
        },
        {
            "text": "poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor",
            "probability": 0.00045178375112052427,
            "start_logit": 7.586005210876465,
            "end_logit": 0.5250232219696045
        },
        {
            "text": "ase",
            "probability": 0.0003868789933639079,
            "start_logit": -0.07530084252357483,
            "end_logit": 8.031237602233887
        }
    ],
    "5880be1dc872c95565000007_005": [
        {
            "text": "PARP",
            "probability": 0.759606525157654,
            "start_logit": 5.983220100402832,
            "end_logit": 5.2728800773620605
        },
        {
            "text": "PARP Inhibitors Containing Planar Nicotinamide Bioisosteres. PARP",
            "probability": 0.08806443995097228,
            "start_logit": 5.149074554443359,
            "end_logit": 3.952293872833252
        },
        {
            "text": "PARP inhibitors niraparib, olaparib, rucaparib",
            "probability": 0.02685686886236113,
            "start_logit": 5.983220100402832,
            "end_logit": 1.9306011199951172
        },
        {
            "text": "PARP-family ADP-ribosyltransferases (PARP",
            "probability": 0.023291476812496947,
            "start_logit": 4.8736162185668945,
            "end_logit": 2.897770881652832
        },
        {
            "text": "PARP inhibitors niraparib, olaparib, rucaparib, talazoparib",
            "probability": 0.022301640988421044,
            "start_logit": 5.983220100402832,
            "end_logit": 1.7447397708892822
        },
        {
            "text": "PARP inhibitors are important research tools and several are being evaluated in cancer treatment. With the exception of a few tankyrase",
            "probability": 0.016966040063421426,
            "start_logit": 5.378263473510742,
            "end_logit": 2.076249837875366
        },
        {
            "text": "sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP",
            "probability": 0.01064132505018519,
            "start_logit": 1.7151645421981812,
            "end_logit": 5.2728800773620605
        },
        {
            "text": "PARP-family ADP-ribosyltransferases",
            "probability": 0.008645133814659381,
            "start_logit": 4.8736162185668945,
            "end_logit": 1.9066799879074097
        },
        {
            "text": "PARP-family ADP-ribosyltransferases (PARPs)",
            "probability": 0.00840150257525607,
            "start_logit": 4.8736162185668945,
            "end_logit": 1.878093957901001
        },
        {
            "text": "PARPs)",
            "probability": 0.006304099293989479,
            "start_logit": 4.5864057540893555,
            "end_logit": 1.878093957901001
        },
        {
            "text": "PARP inhibitors niraparib, olaparib,",
            "probability": 0.005038298069340062,
            "start_logit": 5.983220100402832,
            "end_logit": 0.2571478486061096
        },
        {
            "text": "PARP-family ADP-ribosyltransferases (PARPs",
            "probability": 0.003663652908290896,
            "start_logit": 4.8736162185668945,
            "end_logit": 1.0481441020965576
        },
        {
            "text": "PARP inhibitors niraparib, olaparib",
            "probability": 0.0032931269993082854,
            "start_logit": 5.983220100402832,
            "end_logit": -0.16808292269706726
        },
        {
            "text": "PARP inhibitors niraparib",
            "probability": 0.002792641522450938,
            "start_logit": 5.983220100402832,
            "end_logit": -0.33293256163597107
        },
        {
            "text": "PARPs",
            "probability": 0.0027490358427790153,
            "start_logit": 4.5864057540893555,
            "end_logit": 1.0481441020965576
        },
        {
            "text": "PARP inhibitors niraparib, olaparib, rucaparib,",
            "probability": 0.0026227952293400316,
            "start_logit": 5.983220100402832,
            "end_logit": -0.39567986130714417
        },
        {
            "text": "seven clinical and commonly used PARP",
            "probability": 0.0024255308511040388,
            "start_logit": 0.23646993935108185,
            "end_logit": 5.2728800773620605
        },
        {
            "text": "PARP inhibitors niraparib,",
            "probability": 0.0024015960837678926,
            "start_logit": 5.983220100402832,
            "end_logit": -0.483786940574646
        },
        {
            "text": "PA",
            "probability": 0.0019702701613428957,
            "start_logit": 5.983220100402832,
            "end_logit": -0.6817498207092285
        },
        {
            "text": "PARP Inhibitors Containing Planar Nicotinamide Bioisosteres. PARP-family",
            "probability": 0.001963999762858468,
            "start_logit": 5.149074554443359,
            "end_logit": 0.14920814335346222
        }
    ],
    "5880be1dc872c95565000007_006": [
        {
            "text": "PARP",
            "probability": 0.956792445868145,
            "start_logit": 6.824049949645996,
            "end_logit": 5.499629497528076
        },
        {
            "text": "PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer",
            "probability": 0.025232327054030817,
            "start_logit": 6.824049949645996,
            "end_logit": 1.8641690015792847
        },
        {
            "text": "PA",
            "probability": 0.0035253263796021506,
            "start_logit": 6.824049949645996,
            "end_logit": -0.10398396849632263
        },
        {
            "text": "PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-",
            "probability": 0.00284932441866701,
            "start_logit": 6.824049949645996,
            "end_logit": -0.31687507033348083
        },
        {
            "text": "Niraparib Slows Ovarian Cancer Progression. Results from a phase III trial indicate that maintenance therapy with the PARP",
            "probability": 0.002622275279309436,
            "start_logit": 0.9245058298110962,
            "end_logit": 5.499629497528076
        },
        {
            "text": "PARP inhibitor",
            "probability": 0.0017054109160195298,
            "start_logit": 6.824049949645996,
            "end_logit": -0.8301509022712708
        },
        {
            "text": "RP",
            "probability": 0.001540278306347136,
            "start_logit": 0.39242658019065857,
            "end_logit": 5.499629497528076
        },
        {
            "text": "Ovarian Cancer Progression. Results from a phase III trial indicate that maintenance therapy with the PARP",
            "probability": 0.0013759561494856305,
            "start_logit": 0.27961233258247375,
            "end_logit": 5.499629497528076
        },
        {
            "text": "PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer.",
            "probability": 0.001357124506608364,
            "start_logit": 6.824049949645996,
            "end_logit": -1.0585888624191284
        },
        {
            "text": "PARP inhibitor niraparib",
            "probability": 0.0009264788166089836,
            "start_logit": 6.824049949645996,
            "end_logit": -1.4403210878372192
        },
        {
            "text": "PARP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive",
            "probability": 0.0008746445932287061,
            "start_logit": 6.824049949645996,
            "end_logit": -1.4978946447372437
        },
        {
            "text": "PARP inhibitor niraparib is more effective than placebo",
            "probability": 0.0005519738152603603,
            "start_logit": 6.824049949645996,
            "end_logit": -1.9582116603851318
        },
        {
            "text": "Slows Ovarian Cancer Progression. Results from a phase III trial indicate that maintenance therapy with the PARP",
            "probability": 0.00019538552734260986,
            "start_logit": -1.6723171472549438,
            "end_logit": 5.499629497528076
        },
        {
            "text": "the PARP",
            "probability": 0.0001841955820513015,
            "start_logit": -1.7312936782836914,
            "end_logit": 5.499629497528076
        },
        {
            "text": "ovarian cancer",
            "probability": 9.665893559697933e-05,
            "start_logit": 1.2593573331832886,
            "end_logit": 1.8641690015792847
        },
        {
            "text": "niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer",
            "probability": 6.471887255583194e-05,
            "start_logit": 0.8582215309143066,
            "end_logit": 1.8641690015792847
        },
        {
            "text": "RP inhibitor niraparib is more effective than placebo in slowing the progression of recurrent platinum-sensitive ovarian cancer",
            "probability": 4.0619892169733475e-05,
            "start_logit": 0.39242658019065857,
            "end_logit": 1.8641690015792847
        },
        {
            "text": "recurrent platinum-sensitive ovarian cancer",
            "probability": 3.448251458940264e-05,
            "start_logit": 0.22862105071544647,
            "end_logit": 1.8641690015792847
        },
        {
            "text": "platinum-sensitive ovarian cancer",
            "probability": 1.938691326214896e-05,
            "start_logit": -0.3472330570220947,
            "end_logit": 1.8641690015792847
        },
        {
            "text": "ovarian cancer. Improved progression-free survival was seen regardless of the presence or absence of germline BRCA",
            "probability": 1.0985659118729428e-05,
            "start_logit": 1.2593573331832886,
            "end_logit": -0.3104289472103119
        }
    ],
    "5880be1dc872c95565000007_007": [
        {
            "text": "poly(ADP-ribose) polymerase",
            "probability": 0.5103795529668336,
            "start_logit": 5.330006122589111,
            "end_logit": 6.583942890167236
        },
        {
            "text": "PARP",
            "probability": 0.136163848941022,
            "start_logit": 5.5035295486450195,
            "end_logit": 5.089123725891113
        },
        {
            "text": "poly(ADP-ribose) polymerase (PARP",
            "probability": 0.11447260149995966,
            "start_logit": 5.330006122589111,
            "end_logit": 5.089123725891113
        },
        {
            "text": "PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2 to the sites of DNA damage. The PARP",
            "probability": 0.045510709313380776,
            "start_logit": 5.5035295486450195,
            "end_logit": 3.9932124614715576
        },
        {
            "text": "PARP1 and PARP2 to the sites of DNA damage. The PARP",
            "probability": 0.027901403178069235,
            "start_logit": 5.014258861541748,
            "end_logit": 3.9932124614715576
        },
        {
            "text": "PARP2 to the sites of DNA damage. The PARP",
            "probability": 0.020704724945594423,
            "start_logit": 4.715943813323975,
            "end_logit": 3.9932124614715576
        },
        {
            "text": "PARP-trapping activity. Although they display similar capacity to inhibit PARP catalytic activity, their relative abilities to trap PARP",
            "probability": 0.01571253352429202,
            "start_logit": 4.875729560852051,
            "end_logit": 3.557523488998413
        },
        {
            "text": "PARP-trapping activity. Although they display similar capacity to inhibit PARP",
            "probability": 0.01563303949015829,
            "start_logit": 4.875729560852051,
            "end_logit": 3.5524513721466064
        },
        {
            "text": "PARP) inhibitors kill cancer cells is by trapping PARP",
            "probability": 0.013766609636533372,
            "start_logit": 5.5035295486450195,
            "end_logit": 2.797510862350464
        },
        {
            "text": "poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP",
            "probability": 0.011573553708892103,
            "start_logit": 5.330006122589111,
            "end_logit": 2.797510862350464
        },
        {
            "text": "PARP inhibitors and PARP",
            "probability": 0.011443818730361044,
            "start_logit": 4.452338695526123,
            "end_logit": 3.663905382156372
        },
        {
            "text": "PARP catalytic activity, their relative abilities to trap PARP",
            "probability": 0.01067905669886835,
            "start_logit": 4.489555358886719,
            "end_logit": 3.557523488998413
        },
        {
            "text": "PARP catalytic activity, their relative abilities to trap PARP differ by several orders of magnitude, with the ability to trap PARP",
            "probability": 0.009779879113163484,
            "start_logit": 4.489555358886719,
            "end_logit": 3.4695661067962646
        },
        {
            "text": "PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2",
            "probability": 0.009489539258954165,
            "start_logit": 5.5035295486450195,
            "end_logit": 2.42545485496521
        },
        {
            "text": "PARP) inhibitors kill cancer cells is by trapping PARP1",
            "probability": 0.008715135938751608,
            "start_logit": 5.5035295486450195,
            "end_logit": 2.3403260707855225
        },
        {
            "text": "PARP differ by several orders of magnitude, with the ability to trap PARP",
            "probability": 0.008238590731346376,
            "start_logit": 4.318057537078857,
            "end_logit": 3.4695661067962646
        },
        {
            "text": "poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP2",
            "probability": 0.007977831520310499,
            "start_logit": 5.330006122589111,
            "end_logit": 2.42545485496521
        },
        {
            "text": "PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP",
            "probability": 0.00789416975180915,
            "start_logit": 5.5035295486450195,
            "end_logit": 2.241389274597168
        },
        {
            "text": "poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1",
            "probability": 0.007326792618551855,
            "start_logit": 5.330006122589111,
            "end_logit": 2.3403260707855225
        },
        {
            "text": "poly(ADP-ribose) polymerase (PARP) inhibitors kill cancer cells is by trapping PARP1 and PARP",
            "probability": 0.0066366084331480535,
            "start_logit": 5.330006122589111,
            "end_logit": 2.241389274597168
        }
    ],
    "5880be1dc872c95565000007_008": [
        {
            "text": "poly-ADP-ribose polymerase (PARP",
            "probability": 0.30033283938028243,
            "start_logit": 6.533368110656738,
            "end_logit": 6.895821571350098
        },
        {
            "text": "poly-ADP-ribose polymerase",
            "probability": 0.22507634430074513,
            "start_logit": 6.533368110656738,
            "end_logit": 6.607369899749756
        },
        {
            "text": "poly-ADP-ribose polymerase (PARP) inhibitors. PARP",
            "probability": 0.18482740798455008,
            "start_logit": 6.533368110656738,
            "end_logit": 6.41035270690918
        },
        {
            "text": "PARP",
            "probability": 0.15192081302091956,
            "start_logit": 5.851836204528809,
            "end_logit": 6.895821571350098
        },
        {
            "text": "PARP) inhibitors. PARP",
            "probability": 0.09349337271109458,
            "start_logit": 5.851836204528809,
            "end_logit": 6.41035270690918
        },
        {
            "text": "PARP inhibition. Olaparib, the first and most extensively investigated PARP",
            "probability": 0.016166573596750358,
            "start_logit": 4.809197425842285,
            "end_logit": 5.698046684265137
        },
        {
            "text": "poly-ADP-ribose polymerase (PARP)",
            "probability": 0.01331950450030881,
            "start_logit": 6.533368110656738,
            "end_logit": 3.7801597118377686
        },
        {
            "text": "PARP)",
            "probability": 0.006737558093540802,
            "start_logit": 5.851836204528809,
            "end_logit": 3.7801597118377686
        },
        {
            "text": "Olaparib, the first and most extensively investigated PARP",
            "probability": 0.0017702167971267444,
            "start_logit": 2.59735369682312,
            "end_logit": 5.698046684265137
        },
        {
            "text": "ADP-ribose polymerase (PARP",
            "probability": 0.0009099694439648938,
            "start_logit": 0.7341325283050537,
            "end_logit": 6.895821571350098
        },
        {
            "text": "ADP-ribose polymerase",
            "probability": 0.0006819520512495994,
            "start_logit": 0.7341325283050537,
            "end_logit": 6.607369899749756
        },
        {
            "text": "poly-ADP-ribose polymer",
            "probability": 0.000657869590943366,
            "start_logit": 6.533368110656738,
            "end_logit": 0.7721816897392273
        },
        {
            "text": "poly-ADP-ribose polymerase (PARP) inhibitors.",
            "probability": 0.0006567722159731176,
            "start_logit": 6.533368110656738,
            "end_logit": 0.7705122232437134
        },
        {
            "text": "poly-ADP-ribose polymerase (",
            "probability": 0.000620601099633373,
            "start_logit": 6.533368110656738,
            "end_logit": 0.7138634920120239
        },
        {
            "text": "PARP inhibitors in late phase clinical development in ovarian cancer including rucaparib,",
            "probability": 0.0005620669411243014,
            "start_logit": 4.012999534606934,
            "end_logit": 3.135164499282837
        },
        {
            "text": "ADP-ribose polymerase (PARP) inhibitors. PARP",
            "probability": 0.0005600030087293062,
            "start_logit": 0.7341325283050537,
            "end_logit": 6.41035270690918
        },
        {
            "text": "oly-ADP-ribose polymerase (PARP",
            "probability": 0.0005245865425277212,
            "start_logit": 0.1833319216966629,
            "end_logit": 6.895821571350098
        },
        {
            "text": "homologous recombination DNA repair pathway. Early studies have shown significant efficacy for PARP",
            "probability": 0.0004401584877993864,
            "start_logit": 1.3068041801452637,
            "end_logit": 5.596873760223389
        },
        {
            "text": "oly-ADP-ribose polymerase",
            "probability": 0.0003931372323624047,
            "start_logit": 0.1833319216966629,
            "end_logit": 6.607369899749756
        },
        {
            "text": "RP",
            "probability": 0.00034825300037413744,
            "start_logit": -0.22634926438331604,
            "end_logit": 6.895821571350098
        }
    ],
    "5880be1dc872c95565000007_009": [
        {
            "text": "PARP",
            "probability": 0.8567808293722944,
            "start_logit": 6.760924816131592,
            "end_logit": 5.6625518798828125
        },
        {
            "text": "PARP-1/PARP",
            "probability": 0.038298400195422584,
            "start_logit": 5.396836280822754,
            "end_logit": 3.9188663959503174
        },
        {
            "text": "BRCA1 or BRCA2 genes, are sensitive to PARP",
            "probability": 0.029073150428903134,
            "start_logit": 4.199777126312256,
            "end_logit": 4.840332508087158
        },
        {
            "text": "BRCA2 genes, are sensitive to PARP",
            "probability": 0.018186309201408374,
            "start_logit": 3.730631113052368,
            "end_logit": 4.840332508087158
        },
        {
            "text": "PARP inhibition. Microsatellite instability",
            "probability": 0.010078255597250037,
            "start_logit": 5.648416042327881,
            "end_logit": 2.332258701324463
        },
        {
            "text": "PARP-1",
            "probability": 0.009353049932262802,
            "start_logit": 5.396836280822754,
            "end_logit": 2.5091607570648193
        },
        {
            "text": "PARP-1/PARP-2",
            "probability": 0.0045664456344996504,
            "start_logit": 5.396836280822754,
            "end_logit": 1.7921934127807617
        },
        {
            "text": "BRCA1",
            "probability": 0.004237817415099296,
            "start_logit": 4.199777126312256,
            "end_logit": 2.9145658016204834
        },
        {
            "text": "SN-38",
            "probability": 0.003847179632312058,
            "start_logit": 2.5564475059509277,
            "end_logit": 4.461187362670898
        },
        {
            "text": "BRCA1 or BRCA2 genes",
            "probability": 0.003371067577209117,
            "start_logit": 4.199777126312256,
            "end_logit": 2.685746908187866
        },
        {
            "text": "PARP inhibition. Microsatellite instability (MSI) accounts for 10-15% of colorectal cancer",
            "probability": 0.0033659481225496637,
            "start_logit": 5.648416042327881,
            "end_logit": 1.2355881929397583
        },
        {
            "text": "irinotecan (or SN-38",
            "probability": 0.0026232752379728766,
            "start_logit": 2.1735308170318604,
            "end_logit": 4.461187362670898
        },
        {
            "text": "BRCA1 or BRCA2 genes, are sensitive to PARP inhibition. Microsatellite instability",
            "probability": 0.00236727919296939,
            "start_logit": 4.199777126312256,
            "end_logit": 2.332258701324463
        },
        {
            "text": "BRCA1 or BRCA2",
            "probability": 0.0023335353244119863,
            "start_logit": 4.199777126312256,
            "end_logit": 2.317901849746704
        },
        {
            "text": "PARP-2",
            "probability": 0.002314288919296641,
            "start_logit": 4.717203617095947,
            "end_logit": 1.7921934127807617
        },
        {
            "text": "BRCA2 genes",
            "probability": 0.002108724936703758,
            "start_logit": 3.730631113052368,
            "end_logit": 2.685746908187866
        },
        {
            "text": "PARP-1/PARP-",
            "probability": 0.002098045061711674,
            "start_logit": 5.396836280822754,
            "end_logit": 1.014464259147644
        },
        {
            "text": "PARP-",
            "probability": 0.0020558683800415136,
            "start_logit": 5.396836280822754,
            "end_logit": 0.9941565990447998
        },
        {
            "text": "BRCA2 genes, are sensitive to PARP inhibition. Microsatellite instability",
            "probability": 0.0014808189251688906,
            "start_logit": 3.730631113052368,
            "end_logit": 2.332258701324463
        },
        {
            "text": "BRCA2",
            "probability": 0.0014597109125117367,
            "start_logit": 3.730631113052368,
            "end_logit": 2.317901849746704
        }
    ],
    "58a8903b38c171fb5b000006_000": [
        {
            "text": "HMG-CoA reductase",
            "probability": 0.3421957800389215,
            "start_logit": 3.5735044479370117,
            "end_logit": 3.4869234561920166
        },
        {
            "text": "HMG-CoA reductase inhibitor lovastatin",
            "probability": 0.13187083431771804,
            "start_logit": 3.5735044479370117,
            "end_logit": 2.5333633422851562
        },
        {
            "text": "CDK1",
            "probability": 0.11981342383825849,
            "start_logit": 2.9458367824554443,
            "end_logit": 3.0651438236236572
        },
        {
            "text": "lovastatin",
            "probability": 0.10392338664251449,
            "start_logit": 3.3353354930877686,
            "end_logit": 2.5333633422851562
        },
        {
            "text": "G phase using the HMG-CoA reductase",
            "probability": 0.0711242925006206,
            "start_logit": 2.0025503635406494,
            "end_logit": 3.4869234561920166
        },
        {
            "text": "CDK",
            "probability": 0.04946688137209464,
            "start_logit": 2.9458367824554443,
            "end_logit": 2.180511474609375
        },
        {
            "text": "HMG-CoA reductase inhibitor lovastatin, S phase",
            "probability": 0.03730729472987468,
            "start_logit": 3.5735044479370117,
            "end_logit": 1.2707293033599854
        },
        {
            "text": "lovastatin, S phase",
            "probability": 0.029400742285878488,
            "start_logit": 3.3353354930877686,
            "end_logit": 1.2707293033599854
        },
        {
            "text": "G phase",
            "probability": 0.027932274587933743,
            "start_logit": 2.0025503635406494,
            "end_logit": 2.5522773265838623
        },
        {
            "text": "G phase using the HMG-CoA reductase inhibitor lovastatin",
            "probability": 0.027408928863025313,
            "start_logit": 2.0025503635406494,
            "end_logit": 2.5333633422851562
        },
        {
            "text": "HMG-CoA",
            "probability": 0.008975792790307921,
            "start_logit": 3.5735044479370117,
            "end_logit": -0.15392830967903137
        },
        {
            "text": "G phase using the HMG-CoA reductase inhibitor lovastatin, S phase",
            "probability": 0.007754201242553789,
            "start_logit": 2.0025503635406494,
            "end_logit": 1.2707293033599854
        },
        {
            "text": "phases of the cell cycle, including G phase using the HMG-CoA reductase",
            "probability": 0.0076522647684392105,
            "start_logit": -0.22687692940235138,
            "end_logit": 3.4869234561920166
        },
        {
            "text": "CDK1 inhibitor RO-3306. Cells can also be enriched in mitosis",
            "probability": 0.007094233675232281,
            "start_logit": 2.9458367824554443,
            "end_logit": 0.23849038779735565
        },
        {
            "text": "HMG-CoA reductase inhibitor lovastatin,",
            "probability": 0.0069717874767590594,
            "start_logit": 3.5735044479370117,
            "end_logit": -0.4065879285335541
        },
        {
            "text": "lovastatin,",
            "probability": 0.0054942532917555435,
            "start_logit": 3.3353354930877686,
            "end_logit": -0.4065879285335541
        },
        {
            "text": "cell cycle, including G phase using the HMG-CoA reductase",
            "probability": 0.0047777758137679425,
            "start_logit": -0.6979034543037415,
            "end_logit": 3.4869234561920166
        },
        {
            "text": "phase using the HMG-CoA reductase",
            "probability": 0.00395482249134367,
            "start_logit": -0.8869428634643555,
            "end_logit": 3.4869234561920166
        },
        {
            "text": "including G phase using the HMG-CoA reductase",
            "probability": 0.0035536709639038275,
            "start_logit": -0.9938974380493164,
            "end_logit": 3.4869234561920166
        },
        {
            "text": "different phases of the cell cycle, including G phase using the HMG-CoA reductase",
            "probability": 0.0033273583090968795,
            "start_logit": -1.0596998929977417,
            "end_logit": 3.4869234561920166
        }
    ],
    "58a8903b38c171fb5b000006_001": [
        {
            "text": "SAC",
            "probability": 0.39370607733839363,
            "start_logit": 4.489324569702148,
            "end_logit": 4.916624069213867
        },
        {
            "text": "spindle assembly checkpoint (SAC",
            "probability": 0.2574688268742142,
            "start_logit": 4.0646185874938965,
            "end_logit": 4.916624069213867
        },
        {
            "text": "spindle assembly checkpoint",
            "probability": 0.11404872524838736,
            "start_logit": 4.0646185874938965,
            "end_logit": 4.102351188659668
        },
        {
            "text": "SAC)",
            "probability": 0.11307693773012531,
            "start_logit": 4.489324569702148,
            "end_logit": 3.6690878868103027
        },
        {
            "text": "spindle assembly checkpoint (SAC)",
            "probability": 0.07394802412176227,
            "start_logit": 4.0646185874938965,
            "end_logit": 3.6690878868103027
        },
        {
            "text": "(SAC",
            "probability": 0.00704129688692542,
            "start_logit": 0.46551230549812317,
            "end_logit": 4.916624069213867
        },
        {
            "text": "spindle assembly",
            "probability": 0.006824218629992394,
            "start_logit": 4.0646185874938965,
            "end_logit": 1.2862032651901245
        },
        {
            "text": "SAC) prevents the occurrence of abnormal divisions by halting the metaphase to anaphase",
            "probability": 0.006543781208732412,
            "start_logit": 4.489324569702148,
            "end_logit": 0.8195345997810364
        },
        {
            "text": "the spindle assembly checkpoint (SAC",
            "probability": 0.005614991033865701,
            "start_logit": 0.23915992677211761,
            "end_logit": 4.916624069213867
        },
        {
            "text": "spindle assembly checkpoint (SAC) prevents the occurrence of abnormal divisions by halting the metaphase to anaphase",
            "probability": 0.0042793844649894625,
            "start_logit": 4.0646185874938965,
            "end_logit": 0.8195345997810364
        },
        {
            "text": "spindle",
            "probability": 0.003463582959819165,
            "start_logit": 4.0646185874938965,
            "end_logit": 0.6080290079116821
        },
        {
            "text": "the spindle assembly checkpoint",
            "probability": 0.002487223705751241,
            "start_logit": 0.23915992677211761,
            "end_logit": 4.102351188659668
        },
        {
            "text": "(SAC)",
            "probability": 0.0020223418825659717,
            "start_logit": 0.46551230549812317,
            "end_logit": 3.6690878868103027
        },
        {
            "text": "Spindle Assembly Checkpoint",
            "probability": 0.001926179792278443,
            "start_logit": 2.300496816635132,
            "end_logit": 1.7853858470916748
        },
        {
            "text": "the spindle assembly checkpoint (SAC)",
            "probability": 0.0016126903495724291,
            "start_logit": 0.23915992677211761,
            "end_logit": 3.6690878868103027
        },
        {
            "text": "C",
            "probability": 0.0014976970352022169,
            "start_logit": -1.0823514461517334,
            "end_logit": 4.916624069213867
        },
        {
            "text": "checkpoint (SAC",
            "probability": 0.0013923862820171275,
            "start_logit": -1.1552610397338867,
            "end_logit": 4.916624069213867
        },
        {
            "text": "SAC) prevents the occurrence of abnormal divisions",
            "probability": 0.0010389494052523642,
            "start_logit": 4.489324569702148,
            "end_logit": -1.02077054977417
        },
        {
            "text": "SAC) prevents the occurrence of abnormal divisions by halting the metaphase",
            "probability": 0.0010076841396807648,
            "start_logit": 4.489324569702148,
            "end_logit": -1.051325798034668
        },
        {
            "text": ", the spindle assembly checkpoint (SAC",
            "probability": 0.000999000910472216,
            "start_logit": -1.4872796535491943,
            "end_logit": 4.916624069213867
        }
    ],
    "58a8903b38c171fb5b000006_002": [
        {
            "text": "mitosis. Here, we show that PML is phosphorylated at T409",
            "probability": 0.1625519527204815,
            "start_logit": 1.9032340049743652,
            "end_logit": 2.801926612854004
        },
        {
            "text": "PML p409) in a mitosis-specific manner. More importantly, PML p409",
            "probability": 0.08508905126523558,
            "start_logit": 2.2275326251983643,
            "end_logit": 1.8303287029266357
        },
        {
            "text": "PML p409)",
            "probability": 0.07979775299556201,
            "start_logit": 2.2275326251983643,
            "end_logit": 1.7661256790161133
        },
        {
            "text": "phosphorylated at T409",
            "probability": 0.06776027324259194,
            "start_logit": 1.0282124280929565,
            "end_logit": 2.801926612854004
        },
        {
            "text": "mitosis",
            "probability": 0.06063183565996585,
            "start_logit": 1.76164710521698,
            "end_logit": 1.9573359489440918
        },
        {
            "text": "PML p409",
            "probability": 0.059449251100999155,
            "start_logit": 2.2275326251983643,
            "end_logit": 1.4717533588409424
        },
        {
            "text": "mitosis. Here, we show that PML is phosphorylated at T409 (PML p409)",
            "probability": 0.05769651227721525,
            "start_logit": 1.9032340049743652,
            "end_logit": 1.7661256790161133
        },
        {
            "text": "PML",
            "probability": 0.0524603715457124,
            "start_logit": 1.7239340543746948,
            "end_logit": 1.8502869606018066
        },
        {
            "text": "PML is phosphorylated at T409",
            "probability": 0.05115855908900024,
            "start_logit": 0.7471661567687988,
            "end_logit": 2.801926612854004
        },
        {
            "text": "mitosis. Here, we show that PML is phosphorylated at T409 (PML p409",
            "probability": 0.04298384750521499,
            "start_logit": 1.9032340049743652,
            "end_logit": 1.4717533588409424
        },
        {
            "text": "T409",
            "probability": 0.04140109027917382,
            "start_logit": 0.5355435609817505,
            "end_logit": 2.801926612854004
        },
        {
            "text": "mitosis. Here, we show that PML",
            "probability": 0.03748686551707065,
            "start_logit": 1.9032340049743652,
            "end_logit": 1.3349195718765259
        },
        {
            "text": "PML, which contributed to explore the role of PML",
            "probability": 0.0316284584652543,
            "start_logit": 1.7239340543746948,
            "end_logit": 1.3442862033843994
        },
        {
            "text": "PML in mitosis. Here, we show that PML is phosphorylated at T409",
            "probability": 0.028203557367523755,
            "start_logit": 0.1516844630241394,
            "end_logit": 2.801926612854004
        },
        {
            "text": "PML p409) in a mitosis",
            "probability": 0.02760574446507947,
            "start_logit": 2.2275326251983643,
            "end_logit": 0.7046542167663574
        },
        {
            "text": "mitosis-specific manner. More importantly, PML p409",
            "probability": 0.026083633216323544,
            "start_logit": 1.0451422929763794,
            "end_logit": 1.8303287029266357
        },
        {
            "text": "mitosis. Here, we show that PML is phosphorylated at T409 (PML",
            "probability": 0.02576304772374173,
            "start_logit": 1.9032340049743652,
            "end_logit": 0.9598701596260071
        },
        {
            "text": "phosphorylated at T409 (PML p409)",
            "probability": 0.024050965685852792,
            "start_logit": 1.0282124280929565,
            "end_logit": 1.7661256790161133
        },
        {
            "text": "PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis",
            "probability": 0.02003890951848673,
            "start_logit": 1.2085224390029907,
            "end_logit": 1.4033163785934448
        },
        {
            "text": "PML is phosphorylated at T409 (PML p409)",
            "probability": 0.018158320359514413,
            "start_logit": 0.7471661567687988,
            "end_logit": 1.7661256790161133
        }
    ],
    "58a8903b38c171fb5b000006_003": [
        {
            "text": "RACK1",
            "probability": 0.5417136774077539,
            "start_logit": 7.585979461669922,
            "end_logit": 6.625150680541992
        },
        {
            "text": "RACK1)",
            "probability": 0.36478424631915346,
            "start_logit": 7.585979461669922,
            "end_logit": 6.229719161987305
        },
        {
            "text": "RACK",
            "probability": 0.01904780515742794,
            "start_logit": 7.585979461669922,
            "end_logit": 3.27736496925354
        },
        {
            "text": "(RACK1",
            "probability": 0.016338932285683932,
            "start_logit": 4.084792613983154,
            "end_logit": 6.625150680541992
        },
        {
            "text": ", receptor for activated C kinase 1 (RACK1",
            "probability": 0.011553614962036494,
            "start_logit": 3.7382402420043945,
            "end_logit": 6.625150680541992
        },
        {
            "text": "(RACK1)",
            "probability": 0.011002463751725804,
            "start_logit": 4.084792613983154,
            "end_logit": 6.229719161987305
        },
        {
            "text": "RACK1),",
            "probability": 0.008305279509572995,
            "start_logit": 7.585979461669922,
            "end_logit": 2.4473044872283936
        },
        {
            "text": "receptor for activated C kinase 1 (RACK1",
            "probability": 0.008277234820096561,
            "start_logit": 3.4047508239746094,
            "end_logit": 6.625150680541992
        },
        {
            "text": ", receptor for activated C kinase 1 (RACK1)",
            "probability": 0.007780081806972392,
            "start_logit": 3.7382402420043945,
            "end_logit": 6.229719161987305
        },
        {
            "text": "receptor for activated C kinase 1 (RACK1)",
            "probability": 0.005573802160403711,
            "start_logit": 3.4047508239746094,
            "end_logit": 6.229719161987305
        },
        {
            "text": ", receptor for activated C kinase 1",
            "probability": 0.0013000116460814078,
            "start_logit": 3.7382402420043945,
            "end_logit": 4.440525531768799
        },
        {
            "text": "RACK1), was chosen as a viable option, and its capacity to bind Lck",
            "probability": 0.0010326227379721634,
            "start_logit": 7.585979461669922,
            "end_logit": 0.36251500248908997
        },
        {
            "text": "receptor for activated C kinase 1",
            "probability": 0.0009313536671278665,
            "start_logit": 3.4047508239746094,
            "end_logit": 4.440525531768799
        },
        {
            "text": "(RACK",
            "probability": 0.0005745116131226218,
            "start_logit": 4.084792613983154,
            "end_logit": 3.27736496925354
        },
        {
            "text": ", receptor for activated C kinase 1 (RACK",
            "probability": 0.0004062496773460003,
            "start_logit": 3.7382402420043945,
            "end_logit": 3.27736496925354
        },
        {
            "text": "RA",
            "probability": 0.0003586709654764942,
            "start_logit": 7.585979461669922,
            "end_logit": -0.6949367523193359
        },
        {
            "text": "receptor for activated C kinase 1 (RACK",
            "probability": 0.00029104518248447797,
            "start_logit": 3.4047508239746094,
            "end_logit": 3.27736496925354
        },
        {
            "text": "(RACK1),",
            "probability": 0.0002505002276663009,
            "start_logit": 4.084792613983154,
            "end_logit": 2.4473044872283936
        },
        {
            "text": "adaptor protein, receptor for activated C kinase 1 (RACK1",
            "probability": 0.0002468688399247088,
            "start_logit": -0.10765622556209564,
            "end_logit": 6.625150680541992
        },
        {
            "text": ")",
            "probability": 0.00023102726197071533,
            "start_logit": 0.22145383059978485,
            "end_logit": 6.229719161987305
        }
    ],
    "58a8903b38c171fb5b000006_004": [
        {
            "text": "Zinc finger",
            "probability": 0.43935852195365405,
            "start_logit": 3.106004476547241,
            "end_logit": 1.6607685089111328
        },
        {
            "text": "kinetochores",
            "probability": 0.12700608485166537,
            "start_logit": 1.8597749471664429,
            "end_logit": 1.6659172773361206
        },
        {
            "text": "Zfp207 is a Bub3 binding protein regulating meiotic chromosome alignment in mouse oocytes. Zinc finger",
            "probability": 0.07677299193375206,
            "start_logit": 1.3615416288375854,
            "end_logit": 1.6607685089111328
        },
        {
            "text": "chromosome alignment in mouse oocytes. Zinc finger",
            "probability": 0.051375828134848825,
            "start_logit": 0.9598565101623535,
            "end_logit": 1.6607685089111328
        },
        {
            "text": "meiotic chromosome alignment in mouse oocytes. Zinc finger",
            "probability": 0.031957524034944354,
            "start_logit": 0.48509636521339417,
            "end_logit": 1.6607685089111328
        },
        {
            "text": "Zfp207 localizes at the kinetochores",
            "probability": 0.0305474899530332,
            "start_logit": 0.4348224699497223,
            "end_logit": 1.6659172773361206
        },
        {
            "text": "Zinc finger proteins are a massive, diverse family of proteins that serve a wide variety of biological functions.",
            "probability": 0.02916023619766062,
            "start_logit": 3.106004476547241,
            "end_logit": -1.0517412424087524
        },
        {
            "text": "Bub3 binding protein regulating meiotic chromosome alignment in mouse oocytes. Zinc finger",
            "probability": 0.029011667246456742,
            "start_logit": 0.3883867859840393,
            "end_logit": 1.6607685089111328
        },
        {
            "text": "Zinc finger proteins",
            "probability": 0.02772566898870492,
            "start_logit": 3.106004476547241,
            "end_logit": -1.1021885871887207
        },
        {
            "text": "Zfp207 is a Bub3 binding protein regulating meiotic chromosome alignment",
            "probability": 0.024297126610072557,
            "start_logit": 1.3615416288375854,
            "end_logit": 0.5102736949920654
        },
        {
            "text": "meiosis are not yet clearly defined. Here, we report that Zfp207 localizes at the kinetochores",
            "probability": 0.020390366967912358,
            "start_logit": 0.030602531507611275,
            "end_logit": 1.6659172773361206
        },
        {
            "text": "chromosome alignment",
            "probability": 0.016259428862260616,
            "start_logit": 0.9598565101623535,
            "end_logit": 0.5102736949920654
        },
        {
            "text": "kinetochores during mouse oocyte meiotic maturation. Depletion of Zfp207",
            "probability": 0.015142869157011239,
            "start_logit": 1.8597749471664429,
            "end_logit": -0.46078798174858093
        },
        {
            "text": "the kinetochores",
            "probability": 0.014541028444632485,
            "start_logit": -0.3074858486652374,
            "end_logit": 1.6659172773361206
        },
        {
            "text": "mouse oocytes. Zinc finger",
            "probability": 0.013964466130146817,
            "start_logit": -0.34279531240463257,
            "end_logit": 1.6607685089111328
        },
        {
            "text": "SAC",
            "probability": 0.01359353253873747,
            "start_logit": 0.8679249286651611,
            "end_logit": 0.4231264293193817
        },
        {
            "text": "Zfp207",
            "probability": 0.01020626793427189,
            "start_logit": 1.3615416288375854,
            "end_logit": -0.3570823669433594
        },
        {
            "text": "meiotic chromosome alignment",
            "probability": 0.010113921420328471,
            "start_logit": 0.48509636521339417,
            "end_logit": 0.5102736949920654
        },
        {
            "text": "SAC (Spindle Assembly Checkpoint",
            "probability": 0.009393362364423131,
            "start_logit": 0.8679249286651611,
            "end_logit": 0.05353560671210289
        },
        {
            "text": "Bub3 binding protein regulating meiotic chromosome alignment",
            "probability": 0.00918161627548289,
            "start_logit": 0.3883867859840393,
            "end_logit": 0.5102736949920654
        }
    ],
    "587e07023ec846c24f000001_000": [
        {
            "text": "phyluce",
            "probability": 0.28713727171179654,
            "start_logit": 2.9342644214630127,
            "end_logit": 1.503473162651062
        },
        {
            "text": "Python",
            "probability": 0.2848786729473972,
            "start_logit": 2.6690964698791504,
            "end_logit": 1.7607440948486328
        },
        {
            "text": "phyluce)",
            "probability": 0.06146715956102572,
            "start_logit": 2.9342644214630127,
            "end_logit": -0.03798419609665871
        },
        {
            "text": "phyluce) for the Anaconda Python",
            "probability": 0.04605100539382727,
            "start_logit": 1.1847760677337646,
            "end_logit": 1.42275071144104
        },
        {
            "text": "PHYLUCE",
            "probability": 0.03897863857388192,
            "start_logit": 1.9073963165283203,
            "end_logit": 0.5333946347236633
        },
        {
            "text": "phyluce).",
            "probability": 0.03796384658290752,
            "start_logit": 2.9342644214630127,
            "end_logit": -0.5198529362678528
        },
        {
            "text": "PHYLUCE is written for Python",
            "probability": 0.029764745441567275,
            "start_logit": 0.4103577435016632,
            "end_logit": 1.7607440948486328
        },
        {
            "text": "phyluce). The software manual and a tutorial are available from http://phyluce",
            "probability": 0.028693886887102286,
            "start_logit": 2.9342644214630127,
            "end_logit": -0.7998031377792358
        },
        {
            "text": "Python 2.7",
            "probability": 0.025130664631911173,
            "start_logit": 2.6690964698791504,
            "end_logit": -0.667230486869812
        },
        {
            "text": "PHYLUCE is also available as a package (https://binstar.org/faircloth-lab/phyluce",
            "probability": 0.024524037416749512,
            "start_logit": 0.9210983514785767,
            "end_logit": 1.0563325881958008
        },
        {
            "text": "Anaconda Python",
            "probability": 0.01892391582252598,
            "start_logit": 0.2954529821872711,
            "end_logit": 1.42275071144104
        },
        {
            "text": "phyluce). The software manual and a tutorial are available from http://phyluce.",
            "probability": 0.015365999459933421,
            "start_logit": 2.9342644214630127,
            "end_logit": -1.4243299961090088
        },
        {
            "text": "Python 2.7.",
            "probability": 0.015314240414477398,
            "start_logit": 2.6690964698791504,
            "end_logit": -1.1625361442565918
        },
        {
            "text": "faircloth-lab/phyluce) for the Anaconda Python",
            "probability": 0.015050011183801455,
            "start_logit": 0.06640520691871643,
            "end_logit": 1.42275071144104
        },
        {
            "text": "OSX",
            "probability": 0.013438833266270883,
            "start_logit": 0.16013924777507782,
            "end_logit": 1.2157864570617676
        },
        {
            "text": "PHYLUCE is a software package for the analysis of conserved genomic loci",
            "probability": 0.013261915829656232,
            "start_logit": 1.9073963165283203,
            "end_logit": -0.5447226762771606
        },
        {
            "text": "BSD-style license from https://www.github.com/faircloth-lab/phyluce",
            "probability": 0.012544569038943965,
            "start_logit": 0.41006290912628174,
            "end_logit": 0.897002100944519
        },
        {
            "text": "Python 2",
            "probability": 0.011058055340410093,
            "start_logit": 2.6690964698791504,
            "end_logit": -1.4881601333618164
        },
        {
            "text": "faircloth-lab/phyluce",
            "probability": 0.010432861780079508,
            "start_logit": 0.06640520691871643,
            "end_logit": 1.0563325881958008
        },
        {
            "text": "iPlant Atmosphere (tag: phyluce",
            "probability": 0.01001966871573463,
            "start_logit": -0.4211459457874298,
            "end_logit": 1.503473162651062
        }
    ],
    "58a2e5f760087bc10a000007_000": [
        {
            "text": "alpha-synuclein",
            "probability": 0.9927890107952064,
            "start_logit": 9.651569366455078,
            "end_logit": 8.98488998413086
        },
        {
            "text": "alpha-synuclein (AS",
            "probability": 0.0037060020297784786,
            "start_logit": 9.651569366455078,
            "end_logit": 3.3943254947662354
        },
        {
            "text": "alpha-synuclein fibrils. The protein alpha-synuclein",
            "probability": 0.0009624025518836256,
            "start_logit": 2.71272873878479,
            "end_logit": 8.98488998413086
        },
        {
            "text": "synuclein",
            "probability": 0.0008349002164841269,
            "start_logit": 2.570608139038086,
            "end_logit": 8.98488998413086
        },
        {
            "text": "alpha-synuclein (AS) is the primary fibrillar component of Lewy bodies",
            "probability": 0.00042716501918120287,
            "start_logit": 9.651569366455078,
            "end_logit": 1.233786940574646
        },
        {
            "text": "alpha-synuclein (AS)",
            "probability": 0.000386731779080364,
            "start_logit": 9.651569366455078,
            "end_logit": 1.134347915649414
        },
        {
            "text": "alpha",
            "probability": 0.0003600262098148038,
            "start_logit": 9.651569366455078,
            "end_logit": 1.0627933740615845
        },
        {
            "text": "alpha-synuclein (AS) is the primary fibrillar",
            "probability": 0.00019127834684319427,
            "start_logit": 9.651569366455078,
            "end_logit": 0.43034622073173523
        },
        {
            "text": "lein",
            "probability": 0.00010716779131108003,
            "start_logit": 0.5176916718482971,
            "end_logit": 8.98488998413086
        },
        {
            "text": "alpha-",
            "probability": 8.462644915104966e-05,
            "start_logit": 9.651569366455078,
            "end_logit": -0.38513660430908203
        },
        {
            "text": "-synuclein",
            "probability": 8.172849444621773e-05,
            "start_logit": 0.24669863283634186,
            "end_logit": 8.98488998413086
        },
        {
            "text": "The protein alpha-synuclein",
            "probability": 3.426953699127563e-05,
            "start_logit": -0.6224472522735596,
            "end_logit": 8.98488998413086
        },
        {
            "text": "NMR spectra of alpha-synuclein fibrils. The protein alpha-synuclein",
            "probability": 2.6015904669583702e-05,
            "start_logit": -0.8979960083961487,
            "end_logit": 8.98488998413086
        },
        {
            "text": "alpha-synuclein fibrils. The protein alpha-synuclein (AS",
            "probability": 3.5925718072643323e-06,
            "start_logit": 2.71272873878479,
            "end_logit": 3.3943254947662354
        },
        {
            "text": "synuclein (AS",
            "probability": 3.116615779695539e-06,
            "start_logit": 2.570608139038086,
            "end_logit": 3.3943254947662354
        },
        {
            "text": "Parkinson's disease. Wild-type human AS and the three",
            "probability": 4.639614815048244e-07,
            "start_logit": 2.8727285861968994,
            "end_logit": 1.1875035762786865
        },
        {
            "text": "lein (AS",
            "probability": 4.000487997017791e-07,
            "start_logit": 0.5176916718482971,
            "end_logit": 3.3943254947662354
        },
        {
            "text": "alpha-synuclein fibrils. The protein alpha-synuclein (AS)",
            "probability": 3.7489501498744223e-07,
            "start_logit": 2.71272873878479,
            "end_logit": 1.134347915649414
        },
        {
            "text": "AS",
            "probability": 3.675517004290969e-07,
            "start_logit": 0.4329691231250763,
            "end_logit": 3.3943254947662354
        },
        {
            "text": "synuclein (AS) is the primary fibrillar component of Lewy bodies",
            "probability": 3.5923057478564353e-07,
            "start_logit": 2.570608139038086,
            "end_logit": 1.233786940574646
        }
    ],
    "58a2e5f760087bc10a000007_001": [
        {
            "text": "alpha-synuclein",
            "probability": 0.9934822748018806,
            "start_logit": 9.939453125,
            "end_logit": 9.308858871459961
        },
        {
            "text": "alpha-synuclein, a highly conserved 140 amino acid protein that is predominantly expressed in neurons",
            "probability": 0.003122343528121192,
            "start_logit": 9.939453125,
            "end_logit": 3.5462265014648438
        },
        {
            "text": "alpha-synuclein, a highly conserved 140",
            "probability": 0.0007493415148180188,
            "start_logit": 9.939453125,
            "end_logit": 2.11908221244812
        },
        {
            "text": "synuclein",
            "probability": 0.000445828325406561,
            "start_logit": 2.2304155826568604,
            "end_logit": 9.308858871459961
        },
        {
            "text": "Lewy bodies. The primary structural component of Lewy bodies are fibrils composed primarily of alpha-synuclein",
            "probability": 0.0003911935204139307,
            "start_logit": 2.099684000015259,
            "end_logit": 9.308858871459961
        },
        {
            "text": "Parkinson's disease (PD)",
            "probability": 0.00029320598895511365,
            "start_logit": 5.764679908752441,
            "end_logit": 5.355535984039307
        },
        {
            "text": "alpha",
            "probability": 0.0002838253362327612,
            "start_logit": 9.939453125,
            "end_logit": 1.14824640750885
        },
        {
            "text": "Parkinson's disease",
            "probability": 0.00027764235930589145,
            "start_logit": 5.764679908752441,
            "end_logit": 5.300994396209717
        },
        {
            "text": "alpha-synuclein for the treatment of Parkinson's disease. Parkinson's disease (PD)",
            "probability": 0.00018045137805218378,
            "start_logit": 5.279265880584717,
            "end_logit": 5.355535984039307
        },
        {
            "text": "alpha-synuclein for the treatment of Parkinson's disease. Parkinson's disease",
            "probability": 0.00017087286150242148,
            "start_logit": 5.279265880584717,
            "end_logit": 5.300994396209717
        },
        {
            "text": "alpha-",
            "probability": 0.00013315945601312577,
            "start_logit": 9.939453125,
            "end_logit": 0.3914346992969513
        },
        {
            "text": "Lewy bodies are fibrils composed primarily of alpha-synuclein",
            "probability": 0.00012785230246579188,
            "start_logit": 0.9813573360443115,
            "end_logit": 9.308858871459961
        },
        {
            "text": "-synuclein",
            "probability": 9.971469683665138e-05,
            "start_logit": 0.7327947020530701,
            "end_logit": 9.308858871459961
        },
        {
            "text": "alpha-synuclein,",
            "probability": 8.818343456011893e-05,
            "start_logit": 9.939453125,
            "end_logit": -0.020693499594926834
        },
        {
            "text": "lein",
            "probability": 6.072409535985382e-05,
            "start_logit": 0.2368222028017044,
            "end_logit": 9.308858871459961
        },
        {
            "text": "Parkinson's disease. Parkinson's disease (PD)",
            "probability": 2.565932355346851e-05,
            "start_logit": 3.32871150970459,
            "end_logit": 5.355535984039307
        },
        {
            "text": "Parkinson's disease. Parkinson's disease",
            "probability": 2.4297304277331268e-05,
            "start_logit": 3.32871150970459,
            "end_logit": 5.300994396209717
        },
        {
            "text": "PD)",
            "probability": 2.02275706148385e-05,
            "start_logit": 3.090851068496704,
            "end_logit": 5.355535984039307
        },
        {
            "text": "of alpha-synuclein",
            "probability": 1.58839352420048e-05,
            "start_logit": -1.1042101383209229,
            "end_logit": 9.308858871459961
        },
        {
            "text": "neurons",
            "probability": 7.318266387764913e-06,
            "start_logit": 3.8834874629974365,
            "end_logit": 3.5462265014648438
        }
    ],
    "58a2e5f760087bc10a000007_002": [
        {
            "text": "alpha-synuclein",
            "probability": 0.9978881224169638,
            "start_logit": 9.195472717285156,
            "end_logit": 8.57097053527832
        },
        {
            "text": "synuclein",
            "probability": 0.0004367417245344025,
            "start_logit": 1.4614182710647583,
            "end_logit": 8.57097053527832
        },
        {
            "text": "-synuclein",
            "probability": 0.00036205270216992054,
            "start_logit": 1.273866057395935,
            "end_logit": 8.57097053527832
        },
        {
            "text": "alpha",
            "probability": 0.0002557270993634386,
            "start_logit": 9.195472717285156,
            "end_logit": 0.3016849458217621
        },
        {
            "text": "alpha-synuclein, the major protein component of Lewy bodies",
            "probability": 0.0001956805379563713,
            "start_logit": 9.195472717285156,
            "end_logit": 0.034057509154081345
        },
        {
            "text": "alpha-",
            "probability": 0.00019336115709533971,
            "start_logit": 9.195472717285156,
            "end_logit": 0.022133808583021164
        },
        {
            "text": "lein",
            "probability": 0.00018256438186408698,
            "start_logit": 0.5891791582107544,
            "end_logit": 8.57097053527832
        },
        {
            "text": "alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease",
            "probability": 0.00014176919537741485,
            "start_logit": 9.195472717285156,
            "end_logit": -0.28822556138038635
        },
        {
            "text": "alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson'",
            "probability": 8.22882923525416e-05,
            "start_logit": 9.195472717285156,
            "end_logit": -0.8321970701217651
        },
        {
            "text": "alpha-synuclein,",
            "probability": 7.254043256006677e-05,
            "start_logit": 9.195472717285156,
            "end_logit": -0.9582818150520325
        },
        {
            "text": "alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease,",
            "probability": 6.498407467283293e-05,
            "start_logit": 9.195472717285156,
            "end_logit": -1.0682836771011353
        },
        {
            "text": "VAQKTV",
            "probability": 6.224936482532768e-05,
            "start_logit": 4.927357196807861,
            "end_logit": 3.1568379402160645
        },
        {
            "text": "amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein",
            "probability": 3.4678190760959684e-05,
            "start_logit": -1.0718127489089966,
            "end_logit": 8.57097053527832
        },
        {
            "text": "VAQK",
            "probability": 1.7209574602558043e-05,
            "start_logit": 4.927357196807861,
            "end_logit": 1.8711555004119873
        },
        {
            "text": "VAQKTV)",
            "probability": 6.242801238250906e-06,
            "start_logit": 4.927357196807861,
            "end_logit": 0.8571186065673828
        },
        {
            "text": "VAQKTV).",
            "probability": 1.310940936558601e-06,
            "start_logit": 4.927357196807861,
            "end_logit": -0.703565239906311
        },
        {
            "text": "VAQ",
            "probability": 9.98887555454871e-07,
            "start_logit": 4.927357196807861,
            "end_logit": -0.9754234552383423
        },
        {
            "text": "Parkinson's disease",
            "probability": 5.983783223843758e-07,
            "start_logit": 3.7277402877807617,
            "end_logit": -0.28822556138038635
        },
        {
            "text": "N-methylated peptide inhibitor of alpha-synuclein",
            "probability": 5.132586418983882e-07,
            "start_logit": 0.7825063467025757,
            "end_logit": 2.5035650730133057
        },
        {
            "text": "alpha-synuclein aggregation guided by solid-state NMR.",
            "probability": 3.665882063541189e-07,
            "start_logit": 3.1997873783111572,
            "end_logit": -0.2502566874027252
        }
    ],
    "58a2e5f760087bc10a000007_003": [
        {
            "text": "\u03b1-synuclein",
            "probability": 0.9859170550867351,
            "start_logit": 7.822572231292725,
            "end_logit": 8.232690811157227
        },
        {
            "text": "\u03b1-synuclein (AS",
            "probability": 0.003192010172675263,
            "start_logit": 7.822572231292725,
            "end_logit": 2.499769449234009
        },
        {
            "text": "\u03b1-synuclein amyloid fibrils by solid-state NMR. Fibrillar \u03b1-synuclein",
            "probability": 0.003105532027749072,
            "start_logit": 2.062185049057007,
            "end_logit": 8.232690811157227
        },
        {
            "text": "Fibrillar \u03b1-synuclein",
            "probability": 0.0027660473602785225,
            "start_logit": 1.946419358253479,
            "end_logit": 8.232690811157227
        },
        {
            "text": "\u03b1-synuclein (AS)",
            "probability": 0.0019385152650969008,
            "start_logit": 7.822572231292725,
            "end_logit": 2.0010409355163574
        },
        {
            "text": "\u03b1-synuclein (AS) is the major component of Lewy bodies",
            "probability": 0.0008622181325000498,
            "start_logit": 7.822572231292725,
            "end_logit": 1.1908715963363647
        },
        {
            "text": "\u03b1",
            "probability": 0.0003771586626499943,
            "start_logit": 7.822572231292725,
            "end_logit": 0.36402925848960876
        },
        {
            "text": "\u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease. Mouse",
            "probability": 0.00036091139571657854,
            "start_logit": 7.822572231292725,
            "end_logit": 0.31999579071998596
        },
        {
            "text": "synuclein",
            "probability": 0.00032350546820112894,
            "start_logit": -0.19953925907611847,
            "end_logit": 8.232690811157227
        },
        {
            "text": "lein",
            "probability": 0.00021853527297109108,
            "start_logit": -0.5918078422546387,
            "end_logit": 8.232690811157227
        },
        {
            "text": "human \u03b1-synuclein amyloid fibrils by solid-state NMR. Fibrillar \u03b1-synuclein",
            "probability": 0.0001655641065150233,
            "start_logit": -0.8693968057632446,
            "end_logit": 8.232690811157227
        },
        {
            "text": "-synuclein",
            "probability": 0.00012561771552963187,
            "start_logit": -1.1455119848251343,
            "end_logit": 8.232690811157227
        },
        {
            "text": "\u03b1-",
            "probability": 0.00012461769446921344,
            "start_logit": 7.822572231292725,
            "end_logit": -0.7433860898017883
        },
        {
            "text": "\u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease",
            "probability": 9.685218605641106e-05,
            "start_logit": 7.822572231292725,
            "end_logit": -0.9954507350921631
        },
        {
            "text": "\u03b1-synuclein (AS) is the major component of Lewy bodies, the pathological hallmark of Parkinson's disease.",
            "probability": 8.782493109720902e-05,
            "start_logit": 7.822572231292725,
            "end_logit": -1.0932912826538086
        },
        {
            "text": "-synuclein amyloid fibrils by solid-state NMR. Fibrillar \u03b1-synuclein",
            "probability": 8.600188613424013e-05,
            "start_logit": -1.5243860483169556,
            "end_logit": 8.232690811157227
        },
        {
            "text": "solid-state NMR. Fibrillar \u03b1-synuclein",
            "probability": 8.477131188586443e-05,
            "start_logit": -1.5387980937957764,
            "end_logit": 8.232690811157227
        },
        {
            "text": "NMR. Fibrillar \u03b1-synuclein",
            "probability": 8.112914503949028e-05,
            "start_logit": -1.582713007926941,
            "end_logit": 8.232690811157227
        },
        {
            "text": "synuclein amyloid fibrils by solid-state NMR. Fibrillar \u03b1-synuclein",
            "probability": 7.607769209422236e-05,
            "start_logit": -1.6470001935958862,
            "end_logit": 8.232690811157227
        },
        {
            "text": "\u03b1-synuclein amyloid fibrils by solid-state NMR. Fibrillar \u03b1-synuclein (AS",
            "probability": 1.0054486605135154e-05,
            "start_logit": 2.062185049057007,
            "end_logit": 2.499769449234009
        }
    ],
    "58a2e5f760087bc10a000007_004": [
        {
            "text": "\u03b1-synuclein",
            "probability": 0.9153620782752642,
            "start_logit": 6.491480827331543,
            "end_logit": 7.62947940826416
        },
        {
            "text": "\u03b1-synuclein (\u03b1Syn",
            "probability": 0.054521219169245135,
            "start_logit": 6.491480827331543,
            "end_logit": 4.808749675750732
        },
        {
            "text": "\u03b1Syn",
            "probability": 0.015781812664288398,
            "start_logit": 5.251749038696289,
            "end_logit": 4.808749675750732
        },
        {
            "text": "\u03b1-synuclein (\u03b1Syn)",
            "probability": 0.003873544812147898,
            "start_logit": 6.491480827331543,
            "end_logit": 2.164329767227173
        },
        {
            "text": "Aggregation of \u03b1-synuclein",
            "probability": 0.002833839339786332,
            "start_logit": 0.7137935757637024,
            "end_logit": 7.62947940826416
        },
        {
            "text": "\u03b1-synuclein and fibril formation rates by NMR and fluorescence. Aggregation of \u03b1-synuclein",
            "probability": 0.0014735248165658624,
            "start_logit": 0.05981849133968353,
            "end_logit": 7.62947940826416
        },
        {
            "text": "\u03b1Syn)",
            "probability": 0.0011212434260187642,
            "start_logit": 5.251749038696289,
            "end_logit": 2.164329767227173
        },
        {
            "text": "-synuclein",
            "probability": 0.000798128563511534,
            "start_logit": -0.5533244609832764,
            "end_logit": 7.62947940826416
        },
        {
            "text": "synuclein",
            "probability": 0.0007352088713139763,
            "start_logit": -0.6354395151138306,
            "end_logit": 7.62947940826416
        },
        {
            "text": "lein",
            "probability": 0.0007102563525546547,
            "start_logit": -0.6699681878089905,
            "end_logit": 7.62947940826416
        },
        {
            "text": "\u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease",
            "probability": 0.0006997969070102225,
            "start_logit": 6.491480827331543,
            "end_logit": 0.45319458842277527
        },
        {
            "text": "\u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body",
            "probability": 0.0006021431815673136,
            "start_logit": 6.491480827331543,
            "end_logit": 0.30289968848228455
        },
        {
            "text": "\u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease,",
            "probability": 0.00029512262635060196,
            "start_logit": 6.491480827331543,
            "end_logit": -0.41020461916923523
        },
        {
            "text": "\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease",
            "probability": 0.00020256450346792,
            "start_logit": 5.251749038696289,
            "end_logit": 0.45319458842277527
        },
        {
            "text": "\u03b1-",
            "probability": 0.00019245334861095513,
            "start_logit": 6.491480827331543,
            "end_logit": -0.8377417922019958
        },
        {
            "text": "\u03b1Syn), the primary protein component in Lewy body",
            "probability": 0.00017429747598040569,
            "start_logit": 5.251749038696289,
            "end_logit": 0.30289968848228455
        },
        {
            "text": "Syn",
            "probability": 0.0001696524896667015,
            "start_logit": 0.7188877463340759,
            "end_logit": 4.808749675750732
        },
        {
            "text": "Aggregation of \u03b1-synuclein (\u03b1Syn",
            "probability": 0.00016879044850321795,
            "start_logit": 0.7137935757637024,
            "end_logit": 4.808749675750732
        },
        {
            "text": "\u03b1-synuclein (\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson'",
            "probability": 0.0001444355509994468,
            "start_logit": 6.491480827331543,
            "end_logit": -1.1247621774673462
        },
        {
            "text": "\u03b1Syn), the primary protein component in Lewy body inclusions of patients with Parkinson's disease, arises when the normally soluble intrinsically",
            "probability": 0.00013988717714636517,
            "start_logit": 5.251749038696289,
            "end_logit": 0.0829724371433258
        }
    ],
    "58a2e5f760087bc10a000007_005": [
        {
            "text": "Alpha-synuclein",
            "probability": 0.9920139046081607,
            "start_logit": 7.725917816162109,
            "end_logit": 8.090548515319824
        },
        {
            "text": "Alpha-synuclein (alphaS",
            "probability": 0.0024480949918364264,
            "start_logit": 7.725917816162109,
            "end_logit": 2.0861215591430664
        },
        {
            "text": "alpha-synuclein at low pH. Alpha-synuclein",
            "probability": 0.0013766966447325056,
            "start_logit": 1.1458675861358643,
            "end_logit": 8.090548515319824
        },
        {
            "text": "Alpha-synuclein (alphaS)",
            "probability": 0.0010806048933526507,
            "start_logit": 7.725917816162109,
            "end_logit": 1.2683323621749878
        },
        {
            "text": "C-terminal tail of alpha-synuclein at low pH. Alpha-synuclein",
            "probability": 0.0008712311473700162,
            "start_logit": 0.688332736492157,
            "end_logit": 8.090548515319824
        },
        {
            "text": "synuclein",
            "probability": 0.000583372199398848,
            "start_logit": 0.287250816822052,
            "end_logit": 8.090548515319824
        },
        {
            "text": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies",
            "probability": 0.000336617905403152,
            "start_logit": 7.725917816162109,
            "end_logit": 0.10200458765029907
        },
        {
            "text": "lein",
            "probability": 0.0002861482215075803,
            "start_logit": -0.42506465315818787,
            "end_logit": 8.090548515319824
        },
        {
            "text": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease",
            "probability": 0.00027997774236573523,
            "start_logit": 7.725917816162109,
            "end_logit": -0.08223377913236618
        },
        {
            "text": "-synuclein",
            "probability": 0.0002628594343060471,
            "start_logit": -0.5099551677703857,
            "end_logit": 8.090548515319824
        },
        {
            "text": "Alpha",
            "probability": 0.00014587908591203423,
            "start_logit": 7.725917816162109,
            "end_logit": -0.7341657876968384
        },
        {
            "text": "Alpha-synuclein (alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease.",
            "probability": 0.00011873062651002325,
            "start_logit": 7.725917816162109,
            "end_logit": -0.9400866031646729
        },
        {
            "text": "Alpha-synuclein (alpha",
            "probability": 0.00010451687325523119,
            "start_logit": 7.725917816162109,
            "end_logit": -1.067595362663269
        },
        {
            "text": "alphaS",
            "probability": 4.423618238408128e-05,
            "start_logit": 3.712395429611206,
            "end_logit": 2.0861215591430664
        },
        {
            "text": "alphaS)",
            "probability": 1.952613575326187e-05,
            "start_logit": 3.712395429611206,
            "end_logit": 1.2683323621749878
        },
        {
            "text": "alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease. Aggregation of alphaS",
            "probability": 1.0023398311718607e-05,
            "start_logit": 3.712395429611206,
            "end_logit": 0.6015006899833679
        },
        {
            "text": "alphaS) is the primary component of Lewy bodies",
            "probability": 6.082562607585368e-06,
            "start_logit": 3.712395429611206,
            "end_logit": 0.10200458765029907
        },
        {
            "text": "alphaS) is the primary component of Lewy bodies, the pathological hallmark of Parkinson's Disease",
            "probability": 5.0590955482014735e-06,
            "start_logit": 3.712395429611206,
            "end_logit": -0.08223377913236618
        },
        {
            "text": "alpha-synuclein at low pH. Alpha-synuclein (alphaS",
            "probability": 3.397416251518068e-06,
            "start_logit": 1.1458675861358643,
            "end_logit": 2.0861215591430664
        },
        {
            "text": "Parkinson's Disease. Aggregation of alphaS",
            "probability": 3.0408350329469436e-06,
            "start_logit": 2.5196053981781006,
            "end_logit": 0.6015006899833679
        }
    ],
    "589a246078275d0c4a00002a_000": [
        {
            "text": "fingolimod,",
            "probability": 0.30311681235638177,
            "start_logit": 3.634166955947876,
            "end_logit": 2.3431289196014404
        },
        {
            "text": "Dimethyl fumarate (DMF), fingolimod,",
            "probability": 0.1955076924797758,
            "start_logit": 3.195648431777954,
            "end_logit": 2.3431289196014404
        },
        {
            "text": "Dimethyl fumarate",
            "probability": 0.13845219072988801,
            "start_logit": 3.195648431777954,
            "end_logit": 1.9980542659759521
        },
        {
            "text": "fingolimod",
            "probability": 0.07803132818161189,
            "start_logit": 3.634166955947876,
            "end_logit": 0.9861210584640503
        },
        {
            "text": "multiple",
            "probability": 0.05392342364356077,
            "start_logit": 4.634357452392578,
            "end_logit": -0.3836148679256439
        },
        {
            "text": "Dimethyl fumarate (DMF), fingolimod",
            "probability": 0.05032952410433281,
            "start_logit": 3.195648431777954,
            "end_logit": 0.9861210584640503
        },
        {
            "text": "dimethyl fumarate, fingolimod,",
            "probability": 0.032771025547603604,
            "start_logit": 1.9159289598464966,
            "end_logit": 1.8367934226989746
        },
        {
            "text": "oral disease-modifying therapies (dimethyl fumarate, fingolimod,",
            "probability": 0.017551382079083286,
            "start_logit": 1.291516900062561,
            "end_logit": 1.8367934226989746
        },
        {
            "text": "fingolimod, and teriflunomide",
            "probability": 0.01653746326284692,
            "start_logit": 3.634166955947876,
            "end_logit": -0.5653610229492188
        },
        {
            "text": "dimethyl fumarate",
            "probability": 0.013876214604186799,
            "start_logit": 1.9159289598464966,
            "end_logit": 0.9774248600006104
        },
        {
            "text": "Dimethyl fumarate (DMF)",
            "probability": 0.013035729968020318,
            "start_logit": 3.195648431777954,
            "end_logit": -0.36477676033973694
        },
        {
            "text": "Dimethyl fumarate (DMF),",
            "probability": 0.012923225263136953,
            "start_logit": 3.195648431777954,
            "end_logit": -0.37344470620155334
        },
        {
            "text": "dimethyl fumarate,",
            "probability": 0.011525131040180712,
            "start_logit": 1.9159289598464966,
            "end_logit": 0.7917786240577698
        },
        {
            "text": "Dimethyl fumarate (DMF), fingolimod, and teriflunomide",
            "probability": 0.010666519144398076,
            "start_logit": 3.195648431777954,
            "end_logit": -0.5653610229492188
        },
        {
            "text": "teriflunomide",
            "probability": 0.010153466083650529,
            "start_logit": 2.017119884490967,
            "end_logit": 0.5638728737831116
        },
        {
            "text": "fingolimod, and teriflunomide) in relapsing MS",
            "probability": 0.009747672396449959,
            "start_logit": 2.5776143074035645,
            "end_logit": -0.03740815445780754
        },
        {
            "text": "dimethyl fumarate, fingolimod",
            "probability": 0.009509302480929927,
            "start_logit": 1.9159289598464966,
            "end_logit": 0.5995191931724548
        },
        {
            "text": "fingolimod, and teriflunomide)",
            "probability": 0.008252017711654534,
            "start_logit": 2.5776143074035645,
            "end_logit": -0.20397894084453583
        },
        {
            "text": "oral disease-modifying therapies (dimethyl fumarate",
            "probability": 0.007431770604055674,
            "start_logit": 1.291516900062561,
            "end_logit": 0.9774248600006104
        },
        {
            "text": "fingolimod, and teriflunomide are oral disease-modifying therapies",
            "probability": 0.006658108318251475,
            "start_logit": 3.634166955947876,
            "end_logit": -1.475153923034668
        }
    ],
    "589a246078275d0c4a00002a_001": [
        {
            "text": "Teriflunomide Multiple Sclerosis Oral",
            "probability": 0.43044279395580176,
            "start_logit": 3.1634442806243896,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral",
            "probability": 0.18843276568244396,
            "start_logit": 2.3373711109161377,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "Teriflunomide Multiple Sclerosis",
            "probability": 0.12397570619225384,
            "start_logit": 3.1634442806243896,
            "end_logit": 1.403637170791626
        },
        {
            "text": "NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis",
            "probability": 0.05427221810487371,
            "start_logit": 2.3373711109161377,
            "end_logit": 1.403637170791626
        },
        {
            "text": "Multiple Sclerosis Oral",
            "probability": 0.040231116541853684,
            "start_logit": 0.7932705879211426,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "Teriflunomide",
            "probability": 0.02950354095935812,
            "start_logit": 3.1634442806243896,
            "end_logit": -0.03193816915154457
        },
        {
            "text": "(NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral",
            "probability": 0.022995612834217374,
            "start_logit": 0.23393329977989197,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "Sclerosis Oral",
            "probability": 0.016648802987284318,
            "start_logit": -0.08903183043003082,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "NCT00803049) of the pivotal phase 3 Teriflunomide",
            "probability": 0.012915615962124724,
            "start_logit": 2.3373711109161377,
            "end_logit": -0.03193816915154457
        },
        {
            "text": "Multiple Sclerosis",
            "probability": 0.011587326246867815,
            "start_logit": 0.7932705879211426,
            "end_logit": 1.403637170791626
        },
        {
            "text": "phase 3 Teriflunomide Multiple Sclerosis Oral",
            "probability": 0.011447999793707708,
            "start_logit": -0.46355512738227844,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "Teriflunomide Multiple",
            "probability": 0.011417990033778433,
            "start_logit": 3.1634442806243896,
            "end_logit": -0.9812582731246948
        },
        {
            "text": "Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563",
            "probability": 0.01065858991535875,
            "start_logit": 3.1634442806243896,
            "end_logit": -1.0500823259353638
        },
        {
            "text": "(NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis",
            "probability": 0.006623173579573243,
            "start_logit": 0.23393329977989197,
            "end_logit": 1.403637170791626
        },
        {
            "text": "teriflunomide",
            "probability": 0.0053552609082442105,
            "start_logit": 1.3085683584213257,
            "end_logit": 0.11650688946247101
        },
        {
            "text": "NCT00803049) of the pivotal phase 3 Teriflunomide Multiple",
            "probability": 0.004998395770148199,
            "start_logit": 2.3373711109161377,
            "end_logit": -0.9812582731246948
        },
        {
            "text": "Sclerosis",
            "probability": 0.004795171708267039,
            "start_logit": -0.08903183043003082,
            "end_logit": 1.403637170791626
        },
        {
            "text": "riflunomide Multiple Sclerosis Oral",
            "probability": 0.004642513917376431,
            "start_logit": -1.3661141395568848,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "pivotal phase 3 Teriflunomide Multiple Sclerosis Oral",
            "probability": 0.004572089863426033,
            "start_logit": -1.3813997507095337,
            "end_logit": 2.6483659744262695
        },
        {
            "text": "NCT00803049)",
            "probability": 0.004483315043041187,
            "start_logit": 2.3373711109161377,
            "end_logit": -1.090012550354004
        }
    ],
    "589a246078275d0c4a00002a_002": [
        {
            "text": "multiple sclerosis",
            "probability": 0.7778706525057663,
            "start_logit": 5.151679992675781,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "relapsing forms of multiple sclerosis",
            "probability": 0.16772535934817911,
            "start_logit": 3.6174476146698,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "multiple sclerosis (RMS), with reference to clinical efficacy and safety outcomes. METHODS: In September 2012",
            "probability": 0.011601531755155232,
            "start_logit": 3.4836649894714355,
            "end_logit": 2.337846517562866
        },
        {
            "text": "Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis",
            "probability": 0.01040831066357817,
            "start_logit": 0.8377243280410767,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "of multiple sclerosis",
            "probability": 0.0041461165539916755,
            "start_logit": -0.08270813524723053,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "pregnancy",
            "probability": 0.003977164673161874,
            "start_logit": 1.3147424459457397,
            "end_logit": 3.4362010955810547
        },
        {
            "text": "multiple sclerosis.",
            "probability": 0.003588947714929788,
            "start_logit": 5.151679992675781,
            "end_logit": -0.5034465789794922
        },
        {
            "text": "2012",
            "probability": 0.00272952948011661,
            "start_logit": 2.0366570949554443,
            "end_logit": 2.337846517562866
        },
        {
            "text": "forms of multiple sclerosis",
            "probability": 0.0026289913382217408,
            "start_logit": -0.5382800102233887,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "multiple sclerosis. PURPOSE: The purpose was to summarize US prescribing information for teriflunomide",
            "probability": 0.0023548922552368815,
            "start_logit": 5.151679992675781,
            "end_logit": -0.9248106479644775
        },
        {
            "text": "sing forms of multiple sclerosis",
            "probability": 0.0015806427582385758,
            "start_logit": -1.0470486879348755,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "multiple scle",
            "probability": 0.0015401529621261881,
            "start_logit": 5.151679992675781,
            "end_logit": -1.349423885345459
        },
        {
            "text": "once-daily oral medication for the treatment of relapsing forms of multiple sclerosis",
            "probability": 0.0014279665372598786,
            "start_logit": -1.148628830909729,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "Teriflunomide Oral",
            "probability": 0.0014088429159335625,
            "start_logit": 2.3313310146331787,
            "end_logit": 1.3818120956420898
        },
        {
            "text": "lapsing forms of multiple sclerosis",
            "probability": 0.0013336917189289857,
            "start_logit": -1.2169294357299805,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "rosis",
            "probability": 0.0013062704647883417,
            "start_logit": -1.2377041578292847,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "relapsing",
            "probability": 0.0012948967353488027,
            "start_logit": 3.6174476146698,
            "end_logit": 0.011357706040143967
        },
        {
            "text": "sclerosis",
            "probability": 0.0011525559377372914,
            "start_logit": -1.3628982305526733,
            "end_logit": 4.8752546310424805
        },
        {
            "text": "Teriflunomide Oral in People With Relapsing Multiple Sclerosis",
            "probability": 0.0009696078463646578,
            "start_logit": 2.3313310146331787,
            "end_logit": 1.008179783821106
        },
        {
            "text": "Teriflunomide Oral in People With Relapsing Multiple Sclerosis)",
            "probability": 0.0009538758349366136,
            "start_logit": 2.3313310146331787,
            "end_logit": 0.9918215870857239
        }
    ],
    "589a246078275d0c4a00002a_003": [
        {
            "text": "fingolimod",
            "probability": 0.4325906377496615,
            "start_logit": 5.7704081535339355,
            "end_logit": 3.136201858520508
        },
        {
            "text": "psoriasis",
            "probability": 0.26907466350321546,
            "start_logit": 4.527215003967285,
            "end_logit": 3.9045920372009277
        },
        {
            "text": "fingolimod,",
            "probability": 0.10124167856626076,
            "start_logit": 5.7704081535339355,
            "end_logit": 1.6839205026626587
        },
        {
            "text": "multiple sclerosis",
            "probability": 0.04580452382098158,
            "start_logit": 3.8184406757354736,
            "end_logit": 2.8427603244781494
        },
        {
            "text": "interferon \u03b21a",
            "probability": 0.034665566726531184,
            "start_logit": 2.61080002784729,
            "end_logit": 3.7717649936676025
        },
        {
            "text": "fingolimod, teriflunomide",
            "probability": 0.03410452622732509,
            "start_logit": 5.7704081535339355,
            "end_logit": 0.5958400964736938
        },
        {
            "text": "fingolimod, teriflunomide, and dimethyl fumarate",
            "probability": 0.015859384927981033,
            "start_logit": 5.7704081535339355,
            "end_logit": -0.16982857882976532
        },
        {
            "text": "fingolimod, teriflunomide,",
            "probability": 0.01303769486265996,
            "start_logit": 5.7704081535339355,
            "end_logit": -0.3657452464103699
        },
        {
            "text": "fingolimod, teriflunomide, and dimethyl fumarate (DMF)-",
            "probability": 0.008274803431571586,
            "start_logit": 5.7704081535339355,
            "end_logit": -0.8203748464584351
        },
        {
            "text": "2014, is DMF, which had been used in a different formulation for treatment of psoriasis",
            "probability": 0.006760673927752207,
            "start_logit": 0.8433486819267273,
            "end_logit": 3.9045920372009277
        },
        {
            "text": "multiple sclerosis (MS",
            "probability": 0.0062731026052686234,
            "start_logit": 3.8184406757354736,
            "end_logit": 0.8546485304832458
        },
        {
            "text": "multiple sclerosis (MS)",
            "probability": 0.005132341057034092,
            "start_logit": 3.8184406757354736,
            "end_logit": 0.6539393663406372
        },
        {
            "text": "relapsing forms of multiple sclerosis",
            "probability": 0.0045448177092193565,
            "start_logit": 1.5080454349517822,
            "end_logit": 2.8427603244781494
        },
        {
            "text": "fingolimo",
            "probability": 0.004524100639116062,
            "start_logit": 5.7704081535339355,
            "end_logit": -1.4241712093353271
        },
        {
            "text": "Three oral disease-modifying drugs-fingolimod",
            "probability": 0.00419895727605356,
            "start_logit": 1.1354525089263916,
            "end_logit": 3.136201858520508
        },
        {
            "text": "fingolimod, reduced the annualized relapse rate (ARR) from 0.40",
            "probability": 0.0038745167609856453,
            "start_logit": 4.066027641296387,
            "end_logit": 0.1252114474773407
        },
        {
            "text": "oral disease-modifying drugs-fingolimod",
            "probability": 0.0036718806180847455,
            "start_logit": 1.001320242881775,
            "end_logit": 3.136201858520508
        },
        {
            "text": "psoriasis for decades",
            "probability": 0.002385487626809191,
            "start_logit": 4.527215003967285,
            "end_logit": -0.8209933042526245
        },
        {
            "text": "interferon \u03b21",
            "probability": 0.0020537504953155915,
            "start_logit": 2.61080002784729,
            "end_logit": 0.9456857442855835
        },
        {
            "text": "dimethyl fumarate (DMF)-are available for treatment of relapsing forms of multiple sclerosis",
            "probability": 0.0019268914681727395,
            "start_logit": 0.6499658823013306,
            "end_logit": 2.8427603244781494
        }
    ],
    "58a1c0f178275d0c4a000056_000": [
        {
            "text": "poliovirus",
            "probability": 0.2919247527382035,
            "start_logit": 4.332717418670654,
            "end_logit": 4.282693386077881
        },
        {
            "text": "diphtheria-tetanus-pertussis",
            "probability": 0.1388978143387399,
            "start_logit": 4.390600681304932,
            "end_logit": 3.4820525646209717
        },
        {
            "text": "poliomyelitis. Inactivated poliovirus",
            "probability": 0.12447576382211319,
            "start_logit": 3.480332374572754,
            "end_logit": 4.282693386077881
        },
        {
            "text": "oral poliovirus",
            "probability": 0.0965654014949919,
            "start_logit": 3.243102550506592,
            "end_logit": 4.266032695770264
        },
        {
            "text": "poliovirus vaccine (OPV",
            "probability": 0.054364837181918806,
            "start_logit": 3.839535713195801,
            "end_logit": 3.0950965881347656
        },
        {
            "text": "diphtheria-tetanus",
            "probability": 0.051198133854456124,
            "start_logit": 4.390600681304932,
            "end_logit": 2.4840171337127686
        },
        {
            "text": "oral poliovirus vaccine (OPV",
            "probability": 0.029942665612730634,
            "start_logit": 3.243102550506592,
            "end_logit": 3.0950965881347656
        },
        {
            "text": "polio incidence declined by more than 95 per cent. However, in 1962, when oral poliovirus",
            "probability": 0.02830550322499894,
            "start_logit": 2.0159382820129395,
            "end_logit": 4.266032695770264
        },
        {
            "text": "IPV",
            "probability": 0.024674405294636565,
            "start_logit": 3.0043725967407227,
            "end_logit": 3.1403086185455322
        },
        {
            "text": "polio",
            "probability": 0.024130065901182034,
            "start_logit": 3.2773826122283936,
            "end_logit": 2.8449907302856445
        },
        {
            "text": "Inactivated poliovirus",
            "probability": 0.022582755643037876,
            "start_logit": 1.7734079360961914,
            "end_logit": 4.282693386077881
        },
        {
            "text": "diphtheria-tetanus-pertussis (DTP)",
            "probability": 0.019318292825521364,
            "start_logit": 4.390600681304932,
            "end_logit": 1.509366512298584
        },
        {
            "text": "poliomyelitis",
            "probability": 0.01658072201559535,
            "start_logit": 3.480332374572754,
            "end_logit": 2.2668230533599854
        },
        {
            "text": "diphtheria-tetanus-pertussis (DTP",
            "probability": 0.015138852581081337,
            "start_logit": 4.390600681304932,
            "end_logit": 1.2655785083770752
        },
        {
            "text": "poliovirus vaccine (IPV",
            "probability": 0.014938093590546394,
            "start_logit": 4.332717418670654,
            "end_logit": 1.3101118803024292
        },
        {
            "text": "oliovirus",
            "probability": 0.010752251776614577,
            "start_logit": 1.0313365459442139,
            "end_logit": 4.282693386077881
        },
        {
            "text": "IPV was used extensively in the US and polio incidence declined by more than 95 per cent. However, in 1962, when oral poliovirus",
            "probability": 0.010577609123476777,
            "start_logit": 1.0316214561462402,
            "end_logit": 4.266032695770264
        },
        {
            "text": "1962, when oral poliovirus",
            "probability": 0.009143983538755385,
            "start_logit": 0.8859781622886658,
            "end_logit": 4.266032695770264
        },
        {
            "text": "polio incidence declined by more than 95 per cent. However, in 1962, when oral poliovirus vaccine (OPV",
            "probability": 0.00877687251277226,
            "start_logit": 2.0159382820129395,
            "end_logit": 3.0950965881347656
        },
        {
            "text": "poliovirus vaccine (IPV), developed in the USA by Jonas Salk in the early 1950s, was field tested in 1954",
            "probability": 0.007711222928626983,
            "start_logit": 4.332717418670654,
            "end_logit": 0.6488741040229797
        }
    ],
    "58a1c0f178275d0c4a000056_001": [
        {
            "text": "HIV",
            "probability": 0.5667646203941924,
            "start_logit": 3.2229347229003906,
            "end_logit": 4.399153709411621
        },
        {
            "text": "human immunodeficiency virus (HIV",
            "probability": 0.12715139712825183,
            "start_logit": 1.728369116783142,
            "end_logit": 4.399153709411621
        },
        {
            "text": "polio",
            "probability": 0.052467494957737955,
            "start_logit": 2.6869075298309326,
            "end_logit": 2.5554306507110596
        },
        {
            "text": "polio vaccine samples. It has been suggested that the human immunodeficiency virus (HIV",
            "probability": 0.05050007088331999,
            "start_logit": 0.8049653768539429,
            "end_logit": 4.399153709411621
        },
        {
            "text": "AIDS",
            "probability": 0.044620814805281545,
            "start_logit": 1.7533854246139526,
            "end_logit": 3.3269593715667725
        },
        {
            "text": "oral polio vaccine samples. It has been suggested that the human immunodeficiency virus (HIV",
            "probability": 0.02139406626952075,
            "start_logit": -0.05389575660228729,
            "end_logit": 4.399153709411621
        },
        {
            "text": "olio vaccine samples. It has been suggested that the human immunodeficiency virus (HIV",
            "probability": 0.019200604367481233,
            "start_logit": -0.16206760704517365,
            "end_logit": 4.399153709411621
        },
        {
            "text": "HIV), and thus the acquired immunodeficiency syndrome (AIDS",
            "probability": 0.015949646704037673,
            "start_logit": 3.2229347229003906,
            "end_logit": 0.8286463022232056
        },
        {
            "text": "Wistar Institute, Philadelphia, PA, USA, in the Belgian Congo in 1958 and 1959. The \"OPV/AIDS",
            "probability": 0.013885171717230022,
            "start_logit": 0.5860064625740051,
            "end_logit": 3.3269593715667725
        },
        {
            "text": "polio vaccine (OPV) during a vaccination campaign launched by the Wistar",
            "probability": 0.011843888208649235,
            "start_logit": 2.6869075298309326,
            "end_logit": 1.0670487880706787
        },
        {
            "text": "1958 and 1959. The \"OPV/AIDS",
            "probability": 0.0112718278188872,
            "start_logit": 0.37749147415161133,
            "end_logit": 3.3269593715667725
        },
        {
            "text": "Belgian Congo in 1958 and 1959. The \"OPV/AIDS",
            "probability": 0.010946375234698292,
            "start_logit": 0.34819334745407104,
            "end_logit": 3.3269593715667725
        },
        {
            "text": "oral polio",
            "probability": 0.009613071357012871,
            "start_logit": 0.9898374676704407,
            "end_logit": 2.5554306507110596
        },
        {
            "text": "Philadelphia, PA, USA, in the Belgian Congo in 1958 and 1959. The \"OPV/AIDS",
            "probability": 0.008259263124156648,
            "start_logit": 0.06652034819126129,
            "end_logit": 3.3269593715667725
        },
        {
            "text": "1959. The \"OPV/AIDS",
            "probability": 0.007222009912655502,
            "start_logit": -0.06768172979354858,
            "end_logit": 3.3269593715667725
        },
        {
            "text": "simian immunodeficiency virus",
            "probability": 0.007150786099792806,
            "start_logit": 2.29146146774292,
            "end_logit": 0.9579051733016968
        },
        {
            "text": "olio",
            "probability": 0.0057724551690240475,
            "start_logit": 0.4798111915588379,
            "end_logit": 2.5554306507110596
        },
        {
            "text": "polio vaccine (OPV",
            "probability": 0.00575215823515635,
            "start_logit": 2.6869075298309326,
            "end_logit": 0.34481194615364075
        },
        {
            "text": "HIV)",
            "probability": 0.005158657343771294,
            "start_logit": 3.2229347229003906,
            "end_logit": -0.3001140356063843
        },
        {
            "text": "Congo in 1958 and 1959. The \"OPV/AIDS",
            "probability": 0.005075620269142347,
            "start_logit": -0.4203662872314453,
            "end_logit": 3.3269593715667725
        }
    ],
    "58aa0c6f396a458e50000008_000": [
        {
            "text": "oxytocin",
            "probability": 0.9590734548163145,
            "start_logit": 4.597817897796631,
            "end_logit": 5.104262828826904
        },
        {
            "text": "non-kin, and recent evidence shows that oxytocin",
            "probability": 0.008997876084158017,
            "start_logit": -0.07116121053695679,
            "end_logit": 5.104262828826904
        },
        {
            "text": "xytocin",
            "probability": 0.00331688913360417,
            "start_logit": -1.0691224336624146,
            "end_logit": 5.104262828826904
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring bonding,",
            "probability": 0.003032095904362331,
            "start_logit": 4.597817897796631,
            "end_logit": -0.6524507403373718
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring",
            "probability": 0.0026201419611681315,
            "start_logit": 4.597817897796631,
            "end_logit": -0.7984763383865356
        },
        {
            "text": "social mammals also build long-term cooperative relationships between non-kin, and recent evidence shows that oxytocin",
            "probability": 0.0025302420246234142,
            "start_logit": -1.3398348093032837,
            "end_logit": 5.104262828826904
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring bonding, is likely to facilitate non-kin",
            "probability": 0.0022876380586901598,
            "start_logit": 4.597817897796631,
            "end_logit": -0.9341849684715271
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring bonding",
            "probability": 0.002244124287099711,
            "start_logit": 4.597817897796631,
            "end_logit": -0.9533894658088684
        },
        {
            "text": "oxytocin,",
            "probability": 0.0020274943798935068,
            "start_logit": 4.597817897796631,
            "end_logit": -1.0549041032791138
        },
        {
            "text": "urinary oxytocin",
            "probability": 0.0019798867112851373,
            "start_logit": 0.17266230285167694,
            "end_logit": 3.3464903831481934
        },
        {
            "text": "cooperative relationships between non-kin, and recent evidence shows that oxytocin",
            "probability": 0.0018649981423572947,
            "start_logit": -1.6448897123336792,
            "end_logit": 5.104262828826904
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring bonding, is likely to facilitate non-kin as well as kin bonds",
            "probability": 0.0017455412653479023,
            "start_logit": 4.597817897796631,
            "end_logit": -1.2046401500701904
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring bonding, is likely to facilitate non-kin as well as kin",
            "probability": 0.0015742551450621072,
            "start_logit": 4.597817897796631,
            "end_logit": -1.307922601699829
        },
        {
            "text": "oxytocin, a hormone involved in parent-offspring bonding, is likely to facilitate non-kin as well as kin bonds.",
            "probability": 0.0014440569402332877,
            "start_logit": 4.597817897796631,
            "end_logit": -1.394248366355896
        },
        {
            "text": "oxytocin, a hormone involved in parent",
            "probability": 0.0013287394952528299,
            "start_logit": 4.597817897796631,
            "end_logit": -1.4774740934371948
        },
        {
            "text": "oxytocin, a hormone",
            "probability": 0.0011232506281191876,
            "start_logit": 4.597817897796631,
            "end_logit": -1.6454780101776123
        },
        {
            "text": "chimpanzees may play a key role in social bonding under the influence of oxytocin",
            "probability": 0.001076233846196925,
            "start_logit": 0.6006602048873901,
            "end_logit": 2.3089206218719482
        },
        {
            "text": "oxytocin levels and bonding in related and unrelated wild chimpanzee",
            "probability": 0.0008661937364962947,
            "start_logit": 3.3729920387268066,
            "end_logit": -0.6805256605148315
        },
        {
            "text": "oxytocin levels and bonding in related and unrelated wild chimpanzees",
            "probability": 0.0005077782826755905,
            "start_logit": 3.3729920387268066,
            "end_logit": -1.2145893573760986
        },
        {
            "text": "oxytocin levels and bonding in related and unrelated wild chimpanzees. Humans excel in cooperative exchanges between unrelated",
            "probability": 0.0003591091570594521,
            "start_logit": 3.3729920387268066,
            "end_logit": -1.5610078573226929
        }
    ],
    "58aa0c6f396a458e50000008_001": [
        {
            "text": "oxytocin",
            "probability": 0.8258823041979985,
            "start_logit": 6.665221214294434,
            "end_logit": 7.502072811126709
        },
        {
            "text": "oxytocin (OXT) and its receptor (OXTR)",
            "probability": 0.08989288146445355,
            "start_logit": 6.665221214294434,
            "end_logit": 5.284239292144775
        },
        {
            "text": "oxytocin (OXT) and its receptor (OXTR",
            "probability": 0.02795326851013677,
            "start_logit": 6.665221214294434,
            "end_logit": 4.116154670715332
        },
        {
            "text": "OXTR)",
            "probability": 0.014816752932819147,
            "start_logit": 4.862360954284668,
            "end_logit": 5.284239292144775
        },
        {
            "text": "neurohypophysial hormone oxytocin",
            "probability": 0.008712539980767847,
            "start_logit": 2.113532304763794,
            "end_logit": 7.502072811126709
        },
        {
            "text": "Oxytocin Receptor Specific Manner. The neurohypophysial hormone oxytocin",
            "probability": 0.007797860280469131,
            "start_logit": 2.0026183128356934,
            "end_logit": 7.502072811126709
        },
        {
            "text": "OXTR",
            "probability": 0.004607446845979995,
            "start_logit": 4.862360954284668,
            "end_logit": 4.116154670715332
        },
        {
            "text": "oxytocin (OXT)",
            "probability": 0.004122254030408318,
            "start_logit": 6.665221214294434,
            "end_logit": 2.2020206451416016
        },
        {
            "text": "OXT) and its receptor (OXTR)",
            "probability": 0.003558060162405063,
            "start_logit": 3.4358179569244385,
            "end_logit": 5.284239292144775
        },
        {
            "text": "oxytocin (OXT",
            "probability": 0.002469284500207076,
            "start_logit": 6.665221214294434,
            "end_logit": 1.6895489692687988
        },
        {
            "text": "xytocin",
            "probability": 0.0017080147477310447,
            "start_logit": 0.48410066962242126,
            "end_logit": 7.502072811126709
        },
        {
            "text": "The neurohypophysial hormone oxytocin",
            "probability": 0.0016126492699191407,
            "start_logit": 0.42664727568626404,
            "end_logit": 7.502072811126709
        },
        {
            "text": "OXT) and its receptor (OXTR",
            "probability": 0.001106421437099654,
            "start_logit": 3.4358179569244385,
            "end_logit": 4.116154670715332
        },
        {
            "text": "cin",
            "probability": 0.0009974961573536527,
            "start_logit": -0.05373804271221161,
            "end_logit": 7.502072811126709
        },
        {
            "text": "autism spectrum disorder",
            "probability": 0.0009658794795225511,
            "start_logit": 3.8415920734405518,
            "end_logit": 3.574533462524414
        },
        {
            "text": "(OXTR)",
            "probability": 0.0009521730789506957,
            "start_logit": 2.117594003677368,
            "end_logit": 5.284239292144775
        },
        {
            "text": "neurohypophysial hormone oxytocin (OXT) and its receptor (OXTR)",
            "probability": 0.000948313482156547,
            "start_logit": 2.113532304763794,
            "end_logit": 5.284239292144775
        },
        {
            "text": "Oxtr-Venus",
            "probability": 0.0008267792232407187,
            "start_logit": 2.4818379878997803,
            "end_logit": 4.7787861824035645
        },
        {
            "text": "oxytocin (OXT) and its receptor (OXTR) have critical roles in the regulation of pro-social",
            "probability": 0.0005518162135438293,
            "start_logit": 6.665221214294434,
            "end_logit": 0.19108030200004578
        },
        {
            "text": "oxytocin (OXT) and its receptor",
            "probability": 0.0005178040048367897,
            "start_logit": 6.665221214294434,
            "end_logit": 0.12746205925941467
        }
    ],
    "58aa0c6f396a458e50000008_002": [
        {
            "text": "oxytocin",
            "probability": 0.7181757088976711,
            "start_logit": 5.06192684173584,
            "end_logit": 5.456645965576172
        },
        {
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR)",
            "probability": 0.1497873003843293,
            "start_logit": 5.06192684173584,
            "end_logit": 3.889147996902466
        },
        {
            "text": "Oxytocin",
            "probability": 0.05494755084558688,
            "start_logit": 4.030823707580566,
            "end_logit": 3.9174139499664307
        },
        {
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes (OXTR",
            "probability": 0.03161650533476643,
            "start_logit": 5.06192684173584,
            "end_logit": 2.333611011505127
        },
        {
            "text": "OXTR)",
            "probability": 0.011812687059355908,
            "start_logit": 2.5218846797943115,
            "end_logit": 3.889147996902466
        },
        {
            "text": "oxytocin (OT) hormone pathway",
            "probability": 0.004035693470481323,
            "start_logit": 5.06192684173584,
            "end_logit": 0.2751098573207855
        },
        {
            "text": "owl monkeys and other primates show remarkable interspecific regulatory and protein coding variation. The oxytocin",
            "probability": 0.0037570989671400178,
            "start_logit": -0.1911403089761734,
            "end_logit": 5.456645965576172
        },
        {
            "text": "(OXTR)",
            "probability": 0.0030374382131625535,
            "start_logit": 1.1637250185012817,
            "end_logit": 3.889147996902466
        },
        {
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one of its receptor genes",
            "probability": 0.00284671513714277,
            "start_logit": 5.06192684173584,
            "end_logit": -0.07390254735946655
        },
        {
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes, and one",
            "probability": 0.0026981326466325303,
            "start_logit": 5.06192684173584,
            "end_logit": -0.12750837206840515
        },
        {
            "text": "owl monkey",
            "probability": 0.002539283326654845,
            "start_logit": 1.7102303504943848,
            "end_logit": 3.1635100841522217
        },
        {
            "text": "OXTR",
            "probability": 0.002493374821976065,
            "start_logit": 2.5218846797943115,
            "end_logit": 2.333611011505127
        },
        {
            "text": "xytocin",
            "probability": 0.0022613059663840656,
            "start_logit": -0.6988449096679688,
            "end_logit": 5.456645965576172
        },
        {
            "text": "oxytocin (OT) hormone",
            "probability": 0.0022439881357228485,
            "start_logit": 5.06192684173584,
            "end_logit": -0.3118135929107666
        },
        {
            "text": "oxytocin (OT) hormone pathway is involved in numerous physiological processes,",
            "probability": 0.0020502619826204688,
            "start_logit": 5.06192684173584,
            "end_logit": -0.40210071206092834
        },
        {
            "text": "OXTR) has been implicated in pair bonding behavior in mammalian lineages. This observation is important for understanding social monogamy",
            "probability": 0.0013930186650206137,
            "start_logit": 2.5218846797943115,
            "end_logit": 1.7514469623565674
        },
        {
            "text": "Oxytocin receptor gene sequences in owl monkeys",
            "probability": 0.0013815303281950546,
            "start_logit": 4.030823707580566,
            "end_logit": 0.23422665894031525
        },
        {
            "text": "one of its receptor genes (OXTR)",
            "probability": 0.0012765290176942302,
            "start_logit": 0.29685524106025696,
            "end_logit": 3.889147996902466
        },
        {
            "text": "owl monkey (Aotus azarae",
            "probability": 0.0008691801006683901,
            "start_logit": 1.7102303504943848,
            "end_logit": 2.091423273086548
        },
        {
            "text": "monkey",
            "probability": 0.0007766966987946526,
            "start_logit": 0.5256431102752686,
            "end_logit": 3.1635100841522217
        }
    ],
    "58aa0c6f396a458e50000008_003": [
        {
            "text": "L. reuteri",
            "probability": 0.27279028938357075,
            "start_logit": 5.472650527954102,
            "end_logit": 5.397795677185059
        },
        {
            "text": "Lactobacillus reuteri (L. reuteri",
            "probability": 0.2700896988876486,
            "start_logit": 5.462701320648193,
            "end_logit": 5.397795677185059
        },
        {
            "text": "Lactobacillus reuteri",
            "probability": 0.21216744855673333,
            "start_logit": 5.462701320648193,
            "end_logit": 5.156417369842529
        },
        {
            "text": "L. reuteri)",
            "probability": 0.06971975201025701,
            "start_logit": 5.472650527954102,
            "end_logit": 4.033576011657715
        },
        {
            "text": "Lactobacillus reuteri (L. reuteri)",
            "probability": 0.06902953499379937,
            "start_logit": 5.462701320648193,
            "end_logit": 4.033576011657715
        },
        {
            "text": "oxytocin",
            "probability": 0.030002539450781258,
            "start_logit": 4.137298583984375,
            "end_logit": 4.525726318359375
        },
        {
            "text": "(L. reuteri",
            "probability": 0.018708557137367743,
            "start_logit": 2.7929282188415527,
            "end_logit": 5.397795677185059
        },
        {
            "text": "L. reuteri) is sufficient to up-regulate endogenous oxytocin",
            "probability": 0.008708716985435528,
            "start_logit": 5.472650527954102,
            "end_logit": 1.9534168243408203
        },
        {
            "text": "Lactobacillus reuteri (L. reuteri) is sufficient to up-regulate endogenous oxytocin",
            "probability": 0.008622501752570427,
            "start_logit": 5.462701320648193,
            "end_logit": 1.9534168243408203
        },
        {
            "text": "reuteri (L. reuteri",
            "probability": 0.007395277138684158,
            "start_logit": 1.8647887706756592,
            "end_logit": 5.397795677185059
        },
        {
            "text": "human commensal microbe Lactobacillus reuteri (L. reuteri",
            "probability": 0.0073456760671684555,
            "start_logit": 1.858059048652649,
            "end_logit": 5.397795677185059
        },
        {
            "text": "reuteri",
            "probability": 0.005809318490659069,
            "start_logit": 1.8647887706756592,
            "end_logit": 5.156417369842529
        },
        {
            "text": "human commensal microbe Lactobacillus reuteri",
            "probability": 0.005770354647045232,
            "start_logit": 1.858059048652649,
            "end_logit": 5.156417369842529
        },
        {
            "text": "(L. reuteri)",
            "probability": 0.004781533708675922,
            "start_logit": 2.7929282188415527,
            "end_logit": 4.033576011657715
        },
        {
            "text": "Neuropeptide hormone oxytocin",
            "probability": 0.001958552190035586,
            "start_logit": 1.4082220792770386,
            "end_logit": 4.525726318359375
        },
        {
            "text": "reuteri (L. reuteri)",
            "probability": 0.001890085198125221,
            "start_logit": 1.8647887706756592,
            "end_logit": 4.033576011657715
        },
        {
            "text": "human commensal microbe Lactobacillus reuteri (L. reuteri)",
            "probability": 0.0018774081544762978,
            "start_logit": 1.858059048652649,
            "end_logit": 4.033576011657715
        },
        {
            "text": "oxytocin. Neuropeptide hormone oxytocin",
            "probability": 0.001212046324934478,
            "start_logit": 0.9283266663551331,
            "end_logit": 4.525726318359375
        },
        {
            "text": "commensal microbe Lactobacillus reuteri (L. reuteri",
            "probability": 0.0011681709775245128,
            "start_logit": 0.01938645727932453,
            "end_logit": 5.397795677185059
        },
        {
            "text": "L. reuteri) is sufficient to up-regulate endogenous oxytocin levels and improve wound healing capacity in mice",
            "probability": 0.0009525379445069598,
            "start_logit": 5.472650527954102,
            "end_logit": -0.25953298807144165
        }
    ],
    "58aa0c6f396a458e50000008_004": [
        {
            "text": "love hormone",
            "probability": 0.2948460769931875,
            "start_logit": 3.4229297637939453,
            "end_logit": 3.5394344329833984
        },
        {
            "text": "'love hormone",
            "probability": 0.13800607376656449,
            "start_logit": 2.663774013519287,
            "end_logit": 3.5394344329833984
        },
        {
            "text": "Oxytocin is known as the 'love hormone",
            "probability": 0.09728851361731979,
            "start_logit": 2.314157247543335,
            "end_logit": 3.5394344329833984
        },
        {
            "text": "love hormone' due its role in promoting mother-child and pair bonding. More recent research indicates that oxytocin",
            "probability": 0.08712951143171871,
            "start_logit": 3.4229297637939453,
            "end_logit": 2.3203766345977783
        },
        {
            "text": "love",
            "probability": 0.0626008400841201,
            "start_logit": 3.4229297637939453,
            "end_logit": 1.9897596836090088
        },
        {
            "text": "Oxytocin",
            "probability": 0.05128667456871979,
            "start_logit": 2.314157247543335,
            "end_logit": 2.899184465408325
        },
        {
            "text": "'love hormone' due its role in promoting mother-child and pair bonding. More recent research indicates that oxytocin",
            "probability": 0.0407819629296554,
            "start_logit": 2.663774013519287,
            "end_logit": 2.3203766345977783
        },
        {
            "text": "love hormone'",
            "probability": 0.03246111914784287,
            "start_logit": 3.4229297637939453,
            "end_logit": 1.333024024963379
        },
        {
            "text": "'love",
            "probability": 0.02930103816405059,
            "start_logit": 2.663774013519287,
            "end_logit": 1.9897596836090088
        },
        {
            "text": "oxytocin: implications for psychiatry. Oxytocin is known as the 'love hormone",
            "probability": 0.02611134090921665,
            "start_logit": 0.9988460540771484,
            "end_logit": 3.5394344329833984
        },
        {
            "text": "Oxytocin is known as the 'love",
            "probability": 0.020656007178689022,
            "start_logit": 2.314157247543335,
            "end_logit": 1.9897596836090088
        },
        {
            "text": "the 'love hormone",
            "probability": 0.020243182869502028,
            "start_logit": 0.7442944049835205,
            "end_logit": 3.5394344329833984
        },
        {
            "text": "love hormone' due its role in promoting mother",
            "probability": 0.018344431393022435,
            "start_logit": 3.4229297637939453,
            "end_logit": 0.7623070478439331
        },
        {
            "text": "'love hormone'",
            "probability": 0.015193797554803316,
            "start_logit": 2.663774013519287,
            "end_logit": 1.333024024963379
        },
        {
            "text": "schizophrenia",
            "probability": 0.014052231984180942,
            "start_logit": 1.4543193578720093,
            "end_logit": 2.4643726348876953
        },
        {
            "text": "oxytocin: implications for psychiatry. Oxytocin",
            "probability": 0.013764871041523342,
            "start_logit": 0.9988460540771484,
            "end_logit": 2.899184465408325
        },
        {
            "text": "Oxytocin is known as the 'love hormone'",
            "probability": 0.010710992204659113,
            "start_logit": 2.314157247543335,
            "end_logit": 1.333024024963379
        },
        {
            "text": "love hormone' due its role in promoting mother-child and pair bonding. More recent research indicates that oxytocin may have broader pro-social",
            "probability": 0.009808433568295985,
            "start_logit": 3.4229297637939453,
            "end_logit": 0.13622356951236725
        },
        {
            "text": "oxytocin",
            "probability": 0.008826579968117466,
            "start_logit": 1.1333017349243164,
            "end_logit": 2.3203766345977783
        },
        {
            "text": "'love hormone' due its role in promoting mother",
            "probability": 0.008586320624810719,
            "start_logit": 2.663774013519287,
            "end_logit": 0.7623070478439331
        }
    ],
    "58a9c532396a458e50000002_000": [
        {
            "text": "Cynops fudingensis",
            "probability": 0.2668985572025116,
            "start_logit": 3.8371968269348145,
            "end_logit": 3.3546626567840576
        },
        {
            "text": "defensin",
            "probability": 0.17030306193396597,
            "start_logit": 4.111364841461182,
            "end_logit": 2.6312055587768555
        },
        {
            "text": "fish \u03b2-defensin",
            "probability": 0.11565974844033608,
            "start_logit": 2.8043322563171387,
            "end_logit": 3.5513112545013428
        },
        {
            "text": "\u03b2-defensin",
            "probability": 0.11398308003143126,
            "start_logit": 3.0945074558258057,
            "end_logit": 3.2465333938598633
        },
        {
            "text": "fish \u03b2-defensin. As far as we know, CFBD is the first \u03b2-defensin",
            "probability": 0.08527444475826804,
            "start_logit": 2.8043322563171387,
            "end_logit": 3.2465333938598633
        },
        {
            "text": "\u03b2-defensin. As far as we know, CFBD is the first \u03b2-defensin",
            "probability": 0.06661567607468315,
            "start_logit": 2.5573973655700684,
            "end_logit": 3.2465333938598633
        },
        {
            "text": "salamander, Cynops fudingensis",
            "probability": 0.05301978279078108,
            "start_logit": 2.2209932804107666,
            "end_logit": 3.3546626567840576
        },
        {
            "text": "skin secretions of the salamander, Cynops fudingensis",
            "probability": 0.023736668415982935,
            "start_logit": 1.4173492193222046,
            "end_logit": 3.3546626567840576
        },
        {
            "text": "fish \u03b2-defensin.",
            "probability": 0.018446425772441877,
            "start_logit": 2.8043322563171387,
            "end_logit": 1.715529203414917
        },
        {
            "text": "fish",
            "probability": 0.017542236955560456,
            "start_logit": 2.8043322563171387,
            "end_logit": 1.6652700901031494
        },
        {
            "text": "\u03b2-defensin.",
            "probability": 0.014410192027354492,
            "start_logit": 2.5573973655700684,
            "end_logit": 1.715529203414917
        },
        {
            "text": "salamander defensin",
            "probability": 0.013336085272028213,
            "start_logit": 1.5642588138580322,
            "end_logit": 2.6312055587768555
        },
        {
            "text": "Cynops fudingensis. The cDNA encoding CFBD precursor was cloned from the skin",
            "probability": 0.008115528800331083,
            "start_logit": 3.8371968269348145,
            "end_logit": -0.13842663168907166
        },
        {
            "text": "defensin antimicrobial peptide",
            "probability": 0.0059083270721352315,
            "start_logit": 4.111364841461182,
            "end_logit": -0.7300112843513489
        },
        {
            "text": "defensin antimicrobial peptide.",
            "probability": 0.005824609748025058,
            "start_logit": 4.111364841461182,
            "end_logit": -0.7442820072174072
        },
        {
            "text": "\u03b2-defensin antimicrobial peptide from salamander",
            "probability": 0.0052819279868617005,
            "start_logit": 3.0945074558258057,
            "end_logit": 0.17477455735206604
        },
        {
            "text": "Cynops",
            "probability": 0.004680457603892773,
            "start_logit": 3.8371968269348145,
            "end_logit": -0.6888101100921631
        },
        {
            "text": "skin cDNA library of C. fudingensis",
            "probability": 0.0039924369350315915,
            "start_logit": 1.305587887763977,
            "end_logit": 1.6838047504425049
        },
        {
            "text": "defensin antimicrobial peptide. Antimicrobial peptides have been widely identified from amphibian skins except salamander",
            "probability": 0.0036511677634895883,
            "start_logit": 4.111364841461182,
            "end_logit": -1.2113269567489624
        },
        {
            "text": "\u03b2-",
            "probability": 0.00331958441488794,
            "start_logit": 3.0945074558258057,
            "end_logit": -0.2896770238876343
        }
    ],
    "58a9c532396a458e50000002_001": [
        {
            "text": "six",
            "probability": 0.24343315822815226,
            "start_logit": 5.330764293670654,
            "end_logit": 4.555025577545166
        },
        {
            "text": "six cysteines, which form three",
            "probability": 0.2211869221083283,
            "start_logit": 5.330764293670654,
            "end_logit": 4.45919132232666
        },
        {
            "text": "alpha defensins",
            "probability": 0.16797664377478602,
            "start_logit": 5.597866535186768,
            "end_logit": 3.9169058799743652
        },
        {
            "text": "three",
            "probability": 0.09313151796684657,
            "start_logit": 4.465768814086914,
            "end_logit": 4.45919132232666
        },
        {
            "text": "Alpha defensins contain six",
            "probability": 0.08986217059914266,
            "start_logit": 4.334198951721191,
            "end_logit": 4.555025577545166
        },
        {
            "text": "Alpha defensins contain six cysteines, which form three",
            "probability": 0.08165008034841838,
            "start_logit": 4.334198951721191,
            "end_logit": 4.45919132232666
        },
        {
            "text": "six cysteines",
            "probability": 0.023800508148012336,
            "start_logit": 5.330764293670654,
            "end_logit": 2.2298901081085205
        },
        {
            "text": "Alpha defensins",
            "probability": 0.016379977719926452,
            "start_logit": 4.334198951721191,
            "end_logit": 2.8528082370758057
        },
        {
            "text": "alpha defensin. Human alpha defensins",
            "probability": 0.011471839151677196,
            "start_logit": 2.9139368534088135,
            "end_logit": 3.9169058799743652
        },
        {
            "text": "Alpha defensins contain six cysteines",
            "probability": 0.008785842237393395,
            "start_logit": 4.334198951721191,
            "end_logit": 2.2298901081085205
        },
        {
            "text": "cysteines, which form three",
            "probability": 0.008325395054986197,
            "start_logit": 2.0510666370391846,
            "end_logit": 4.45919132232666
        },
        {
            "text": "six cysteines,",
            "probability": 0.007436275936503853,
            "start_logit": 5.330764293670654,
            "end_logit": 1.0665533542633057
        },
        {
            "text": "alpha defensins are a class of antimicrobial peptides with additional antiviral activity",
            "probability": 0.00436131415344826,
            "start_logit": 5.597866535186768,
            "end_logit": 0.2658543586730957
        },
        {
            "text": "six cysteines, which form three well defined disulfide bridges",
            "probability": 0.004217965196092567,
            "start_logit": 5.330764293670654,
            "end_logit": 0.49953600764274597
        },
        {
            "text": "defensins contain six",
            "probability": 0.004017609119820806,
            "start_logit": 1.2266088724136353,
            "end_logit": 4.555025577545166
        },
        {
            "text": "defensins contain six cysteines, which form three",
            "probability": 0.0036504583102629495,
            "start_logit": 1.2266088724136353,
            "end_logit": 4.45919132232666
        },
        {
            "text": "alpha defensins are a class of antimicrobial peptides with additional antiviral",
            "probability": 0.0036107735243946786,
            "start_logit": 5.597866535186768,
            "end_logit": 0.07700295746326447
        },
        {
            "text": "Alpha defensins contain six cysteines,",
            "probability": 0.002745065223210536,
            "start_logit": 4.334198951721191,
            "end_logit": 1.0665533542633057
        },
        {
            "text": "alpha defensins are a class of antimicrobial peptide",
            "probability": 0.0020210404182192054,
            "start_logit": 5.597866535186768,
            "end_logit": -0.5033066272735596
        },
        {
            "text": "alpha defensin.",
            "probability": 0.0019354427803775344,
            "start_logit": 2.9139368534088135,
            "end_logit": 2.1373467445373535
        }
    ],
    "58a9c532396a458e50000002_002": [
        {
            "text": "six",
            "probability": 0.34870581785097843,
            "start_logit": 4.616517543792725,
            "end_logit": 3.606920003890991
        },
        {
            "text": "six conserved cysteines whose three",
            "probability": 0.25151045477421385,
            "start_logit": 4.616517543792725,
            "end_logit": 3.2801759243011475
        },
        {
            "text": "Defensins are small, multifunctional cationic peptides. They typically contain six",
            "probability": 0.0993777371351792,
            "start_logit": 3.3612170219421387,
            "end_logit": 3.606920003890991
        },
        {
            "text": "Defensins are small, multifunctional cationic peptides. They typically contain six conserved cysteines whose three",
            "probability": 0.07167801218614245,
            "start_logit": 3.3612170219421387,
            "end_logit": 3.2801759243011475
        },
        {
            "text": "three",
            "probability": 0.06520161097838846,
            "start_logit": 3.266517162322998,
            "end_logit": 3.2801759243011475
        },
        {
            "text": "six conserved cysteines whose three intramolecular disulfides stabilize a largely \u03b2-sheet",
            "probability": 0.059535138949537623,
            "start_logit": 4.616517543792725,
            "end_logit": 1.839258074760437
        },
        {
            "text": "six conserved cysteines",
            "probability": 0.02193350028224186,
            "start_logit": 4.616517543792725,
            "end_logit": 0.8407065272331238
        },
        {
            "text": "three intramolecular disulfides stabilize a largely \u03b2-sheet",
            "probability": 0.015433899051301124,
            "start_logit": 3.266517162322998,
            "end_logit": 1.839258074760437
        },
        {
            "text": "three intramolecular disulfides stabilize a largely \u03b2-sheet structure. This review of human \u03b1-defensins",
            "probability": 0.015036059268865433,
            "start_logit": 3.266517162322998,
            "end_logit": 1.813143014907837
        },
        {
            "text": "six conserved cysteines whose three intramolecular disulfides",
            "probability": 0.012712854888853979,
            "start_logit": 4.616517543792725,
            "end_logit": 0.2953050434589386
        },
        {
            "text": "Defensins are small, multifunctional cationic peptides. They typically contain six conserved cysteines",
            "probability": 0.006250832403474608,
            "start_logit": 3.3612170219421387,
            "end_logit": 0.8407065272331238
        },
        {
            "text": "six conserved cysteines whose three intramolecular disulfides stabilize a largely \u03b2-sheet structure.",
            "probability": 0.00567990261876469,
            "start_logit": 4.616517543792725,
            "end_logit": -0.5103745460510254
        },
        {
            "text": "three intramolecular disulfides stabilize a largely \u03b2-sheet structure. This review of human \u03b1-",
            "probability": 0.004876688580417443,
            "start_logit": 3.266517162322998,
            "end_logit": 0.6871581673622131
        },
        {
            "text": "Defensin",
            "probability": 0.003688708021479556,
            "start_logit": 3.3612170219421387,
            "end_logit": 0.31326815485954285
        },
        {
            "text": "three intramolecular disulfides",
            "probability": 0.0032956825577365374,
            "start_logit": 3.266517162322998,
            "end_logit": 0.2953050434589386
        },
        {
            "text": "Paneth cell \u03b1-defensin, are contrasted with those of the four myeloid \u03b1-defensins",
            "probability": 0.0032300204651932985,
            "start_logit": 2.279202461242676,
            "end_logit": 1.2624949216842651
        },
        {
            "text": "Paneth cell \u03b1-defensin",
            "probability": 0.0031828301176076764,
            "start_logit": 2.279202461242676,
            "end_logit": 1.2477772235870361
        },
        {
            "text": "cationic peptides. They typically contain six",
            "probability": 0.0029689945062505384,
            "start_logit": -0.14948774874210358,
            "end_logit": 3.606920003890991
        },
        {
            "text": "\u03b2-sheet",
            "probability": 0.0028878477226455556,
            "start_logit": 1.590462327003479,
            "end_logit": 1.839258074760437
        },
        {
            "text": "\u03b2-sheet structure. This review of human \u03b1-defensins",
            "probability": 0.0028134076407280917,
            "start_logit": 1.590462327003479,
            "end_logit": 1.813143014907837
        }
    ],
    "58a9c532396a458e50000002_003": [
        {
            "text": "three",
            "probability": 0.6561303605866775,
            "start_logit": 4.906185626983643,
            "end_logit": 4.6475396156311035
        },
        {
            "text": "three subfamilies of defensins",
            "probability": 0.0688655088063686,
            "start_logit": 4.906185626983643,
            "end_logit": 2.3933355808258057
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1, \u03b2 and \u03b8-defensins",
            "probability": 0.06425255083193905,
            "start_logit": 4.906185626983643,
            "end_logit": 2.3240015506744385
        },
        {
            "text": "cysteine-rich antimicrobial ability that contribute to host defence against bacterial, fungal and viral infections. There are three",
            "probability": 0.06386377130077851,
            "start_logit": 2.576578378677368,
            "end_logit": 4.6475396156311035
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1, \u03b2 and \u03b8-defensins. \u03b1-defensins",
            "probability": 0.04101205825240847,
            "start_logit": 4.906185626983643,
            "end_logit": 1.8750462532043457
        },
        {
            "text": "three subfamilies",
            "probability": 0.012497584150163707,
            "start_logit": 4.906185626983643,
            "end_logit": 0.6867154836654663
        },
        {
            "text": "six",
            "probability": 0.011942518973551764,
            "start_logit": 2.5784552097320557,
            "end_logit": 2.969015598297119
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1, \u03b2 and \u03b8",
            "probability": 0.010642493683327701,
            "start_logit": 4.906185626983643,
            "end_logit": 0.526034951210022
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1, \u03b2 and \u03b8-defensins. \u03b1-",
            "probability": 0.01037311267716845,
            "start_logit": 4.906185626983643,
            "end_logit": 0.500397264957428
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1, \u03b2 and \u03b8-",
            "probability": 0.007559264103509692,
            "start_logit": 4.906185626983643,
            "end_logit": 0.18395397067070007
        },
        {
            "text": "\u03b1-defensins are most present in neutrophils and Paneth cells; \u03b2-defensins",
            "probability": 0.007030819068368292,
            "start_logit": 2.9330856800079346,
            "end_logit": 2.084583282470703
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1, \u03b2 and \u03b8-defensins.",
            "probability": 0.006686308805595124,
            "start_logit": 4.906185626983643,
            "end_logit": 0.06124209985136986
        },
        {
            "text": "three subfamilies of defensins in primates: \u03b1,",
            "probability": 0.006642402000911546,
            "start_logit": 4.906185626983643,
            "end_logit": 0.054653771221637726
        },
        {
            "text": "rhesus macaques. All three kinds of defensins have six",
            "probability": 0.00574555669604305,
            "start_logit": 1.8467769622802734,
            "end_logit": 2.969015598297119
        },
        {
            "text": "\u03b1-defensins",
            "probability": 0.005701710287117351,
            "start_logit": 2.9330856800079346,
            "end_logit": 1.8750462532043457
        },
        {
            "text": "antimicrobial ability that contribute to host defence against bacterial, fungal and viral infections. There are three",
            "probability": 0.005622572047065518,
            "start_logit": 0.14661535620689392,
            "end_logit": 4.6475396156311035
        },
        {
            "text": "\u03b1, \u03b2 and \u03b8-defensins",
            "probability": 0.005490197334526039,
            "start_logit": 2.4463284015655518,
            "end_logit": 2.3240015506744385
        },
        {
            "text": "\u03b8-defensins",
            "probability": 0.003576422268169611,
            "start_logit": 2.0177271366119385,
            "end_logit": 2.3240015506744385
        },
        {
            "text": "\u03b1, \u03b2 and \u03b8-defensins. \u03b1-defensins",
            "probability": 0.00350436348417896,
            "start_logit": 2.4463284015655518,
            "end_logit": 1.8750462532043457
        },
        {
            "text": "six conserved cysteines, three",
            "probability": 0.002860424642130973,
            "start_logit": 2.5784552097320557,
            "end_logit": 1.539880633354187
        }
    ],
    "58a3428d60087bc10a00001b_000": [
        {
            "text": "HTT gene",
            "probability": 0.37953287354104215,
            "start_logit": 7.207515239715576,
            "end_logit": 4.459230422973633
        },
        {
            "text": "Huntington disease",
            "probability": 0.3101563412585658,
            "start_logit": 5.526028633117676,
            "end_logit": 5.938852310180664
        },
        {
            "text": "HTT",
            "probability": 0.23595692070759886,
            "start_logit": 7.207515239715576,
            "end_logit": 3.983938455581665
        },
        {
            "text": "CAG (polyQ) motif in the HTT gene",
            "probability": 0.02790844027618233,
            "start_logit": 4.597503185272217,
            "end_logit": 4.459230422973633
        },
        {
            "text": "CAG (polyQ) motif in the HTT",
            "probability": 0.017350775356769717,
            "start_logit": 4.597503185272217,
            "end_logit": 3.983938455581665
        },
        {
            "text": "Huntington",
            "probability": 0.007406074019254136,
            "start_logit": 5.526028633117676,
            "end_logit": 2.2040762901306152
        },
        {
            "text": "CAG (polyQ",
            "probability": 0.005149554827355,
            "start_logit": 4.597503185272217,
            "end_logit": 2.769211530685425
        },
        {
            "text": "CAG",
            "probability": 0.004312830078003756,
            "start_logit": 4.597503185272217,
            "end_logit": 2.591895580291748
        },
        {
            "text": "H",
            "probability": 0.0028652302092157687,
            "start_logit": 7.207515239715576,
            "end_logit": -0.42706209421157837
        },
        {
            "text": "polyQ) motif in the HTT gene",
            "probability": 0.0014129508685739184,
            "start_logit": 1.614254355430603,
            "end_logit": 4.459230422973633
        },
        {
            "text": "CAG Repeats upon In Vitro Differentiation into Cardiomyocytes. Huntington disease",
            "probability": 0.001273265215139124,
            "start_logit": 0.030536772683262825,
            "end_logit": 5.938852310180664
        },
        {
            "text": "CAG (polyQ) motif",
            "probability": 0.0010995581881056847,
            "start_logit": 4.597503185272217,
            "end_logit": 1.2252097129821777
        },
        {
            "text": "CAG (polyQ)",
            "probability": 0.0009924573453437451,
            "start_logit": 4.597503185272217,
            "end_logit": 1.122730016708374
        },
        {
            "text": "Huntington disease (HD; OMIM 143100)",
            "probability": 0.0008880094486079311,
            "start_logit": 5.526028633117676,
            "end_logit": 0.08300291746854782
        },
        {
            "text": "polyQ) motif in the HTT",
            "probability": 0.0008784365184213115,
            "start_logit": 1.614254355430603,
            "end_logit": 3.983938455581665
        },
        {
            "text": "the HTT gene",
            "probability": 0.0008374686853211061,
            "start_logit": 1.0912026166915894,
            "end_logit": 4.459230422973633
        },
        {
            "text": "disease",
            "probability": 0.0005916026843855452,
            "start_logit": -0.7359678745269775,
            "end_logit": 5.938852310180664
        },
        {
            "text": "the HTT",
            "probability": 0.0005206572235330766,
            "start_logit": 1.0912026166915894,
            "end_logit": 3.983938455581665
        },
        {
            "text": "Huntington disease (HD; OMIM 143100), a progressive neurodegenerative disorder, is caused by an expanded",
            "probability": 0.0005164405407970938,
            "start_logit": 5.526028633117676,
            "end_logit": -0.4590193033218384
        },
        {
            "text": "TT gene",
            "probability": 0.00035011300778398893,
            "start_logit": 0.21907472610473633,
            "end_logit": 4.459230422973633
        }
    ],
    "58a3428d60087bc10a00001b_001": [
        {
            "text": "huntingtin",
            "probability": 0.608751084962543,
            "start_logit": 7.613362789154053,
            "end_logit": 8.397439956665039
        },
        {
            "text": "huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease",
            "probability": 0.1652743741412074,
            "start_logit": 7.613362789154053,
            "end_logit": 7.093637466430664
        },
        {
            "text": "Huntington's disease",
            "probability": 0.14470927874021267,
            "start_logit": 7.480482578277588,
            "end_logit": 7.093637466430664
        },
        {
            "text": "huntingtin protein (HTT) gene",
            "probability": 0.024724195699886136,
            "start_logit": 7.613362789154053,
            "end_logit": 5.193812847137451
        },
        {
            "text": "huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease (HD)",
            "probability": 0.018297110079875813,
            "start_logit": 7.613362789154053,
            "end_logit": 4.892773628234863
        },
        {
            "text": "Huntington's disease (HD)",
            "probability": 0.016020400116154153,
            "start_logit": 7.480482578277588,
            "end_logit": 4.892773628234863
        },
        {
            "text": "Huntingtin",
            "probability": 0.0063730583372439776,
            "start_logit": 5.82889986038208,
            "end_logit": 5.622572898864746
        },
        {
            "text": "Mutations of the huntingtin",
            "probability": 0.005823613862285824,
            "start_logit": 2.963874340057373,
            "end_logit": 8.397439956665039
        },
        {
            "text": "huntingtin protein",
            "probability": 0.0032192365404919705,
            "start_logit": 7.613362789154053,
            "end_logit": 3.155174732208252
        },
        {
            "text": "Mutations of the huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease",
            "probability": 0.0015810963793002066,
            "start_logit": 2.963874340057373,
            "end_logit": 7.093637466430664
        },
        {
            "text": "the huntingtin",
            "probability": 0.0009428887887162512,
            "start_logit": 1.1431463956832886,
            "end_logit": 8.397439956665039
        },
        {
            "text": "Huntingtin Mutations Alter the Division of Human Embryonic Stem Cells-Derived Neural Cells. Mutations",
            "probability": 0.0008087205153415551,
            "start_logit": 5.82889986038208,
            "end_logit": 3.5581915378570557
        },
        {
            "text": "tin",
            "probability": 0.0005765296665319213,
            "start_logit": 0.6512248516082764,
            "end_logit": 8.397439956665039
        },
        {
            "text": "huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease (HD). HTT",
            "probability": 0.0005680357108090371,
            "start_logit": 7.613362789154053,
            "end_logit": 1.420459508895874
        },
        {
            "text": "Huntington's disease (HD). HTT",
            "probability": 0.0004973550100370041,
            "start_logit": 7.480482578277588,
            "end_logit": 1.420459508895874
        },
        {
            "text": "huntingtin protein (HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease (HD",
            "probability": 0.00039520096931033524,
            "start_logit": 7.613362789154053,
            "end_logit": 1.0576696395874023
        },
        {
            "text": "huntingtin protein (HTT) gene underlie both adult-onset and juvenile",
            "probability": 0.000368893073087492,
            "start_logit": 7.613362789154053,
            "end_logit": 0.9887820482254028
        },
        {
            "text": "juvenile forms of Huntington's disease",
            "probability": 0.0003624103263118019,
            "start_logit": 1.490777611732483,
            "end_logit": 7.093637466430664
        },
        {
            "text": "HTT) gene underlie both adult-onset and juvenile forms of Huntington's disease",
            "probability": 0.0003560949444828473,
            "start_logit": 1.4731979370117188,
            "end_logit": 7.093637466430664
        },
        {
            "text": "huntingtin protein (HTT)",
            "probability": 0.00035042213617093426,
            "start_logit": 7.613362789154053,
            "end_logit": 0.93741375207901
        }
    ],
    "58a3428d60087bc10a00001b_002": [
        {
            "text": "huntingtin",
            "probability": 0.3838836870303007,
            "start_logit": 6.707175254821777,
            "end_logit": 6.726344585418701
        },
        {
            "text": "Huntington's disease",
            "probability": 0.3369469835898267,
            "start_logit": 6.6135945320129395,
            "end_logit": 6.689511299133301
        },
        {
            "text": "Huntington's disease (HD)",
            "probability": 0.14043341107167384,
            "start_logit": 6.6135945320129395,
            "end_logit": 5.814319133758545
        },
        {
            "text": "N-terminal regions of huntingtin",
            "probability": 0.05509819409917019,
            "start_logit": 4.7659525871276855,
            "end_logit": 6.726344585418701
        },
        {
            "text": "HD) is caused by a genetic mutation that results in polyglutamine expansion in the N-terminal regions of huntingtin",
            "probability": 0.023320961774646497,
            "start_logit": 3.9061882495880127,
            "end_logit": 6.726344585418701
        },
        {
            "text": "huntingtin. As a result, this polyQ expansion leads to the misfolding and aggregation of mutant huntingtin",
            "probability": 0.016867150620978665,
            "start_logit": 6.707175254821777,
            "end_logit": 3.6013729572296143
        },
        {
            "text": "HD)",
            "probability": 0.009368257859217924,
            "start_logit": 3.9061882495880127,
            "end_logit": 5.814319133758545
        },
        {
            "text": "Huntington's disease (HD) is caused by a genetic mutation that results in polyglutamine",
            "probability": 0.00848255133664289,
            "start_logit": 6.6135945320129395,
            "end_logit": 3.007596969604492
        },
        {
            "text": "Huntington's disease and therapy. Huntington's disease",
            "probability": 0.008241290119825826,
            "start_logit": 2.9028258323669434,
            "end_logit": 6.689511299133301
        },
        {
            "text": "Huntington's disease and therapy. Huntington's disease (HD)",
            "probability": 0.0034348207270711068,
            "start_logit": 2.9028258323669434,
            "end_logit": 5.814319133758545
        },
        {
            "text": "polyglutamine expansion in the N-terminal regions of huntingtin",
            "probability": 0.0027188734169349324,
            "start_logit": 1.757053256034851,
            "end_logit": 6.726344585418701
        },
        {
            "text": "huntingtin ubiquitously or selectively in different cell types, and knock-in mice that express full-length mutant Htt",
            "probability": 0.0025120855517355278,
            "start_logit": 4.374819278717041,
            "end_logit": 4.029474258422852
        },
        {
            "text": "Huntington's disease (HD) is caused by a genetic mutation that results in polyglutamine expansion in the N-terminal regions",
            "probability": 0.0017778324924916519,
            "start_logit": 6.6135945320129395,
            "end_logit": 1.4449806213378906
        },
        {
            "text": "the N-terminal regions of huntingtin",
            "probability": 0.001523993875381281,
            "start_logit": 1.178170084953308,
            "end_logit": 6.726344585418701
        },
        {
            "text": "huntingtin. As a result, this polyQ",
            "probability": 0.0013834542671956299,
            "start_logit": 6.707175254821777,
            "end_logit": 1.1005884408950806
        },
        {
            "text": "Huntington's disease (HD) is caused by a genetic mutation that results in polyglutamine expansion",
            "probability": 0.0010090848846723466,
            "start_logit": 6.6135945320129395,
            "end_logit": 0.8786295652389526
        },
        {
            "text": "Htt",
            "probability": 0.000820613481327339,
            "start_logit": 3.256002902984619,
            "end_logit": 4.029474258422852
        },
        {
            "text": "huntingtin. As a result, this polyQ expansion",
            "probability": 0.0007694566956717141,
            "start_logit": 6.707175254821777,
            "end_logit": 0.5139343738555908
        },
        {
            "text": "huntingtin.",
            "probability": 0.0007278480600218984,
            "start_logit": 6.707175254821777,
            "end_logit": 0.4583420157432556
        },
        {
            "text": "Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy. Huntington's disease",
            "probability": 0.0006794490452136668,
            "start_logit": 0.40719589591026306,
            "end_logit": 6.689511299133301
        }
    ],
    "58a872bd38c171fb5b000002_000": [
        {
            "text": "SMIM1",
            "probability": 0.2877647223982226,
            "start_logit": 2.0525474548339844,
            "end_logit": 1.5791819095611572
        },
        {
            "text": "small integral membrane protein 1 (SMIM1",
            "probability": 0.16870520235708172,
            "start_logit": 1.518557071685791,
            "end_logit": 1.5791819095611572
        },
        {
            "text": "Vel",
            "probability": 0.16690924423158143,
            "start_logit": 2.119994878768921,
            "end_logit": 0.9670414924621582
        },
        {
            "text": "Vel blood group",
            "probability": 0.10584905888157137,
            "start_logit": 2.119994878768921,
            "end_logit": 0.5116053819656372
        },
        {
            "text": "Vel blood group antigen",
            "probability": 0.046162165868006325,
            "start_logit": 2.119994878768921,
            "end_logit": -0.3182481825351715
        },
        {
            "text": "Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous",
            "probability": 0.03197814127970247,
            "start_logit": 2.119994878768921,
            "end_logit": -0.6853561401367188
        },
        {
            "text": "small integral membrane protein 1",
            "probability": 0.02243134424931025,
            "start_logit": 1.518557071685791,
            "end_logit": -0.4385116398334503
        },
        {
            "text": "SMIM",
            "probability": 0.020908880794633947,
            "start_logit": 2.0525474548339844,
            "end_logit": -1.0427873134613037
        },
        {
            "text": "SMIM1 encoded the Vel",
            "probability": 0.020616687296583485,
            "start_logit": 0.0286454726010561,
            "end_logit": 0.9670414924621582
        },
        {
            "text": "small integral membrane",
            "probability": 0.01868906883451126,
            "start_logit": 1.518557071685791,
            "end_logit": -0.6210321187973022
        },
        {
            "text": "(SMIM1",
            "probability": 0.01640225967678438,
            "start_logit": -0.8121766448020935,
            "end_logit": 1.5791819095611572
        },
        {
            "text": "Vel blood group antigen.",
            "probability": 0.014893272400904992,
            "start_logit": 2.119994878768921,
            "end_logit": -1.4494991302490234
        },
        {
            "text": "integral membrane protein 1 (SMIM1",
            "probability": 0.013728698974350348,
            "start_logit": -0.9901072978973389,
            "end_logit": 1.5791819095611572
        },
        {
            "text": "SMIM1 encoded the Vel blood group",
            "probability": 0.013074512185623438,
            "start_logit": 0.0286454726010561,
            "end_logit": 0.5116053819656372
        },
        {
            "text": "small integral membrane protein 1 (SMIM",
            "probability": 0.012258059070344917,
            "start_logit": 1.518557071685791,
            "end_logit": -1.0427873134613037
        },
        {
            "text": "blood group",
            "probability": 0.010321480395379496,
            "start_logit": -0.2077920287847519,
            "end_logit": 0.5116053819656372
        },
        {
            "text": "small integral membrane protein 1 (",
            "probability": 0.009700764884212324,
            "start_logit": 1.518557071685791,
            "end_logit": -1.2767661809921265
        },
        {
            "text": "SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1",
            "probability": 0.007293010997524669,
            "start_logit": -0.25018373131752014,
            "end_logit": 0.2066863775253296
        },
        {
            "text": "Vel cell surface reactivity, confirming that SMIM1 encoded the Vel",
            "probability": 0.00661145860693119,
            "start_logit": -1.108651041984558,
            "end_logit": 0.9670414924621582
        },
        {
            "text": "SMIM1 encoded the Vel blood group antigen",
            "probability": 0.005701966616739551,
            "start_logit": 0.0286454726010561,
            "end_logit": -0.3182481825351715
        }
    ],
    "58a872bd38c171fb5b000002_001": [
        {
            "text": "Vel blood group antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM1",
            "probability": 0.3808292811057279,
            "start_logit": 2.5567386150360107,
            "end_logit": 3.536503553390503
        },
        {
            "text": "SMIM1",
            "probability": 0.33366408056705815,
            "start_logit": 2.4245221614837646,
            "end_logit": 3.536503553390503
        },
        {
            "text": "17 bp deletion in the coding region of the SMIM1",
            "probability": 0.032942231870916446,
            "start_logit": 0.10914289951324463,
            "end_logit": 3.536503553390503
        },
        {
            "text": "Vel blood group antigen",
            "probability": 0.02928663634300791,
            "start_logit": 2.5567386150360107,
            "end_logit": 0.9712836742401123
        },
        {
            "text": "homozygosity for a 17 bp deletion in the coding region of the SMIM1",
            "probability": 0.02418471993886261,
            "start_logit": -0.19989155232906342,
            "end_logit": 3.536503553390503
        },
        {
            "text": "SMIM1 gene",
            "probability": 0.02178287084056299,
            "start_logit": 2.4245221614837646,
            "end_logit": 0.807492733001709
        },
        {
            "text": "antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM1",
            "probability": 0.019937647931779896,
            "start_logit": -0.39300277829170227,
            "end_logit": 3.536503553390503
        },
        {
            "text": "SMIM1 protein carries the Vel blood group antigen",
            "probability": 0.01705211084695812,
            "start_logit": 2.015881299972534,
            "end_logit": 0.9712836742401123
        },
        {
            "text": "Vel blood group antigen,",
            "probability": 0.016558706008699298,
            "start_logit": 2.5567386150360107,
            "end_logit": 0.40106436610221863
        },
        {
            "text": "Vel blood group antigen, and homozygosity for a 17 bp deletion in the coding region of the SMIM",
            "probability": 0.014305240035358161,
            "start_logit": 2.5567386150360107,
            "end_logit": 0.25477826595306396
        },
        {
            "text": "TaqMan-PCR and PCR-SSP, represent reliable methods for the detection of the SMIM1",
            "probability": 0.01366373239328439,
            "start_logit": 0.6963122487068176,
            "end_logit": 2.069323778152466
        },
        {
            "text": "Vel blood group",
            "probability": 0.013662848774078551,
            "start_logit": 2.5567386150360107,
            "end_logit": 0.2088327407836914
        },
        {
            "text": "Vel",
            "probability": 0.012945898715464465,
            "start_logit": 2.5567386150360107,
            "end_logit": 0.15493139624595642
        },
        {
            "text": "SMIM",
            "probability": 0.012533555061286646,
            "start_logit": 2.4245221614837646,
            "end_logit": 0.25477826595306396
        },
        {
            "text": "Vel blood group antigen, and homozygosity for a 17 bp deletion",
            "probability": 0.011687768831279994,
            "start_logit": 2.5567386150360107,
            "end_logit": 0.05269525572657585
        },
        {
            "text": "Vel blood group antigen, and homozygosity",
            "probability": 0.010392729584194823,
            "start_logit": 2.5567386150360107,
            "end_logit": -0.06474115699529648
        },
        {
            "text": "SMIM1 protein carries the Vel blood group antigen,",
            "probability": 0.0096412878227289,
            "start_logit": 2.015881299972534,
            "end_logit": 0.40106436610221863
        },
        {
            "text": "Vel blood group antigen, and homozygosity for a 17",
            "probability": 0.009435740234320164,
            "start_logit": 2.5567386150360107,
            "end_logit": -0.16134300827980042
        },
        {
            "text": "SMIM1 protein carries the Vel blood group",
            "probability": 0.007955178227097308,
            "start_logit": 2.015881299972534,
            "end_logit": 0.2088327407836914
        },
        {
            "text": "SMIM1 protein carries the Vel",
            "probability": 0.007537734867333007,
            "start_logit": 2.015881299972534,
            "end_logit": 0.15493139624595642
        }
    ],
    "5895bc397d9090f35300000b_000": [
        {
            "text": "X-linked Christianson syndrome",
            "probability": 0.7624764260556702,
            "start_logit": 8.679343223571777,
            "end_logit": 7.856089115142822
        },
        {
            "text": "Christianson syndrome",
            "probability": 0.22073803909576775,
            "start_logit": 8.291825294494629,
            "end_logit": 7.004012107849121
        },
        {
            "text": "Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males",
            "probability": 0.0036573402881190046,
            "start_logit": 8.291825294494629,
            "end_logit": 2.9037716388702393
        },
        {
            "text": "X-linked Christianson",
            "probability": 0.0031008540488656265,
            "start_logit": 8.679343223571777,
            "end_logit": 2.3511950969696045
        },
        {
            "text": ". Christianson syndrome",
            "probability": 0.0025485447294361515,
            "start_logit": 3.830371141433716,
            "end_logit": 7.004012107849121
        },
        {
            "text": "Christianson",
            "probability": 0.0016610410855423293,
            "start_logit": 8.291825294494629,
            "end_logit": 2.1144800186157227
        },
        {
            "text": "-linked Christianson syndrome",
            "probability": 0.0014095913100422724,
            "start_logit": 2.3860714435577393,
            "end_logit": 7.856089115142822
        },
        {
            "text": "Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities. Christianson syndrome",
            "probability": 0.0010123790535262341,
            "start_logit": 2.907151699066162,
            "end_logit": 7.004012107849121
        },
        {
            "text": "X-linked Christianson syndrome: heterozygous female Slc9a6",
            "probability": 0.0009478977002136398,
            "start_logit": 8.679343223571777,
            "end_logit": 1.1660088300704956
        },
        {
            "text": "Christianson syndrome (CS)",
            "probability": 0.000870653261616962,
            "start_logit": 8.291825294494629,
            "end_logit": 1.4685239791870117
        },
        {
            "text": "Christianson syndrome (CS",
            "probability": 0.0003761693026751981,
            "start_logit": 8.291825294494629,
            "end_logit": 0.6293194890022278
        },
        {
            "text": "X",
            "probability": 0.00029526772681521103,
            "start_logit": 8.679343223571777,
            "end_logit": -0.00035526190185919404
        },
        {
            "text": "X-linked",
            "probability": 0.00023898180278548255,
            "start_logit": 8.679343223571777,
            "end_logit": -0.2118503451347351
        },
        {
            "text": "linked Christianson syndrome",
            "probability": 0.0001916442071263916,
            "start_logit": 0.3906569182872772,
            "end_logit": 7.856089115142822
        },
        {
            "text": "Christians",
            "probability": 0.0001890458358250516,
            "start_logit": 8.291825294494629,
            "end_logit": -0.05873032286763191
        },
        {
            "text": "syndrome",
            "probability": 0.0001523723628828403,
            "start_logit": 0.16134363412857056,
            "end_logit": 7.856089115142822
        },
        {
            "text": "heterozygous female Slc9a6 knockout mice develop mosaic neuropathological changes and related behavioral abnormalities. Christianson syndrome",
            "probability": 4.43799108996703e-05,
            "start_logit": -0.22011972963809967,
            "end_logit": 7.004012107849121
        },
        {
            "text": ". Christianson syndrome (CS) is an X-linked neurodevelopmental and neurological disorder characterized in males",
            "probability": 4.222604927189868e-05,
            "start_logit": 3.830371141433716,
            "end_logit": 2.9037716388702393
        },
        {
            "text": "on syndrome",
            "probability": 2.4366705301835e-05,
            "start_logit": -0.8196889758110046,
            "end_logit": 7.004012107849121
        },
        {
            "text": "\u03b2-galactosidase",
            "probability": 2.2779467616425192e-05,
            "start_logit": 2.893867254257202,
            "end_logit": 3.223097801208496
        }
    ],
    "5895bc397d9090f35300000b_001": [
        {
            "text": "Christianson syndrome",
            "probability": 0.5134586751228325,
            "start_logit": 8.470525741577148,
            "end_logit": 7.844875335693359
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christianson syndrome",
            "probability": 0.47719761848585285,
            "start_logit": 8.470525741577148,
            "end_logit": 7.771636486053467
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christianson",
            "probability": 0.002401436307308403,
            "start_logit": 8.470525741577148,
            "end_logit": 2.4797728061676025
        },
        {
            "text": "Christianson",
            "probability": 0.0022279938076636427,
            "start_logit": 8.470525741577148,
            "end_logit": 2.4048073291778564
        },
        {
            "text": ". Christianson syndrome",
            "probability": 0.0017075572495293696,
            "start_logit": 2.8376588821411133,
            "end_logit": 7.771636486053467
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christianson syndrome (CS) is caused by mutations in SLC9A6",
            "probability": 0.00075675957931669,
            "start_logit": 8.470525741577148,
            "end_logit": 1.3249961137771606
        },
        {
            "text": "Christianson syndrome (CS) is caused by mutations in SLC9A6",
            "probability": 0.0006537501620782367,
            "start_logit": 8.32420539855957,
            "end_logit": 1.3249961137771606
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christianson syndrome (CS",
            "probability": 0.00023826363361465036,
            "start_logit": 8.470525741577148,
            "end_logit": 0.16932827234268188
        },
        {
            "text": "Christianson syndrome (CS",
            "probability": 0.00020583140716048015,
            "start_logit": 8.32420539855957,
            "end_logit": 0.16932827234268188
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christians",
            "probability": 0.0001559890935257238,
            "start_logit": 8.470525741577148,
            "end_logit": -0.25426340103149414
        },
        {
            "text": "Christianson syndrome (CS) is caused by mutations in SLC9A6 and is characterized by severe intellectual disability",
            "probability": 0.00014760062471639278,
            "start_logit": 8.32420539855957,
            "end_logit": -0.16321900486946106
        },
        {
            "text": "syndrome",
            "probability": 0.0001443807780362095,
            "start_logit": 0.3672938644886017,
            "end_logit": 7.771636486053467
        },
        {
            "text": "Christians",
            "probability": 0.00013475600172376976,
            "start_logit": 8.32420539855957,
            "end_logit": -0.25426340103149414
        },
        {
            "text": "syndrome: spectrum of neuroimaging findings. Christianson syndrome",
            "probability": 0.00012008567668162916,
            "start_logit": 0.18304522335529327,
            "end_logit": 7.771636486053467
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christianson syndrome (CS)",
            "probability": 0.00010215954663648327,
            "start_logit": 8.470525741577148,
            "end_logit": -0.6775137186050415
        },
        {
            "text": "Christianson syndrome (CS)",
            "probability": 8.82536831998146e-05,
            "start_logit": 8.32420539855957,
            "end_logit": -0.6775137186050415
        },
        {
            "text": "on syndrome",
            "probability": 8.363466159125347e-05,
            "start_logit": -0.1787021905183792,
            "end_logit": 7.771636486053467
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings. Christianson syndrome (CS) is caused by mutations",
            "probability": 6.140080458177097e-05,
            "start_logit": 8.470525741577148,
            "end_logit": -1.1866265535354614
        },
        {
            "text": "Christianson syndrome: spectrum of neuroimaging findings.",
            "probability": 6.081039036052179e-05,
            "start_logit": 8.470525741577148,
            "end_logit": -1.196288824081421
        },
        {
            "text": "Christianson syndrome (CS) is caused by mutations",
            "probability": 5.3042983589730996e-05,
            "start_logit": 8.32420539855957,
            "end_logit": -1.1866265535354614
        }
    ],
    "5895bc397d9090f35300000b_002": [
        {
            "text": "X-linked clinical syndrome first described by Christianson in 1999",
            "probability": 0.153504453271904,
            "start_logit": 1.387552261352539,
            "end_logit": 2.542121410369873
        },
        {
            "text": "1999",
            "probability": 0.0968256908412983,
            "start_logit": 0.9267350435256958,
            "end_logit": 2.542121410369873
        },
        {
            "text": "Mutations of SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999",
            "probability": 0.09094331564323799,
            "start_logit": 0.8640590906143188,
            "end_logit": 2.542121410369873
        },
        {
            "text": "SLC9A6 may cause an X-linked clinical syndrome first described by Christianson in 1999",
            "probability": 0.08262548509913709,
            "start_logit": 0.7681408524513245,
            "end_logit": 2.542121410369873
        },
        {
            "text": "Christianson in 1999",
            "probability": 0.07231345673594124,
            "start_logit": 0.6348329186439514,
            "end_logit": 2.542121410369873
        },
        {
            "text": "felbamate",
            "probability": 0.06067124048678269,
            "start_logit": 0.8827915787696838,
            "end_logit": 2.118622303009033
        },
        {
            "text": "Felbamate in a Patient With SLC9A6",
            "probability": 0.04569596794395658,
            "start_logit": 0.9821895360946655,
            "end_logit": 1.7357646226882935
        },
        {
            "text": "Felbamate in a Patient With SLC9A6 Mutation. BACKGROUND: Mutations",
            "probability": 0.042552476253104654,
            "start_logit": 0.9821895360946655,
            "end_logit": 1.6644926071166992
        },
        {
            "text": "Felbamate",
            "probability": 0.04044517134259821,
            "start_logit": 0.9821895360946655,
            "end_logit": 1.6137018203735352
        },
        {
            "text": "Mutations",
            "probability": 0.03781128504215866,
            "start_logit": 0.8640590906143188,
            "end_logit": 1.6644926071166992
        },
        {
            "text": "SLC9A6",
            "probability": 0.03318122104565277,
            "start_logit": 0.6621635556221008,
            "end_logit": 1.7357646226882935
        },
        {
            "text": "Mutations of SLC9A6",
            "probability": 0.03138523645041105,
            "start_logit": 0.8640590906143188,
            "end_logit": 1.4782226085662842
        },
        {
            "text": "SLC9A6 Mutation. BACKGROUND: Mutations",
            "probability": 0.03089863688467703,
            "start_logit": 0.6621635556221008,
            "end_logit": 1.6644926071166992
        },
        {
            "text": "sleep. RESULTS: Our patient's electrographic status epilepticus of sleep resolved after treatment with felbamate",
            "probability": 0.030247766079359,
            "start_logit": 0.18674412369728088,
            "end_logit": 2.118622303009033
        },
        {
            "text": "X-linked clinical syndrome first described by Christianson in 1999 in which affected males",
            "probability": 0.02977032154361043,
            "start_logit": 1.387552261352539,
            "end_logit": 0.9019038081169128
        },
        {
            "text": "sleep",
            "probability": 0.027089103641251715,
            "start_logit": 0.18674412369728088,
            "end_logit": 2.008331537246704
        },
        {
            "text": "SLC9A6 mutation and an electroencephalographic pattern consistent with electrographic status epilepticus",
            "probability": 0.026629791743284788,
            "start_logit": 0.022402973845601082,
            "end_logit": 2.155571699142456
        },
        {
            "text": "SLC9A6 Mutation. BACKGROUND: Mutations of SLC9A6",
            "probability": 0.02564739663144802,
            "start_logit": 0.6621635556221008,
            "end_logit": 1.4782226085662842
        },
        {
            "text": "SLC9A6 mutation and an electroencephalographic pattern consistent with electrographic status epilepticus of sleep",
            "probability": 0.02298381833156609,
            "start_logit": 0.022402973845601082,
            "end_logit": 2.008331537246704
        },
        {
            "text": "1999 in which affected males",
            "probability": 0.018778164988619627,
            "start_logit": 0.9267350435256958,
            "end_logit": 0.9019038081169128
        }
    ],
    "5895bc397d9090f35300000b_003": [
        {
            "text": "Christianson syndrome",
            "probability": 0.9355992104598396,
            "start_logit": 8.721930503845215,
            "end_logit": 8.996133804321289
        },
        {
            "text": "Christianson Syndrome",
            "probability": 0.060754478584123285,
            "start_logit": 8.559926986694336,
            "end_logit": 6.42379093170166
        },
        {
            "text": "syndrome",
            "probability": 0.0009887820954674336,
            "start_logit": 1.869462013244629,
            "end_logit": 8.996133804321289
        },
        {
            "text": "Christianson syndrome-",
            "probability": 0.0008767982510374047,
            "start_logit": 8.721930503845215,
            "end_logit": 2.023468255996704
        },
        {
            "text": "Christianson",
            "probability": 0.0004536256744927414,
            "start_logit": 8.721930503845215,
            "end_logit": 1.3644636869430542
        },
        {
            "text": "Christianson syndrome-linked deletion mutation (\u2206(287)ES(288)) in SLC9A6",
            "probability": 0.00043347290631320744,
            "start_logit": 8.721930503845215,
            "end_logit": 1.3190206289291382
        },
        {
            "text": "Christianson syndrome-linked",
            "probability": 0.00035003696335272953,
            "start_logit": 8.721930503845215,
            "end_logit": 1.1052300930023193
        },
        {
            "text": "on syndrome",
            "probability": 0.00013262684341258408,
            "start_logit": -0.13947246968746185,
            "end_logit": 8.996133804321289
        },
        {
            "text": "Christianson syndrome-linked deletion",
            "probability": 0.0001247024830311708,
            "start_logit": 8.721930503845215,
            "end_logit": 0.07312209904193878
        },
        {
            "text": "NHE6",
            "probability": 0.00010400344839767863,
            "start_logit": 4.595428466796875,
            "end_logit": 4.018117427825928
        },
        {
            "text": "Christianson Syndrome, a recently identified X-linked neurodevelopmental disorder, is caused by mutations",
            "probability": 7.11092510473614e-05,
            "start_logit": 8.559926986694336,
            "end_logit": -0.3265877068042755
        },
        {
            "text": "Christians",
            "probability": 6.56283403420233e-05,
            "start_logit": 8.721930503845215,
            "end_logit": -0.5688010454177856
        },
        {
            "text": "SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger NHE6",
            "probability": 1.884634449289175e-05,
            "start_logit": 2.8873233795166016,
            "end_logit": 4.018117427825928
        },
        {
            "text": "NHE",
            "probability": 7.695032592918224e-06,
            "start_logit": 4.595428466796875,
            "end_logit": 1.4142683744430542
        },
        {
            "text": "SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger",
            "probability": 7.171790422767629e-06,
            "start_logit": 2.8873233795166016,
            "end_logit": 3.0519537925720215
        },
        {
            "text": "SLC9A6",
            "probability": 3.9531247010531725e-06,
            "start_logit": 2.8873233795166016,
            "end_logit": 2.4563047885894775
        },
        {
            "text": "on Syndrome",
            "probability": 2.66662555576886e-06,
            "start_logit": -1.4738552570343018,
            "end_logit": 6.42379093170166
        },
        {
            "text": "NHE6.",
            "probability": 2.3889675785204452e-06,
            "start_logit": 4.595428466796875,
            "end_logit": 0.24455466866493225
        },
        {
            "text": "alkali cation/proton exchanger NHE6",
            "probability": 1.40840585004268e-06,
            "start_logit": 0.293462872505188,
            "end_logit": 4.018117427825928
        },
        {
            "text": "SLC9A6 encoding the recycling endosomal alkali cation/proton exchanger NHE",
            "probability": 1.3944079486253252e-06,
            "start_logit": 2.8873233795166016,
            "end_logit": 1.4142683744430542
        }
    ],
    "5895bc397d9090f35300000b_004": [
        {
            "text": "Christianson syndrome",
            "probability": 0.6309206477162707,
            "start_logit": 9.833634376525879,
            "end_logit": 9.483137130737305
        },
        {
            "text": "Christianson syndrome. OBJECTIVE: Recently, Christianson syndrome",
            "probability": 0.3579902909414669,
            "start_logit": 9.266960144042969,
            "end_logit": 9.483137130737305
        },
        {
            "text": "Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H(+) exchanger",
            "probability": 0.007121822628285951,
            "start_logit": 9.833634376525879,
            "end_logit": 4.999120712280273
        },
        {
            "text": "Christianson",
            "probability": 0.0017783908376393111,
            "start_logit": 9.833634376525879,
            "end_logit": 3.611665964126587
        },
        {
            "text": "Christianson syndrome. OBJECTIVE: Recently, Christianson",
            "probability": 0.0010090756352301856,
            "start_logit": 9.266960144042969,
            "end_logit": 3.611665964126587
        },
        {
            "text": "syndrome",
            "probability": 0.00020851942231096156,
            "start_logit": 1.7894638776779175,
            "end_logit": 9.512404441833496
        },
        {
            "text": "syndrome. OBJECTIVE: Recently, Christianson syndrome",
            "probability": 0.00020250506090845066,
            "start_logit": 1.7894638776779175,
            "end_logit": 9.483137130737305
        },
        {
            "text": "Christianson syndrome.",
            "probability": 0.00013089658953768088,
            "start_logit": 9.266960144042969,
            "end_logit": 1.5692836046218872
        },
        {
            "text": "Christianson syndrome (CS) has been determined to be caused by mutations",
            "probability": 8.900288358017573e-05,
            "start_logit": 9.833634376525879,
            "end_logit": 0.6168705224990845
        },
        {
            "text": "Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H(+) exchange",
            "probability": 8.140005952884648e-05,
            "start_logit": 9.833634376525879,
            "end_logit": 0.5275777578353882
        },
        {
            "text": "Christians",
            "probability": 6.648814290135011e-05,
            "start_logit": 9.833634376525879,
            "end_logit": 0.3252253830432892
        },
        {
            "text": "on syndrome",
            "probability": 6.180242376456283e-05,
            "start_logit": 0.5733742713928223,
            "end_logit": 9.512404441833496
        },
        {
            "text": "on syndrome. OBJECTIVE: Recently, Christianson syndrome",
            "probability": 6.001984587348802e-05,
            "start_logit": 0.5733742713928223,
            "end_logit": 9.483137130737305
        },
        {
            "text": "Christianson syndrome. OBJECTIVE: Recently, Christianson syndrome (CS) has been determined to be caused by mutations",
            "probability": 5.050107062247431e-05,
            "start_logit": 9.266960144042969,
            "end_logit": 0.6168705224990845
        },
        {
            "text": "X-linked Na(+) /H(+) exchanger 6",
            "probability": 5.011554138755266e-05,
            "start_logit": 4.831485271453857,
            "end_logit": 5.044682025909424
        },
        {
            "text": "X-linked Na(+) /H(+) exchanger",
            "probability": 4.7883446191443e-05,
            "start_logit": 4.831485271453857,
            "end_logit": 4.999120712280273
        },
        {
            "text": "Christianson syndrome. OBJECTIVE: Recently, Christians",
            "probability": 3.772599566612397e-05,
            "start_logit": 9.266960144042969,
            "end_logit": 0.3252253830432892
        },
        {
            "text": "Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked",
            "probability": 3.390087944756399e-05,
            "start_logit": 9.833634376525879,
            "end_logit": -0.34835729002952576
        },
        {
            "text": "NHE6 mutations in Christianson syndrome",
            "probability": 2.9811301037007435e-05,
            "start_logit": -0.15568076074123383,
            "end_logit": 9.512404441833496
        },
        {
            "text": "Christianson syndrome (CS) has been determined to be caused by mutations in the X-linked Na(+) /H",
            "probability": 2.9199578349425482e-05,
            "start_logit": 9.833634376525879,
            "end_logit": -0.49764397740364075
        }
    ],
    "5895bc397d9090f35300000b_005": [
        {
            "text": "Christianson syndrome",
            "probability": 0.9890390608050758,
            "start_logit": 9.44386100769043,
            "end_logit": 9.203729629516602
        },
        {
            "text": "endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome",
            "probability": 0.0029911969539948,
            "start_logit": 3.642800807952881,
            "end_logit": 9.203729629516602
        },
        {
            "text": "Christianson",
            "probability": 0.0017012253245176213,
            "start_logit": 9.44386100769043,
            "end_logit": 2.8383445739746094
        },
        {
            "text": "endosomal Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome",
            "probability": 0.0010076459053994778,
            "start_logit": 2.438494920730591,
            "end_logit": 9.319978713989258
        },
        {
            "text": "SLC9A6) causes Christianson syndrome",
            "probability": 0.0009918601474309667,
            "start_logit": 2.4227049350738525,
            "end_logit": 9.319978713989258
        },
        {
            "text": "Christianson syndrome, a syndromic form of X-linked intellectual disability",
            "probability": 0.0008517261626393995,
            "start_logit": 9.44386100769043,
            "end_logit": 2.14650559425354
        },
        {
            "text": "(SLC9A6) causes Christianson syndrome",
            "probability": 0.0007167878826056523,
            "start_logit": 2.097902774810791,
            "end_logit": 9.319978713989258
        },
        {
            "text": "Christianson syndrome with electrical status epilepticus during slow-wave sleep",
            "probability": 0.0006889185706203196,
            "start_logit": 9.302651405334473,
            "end_logit": 2.075573205947876
        },
        {
            "text": "syndrome",
            "probability": 0.0005865401966353133,
            "start_logit": 1.8973640203475952,
            "end_logit": 9.319978713989258
        },
        {
            "text": "Christianson syndrome with electrical status epilepticus during slow-wave sleep (ESES). Mutations",
            "probability": 0.0003678776232892831,
            "start_logit": 9.302651405334473,
            "end_logit": 1.4482004642486572
        },
        {
            "text": "Na+/H+ exchanger NHE6 (SLC9A6) causes Christianson syndrome",
            "probability": 0.00033259225461374593,
            "start_logit": 1.3300400972366333,
            "end_logit": 9.319978713989258
        },
        {
            "text": "NHE6 (SLC9A6) causes Christianson syndrome",
            "probability": 0.00023283330682336681,
            "start_logit": 0.9734455943107605,
            "end_logit": 9.319978713989258
        },
        {
            "text": "on syndrome",
            "probability": 0.00017458322916659457,
            "start_logit": 0.6855244040489197,
            "end_logit": 9.319978713989258
        },
        {
            "text": "Na+/H+ exchanger 6 (NHE6) are associated with Christianson syndrome",
            "probability": 0.0001442245730785435,
            "start_logit": 0.610743522644043,
            "end_logit": 9.203729629516602
        },
        {
            "text": "NHE6) are associated with Christianson syndrome",
            "probability": 0.00013923599634735854,
            "start_logit": 0.5755422115325928,
            "end_logit": 9.203729629516602
        },
        {
            "text": "endosomal Na+/H+ exchanger",
            "probability": 1.0288288997773023e-05,
            "start_logit": 3.642800807952881,
            "end_logit": 3.5313069820404053
        },
        {
            "text": "endosomal Na+/H+ exchanger 6",
            "probability": 7.55502715428429e-06,
            "start_logit": 3.642800807952881,
            "end_logit": 3.2225139141082764
        },
        {
            "text": "SLC9A6) gene, encoding the endosomal Na+/H+ exchanger",
            "probability": 6.171051527189594e-06,
            "start_logit": 3.1316637992858887,
            "end_logit": 3.5313069820404053
        },
        {
            "text": "endosomal Na+/H+ exchanger 6 (NHE6) are associated with Christianson",
            "probability": 5.1450950831140404e-06,
            "start_logit": 3.642800807952881,
            "end_logit": 2.8383445739746094
        },
        {
            "text": "SLC9A6) gene, encoding the endosomal Na+/H+ exchanger 6",
            "probability": 4.531604999480157e-06,
            "start_logit": 3.1316637992858887,
            "end_logit": 3.2225139141082764
        }
    ],
    "58a8045860087bc10a000035_000": [
        {
            "text": "trichotillomania",
            "probability": 0.5407690970739545,
            "start_logit": 2.4481186866760254,
            "end_logit": 2.3830318450927734
        },
        {
            "text": "trichotillomani",
            "probability": 0.13178572825342091,
            "start_logit": 2.4481186866760254,
            "end_logit": 0.9712167978286743
        },
        {
            "text": "pediatric trichotillomania",
            "probability": 0.09456511616535011,
            "start_logit": 0.704414963722229,
            "end_logit": 2.3830318450927734
        },
        {
            "text": "HPD",
            "probability": 0.03852020989180956,
            "start_logit": 1.2604331970214844,
            "end_logit": 0.9289079904556274
        },
        {
            "text": "trichotillomania (hair pulling disorder",
            "probability": 0.03170878993907416,
            "start_logit": 2.4481186866760254,
            "end_logit": -0.45336660742759705
        },
        {
            "text": "HPD. METHODS: Sixteen and 23 children between 9 and 17 years of age meeting DSM-5 diagnostic criteria for HPD",
            "probability": 0.023201964433287797,
            "start_logit": 0.7534871101379395,
            "end_logit": 0.9289079904556274
        },
        {
            "text": "pediatric trichotillomani",
            "probability": 0.023045571147930606,
            "start_logit": 0.704414963722229,
            "end_logit": 0.9712167978286743
        },
        {
            "text": "ediatric trichotillomania",
            "probability": 0.014760233499571477,
            "start_logit": -1.1529370546340942,
            "end_logit": 2.3830318450927734
        },
        {
            "text": "trichotillomania (hair pulling",
            "probability": 0.013530929124196713,
            "start_logit": 2.4481186866760254,
            "end_logit": -1.3049824237823486
        },
        {
            "text": "reversal learning",
            "probability": 0.01264896062869395,
            "start_logit": 0.05227114260196686,
            "end_logit": 1.0234620571136475
        },
        {
            "text": "trichotillo",
            "probability": 0.010905778034057748,
            "start_logit": 2.4481186866760254,
            "end_logit": -1.5206677913665771
        },
        {
            "text": "richotillomania",
            "probability": 0.009586849684807448,
            "start_logit": -1.5844813585281372,
            "end_logit": 2.3830318450927734
        },
        {
            "text": "trichotillomania (hair pulling disorder; HPD",
            "probability": 0.008566948275220893,
            "start_logit": 2.4481186866760254,
            "end_logit": -1.7620489597320557
        },
        {
            "text": "trichotillomania (hair pulling disorder; HPD) have taken place.",
            "probability": 0.007783640448540984,
            "start_logit": 2.4481186866760254,
            "end_logit": -1.8579363822937012
        },
        {
            "text": "HPD. METHODS: Sixteen",
            "probability": 0.007278906678952871,
            "start_logit": 0.7534871101379395,
            "end_logit": -0.23034828901290894
        },
        {
            "text": "trichotillomania (hair pulling disorder; HPD)",
            "probability": 0.0072656899696267934,
            "start_logit": 2.4481186866760254,
            "end_logit": -1.9267972707748413
        },
        {
            "text": "CANTAB) assessing cognitive flexibility/reversal learning",
            "probability": 0.006323920057829508,
            "start_logit": -0.6409646272659302,
            "end_logit": 1.0234620571136475
        },
        {
            "text": "youths",
            "probability": 0.006296971190643875,
            "start_logit": 0.15535931289196014,
            "end_logit": 0.22286759316921234
        },
        {
            "text": "CANTAB",
            "probability": 0.0059097310805507975,
            "start_logit": -0.6409646272659302,
            "end_logit": 0.9557231068611145
        },
        {
            "text": "pediatric trichotillomania (hair pulling disorder",
            "probability": 0.005544964422479115,
            "start_logit": 0.704414963722229,
            "end_logit": -0.45336660742759705
        }
    ],
    "58a8045860087bc10a000035_001": [
        {
            "text": "Hair pulling disorder",
            "probability": 0.409953827725766,
            "start_logit": 2.1861605644226074,
            "end_logit": 2.319253921508789
        },
        {
            "text": "hair pulling disorder. Hair pulling disorder",
            "probability": 0.127111154861723,
            "start_logit": 1.0151779651641846,
            "end_logit": 2.319253921508789
        },
        {
            "text": "Hair pulling disorder (HPD; trichotillomania)",
            "probability": 0.0919445608809869,
            "start_logit": 2.1861605644226074,
            "end_logit": 0.8243951797485352
        },
        {
            "text": "Hair pulling disorder (HPD; trichotillomania",
            "probability": 0.06478540598014093,
            "start_logit": 2.1861605644226074,
            "end_logit": 0.47428974509239197
        },
        {
            "text": "Hair pulling disorder (HPD",
            "probability": 0.03777933113512145,
            "start_logit": 2.1861605644226074,
            "end_logit": -0.06502845883369446
        },
        {
            "text": "Hair pulling",
            "probability": 0.0347413723911556,
            "start_logit": 2.1861605644226074,
            "end_logit": -0.14885935187339783
        },
        {
            "text": "trichotillomania)",
            "probability": 0.02997321053083183,
            "start_logit": 1.0652787685394287,
            "end_logit": 0.8243951797485352
        },
        {
            "text": "hair pulling disorder. Hair pulling disorder (HPD; trichotillomania)",
            "probability": 0.028508525903200625,
            "start_logit": 1.0151779651641846,
            "end_logit": 0.8243951797485352
        },
        {
            "text": "hair pulling disorder",
            "probability": 0.02484743205425268,
            "start_logit": 1.0151779651641846,
            "end_logit": 0.6869463920593262
        },
        {
            "text": "trichotillomania",
            "probability": 0.021119537623130066,
            "start_logit": 1.0652787685394287,
            "end_logit": 0.47428974509239197
        },
        {
            "text": "Hair",
            "probability": 0.02067509324533407,
            "start_logit": 2.1861605644226074,
            "end_logit": -0.6678608655929565
        },
        {
            "text": "hair pulling disorder. Hair pulling disorder (HPD; trichotillomania",
            "probability": 0.02008750062904637,
            "start_logit": 1.0151779651641846,
            "end_logit": 0.47428974509239197
        },
        {
            "text": "Hair pulling disorder (HPD; trichotillomani",
            "probability": 0.019783512672085352,
            "start_logit": 2.1861605644226074,
            "end_logit": -0.7119417190551758
        },
        {
            "text": "hair pulling disorder. Hair pulling disorder (HPD",
            "probability": 0.011713939682253918,
            "start_logit": 1.0151779651641846,
            "end_logit": -0.06502845883369446
        },
        {
            "text": "HPD; trichotillomania)",
            "probability": 0.011558114573656993,
            "start_logit": 0.11236251890659332,
            "end_logit": 0.8243951797485352
        },
        {
            "text": "adults with hair pulling disorder. Hair pulling disorder",
            "probability": 0.011534591177917355,
            "start_logit": -1.3845335245132446,
            "end_logit": 2.319253921508789
        },
        {
            "text": "hair pulling disorder. Hair pulling",
            "probability": 0.010771983739288348,
            "start_logit": 1.0151779651641846,
            "end_logit": -0.14885935187339783
        },
        {
            "text": "pulling disorder",
            "probability": 0.008517627217437842,
            "start_logit": -1.6877461671829224,
            "end_logit": 2.319253921508789
        },
        {
            "text": "HPD; trichotillomania",
            "probability": 0.008144006973817574,
            "start_logit": 0.11236251890659332,
            "end_logit": 0.47428974509239197
        },
        {
            "text": "trichotillomani",
            "probability": 0.00644927100285292,
            "start_logit": 1.0652787685394287,
            "end_logit": -0.7119417190551758
        }
    ],
    "58a8045860087bc10a000035_002": [
        {
            "text": "inhibitory control",
            "probability": 0.3974072053530792,
            "start_logit": 3.650750160217285,
            "end_logit": 3.6108899116516113
        },
        {
            "text": "Trichotillomania (hair pulling disorder",
            "probability": 0.15670160839474098,
            "start_logit": 3.6804370880126953,
            "end_logit": 2.6505849361419678
        },
        {
            "text": "stop-signal task (SST)--assessing inhibitory control",
            "probability": 0.12915085987194488,
            "start_logit": 2.5267698764801025,
            "end_logit": 3.6108899116516113
        },
        {
            "text": "inhibitory control. Youth with HPD",
            "probability": 0.06343306559867297,
            "start_logit": 3.650750160217285,
            "end_logit": 1.7759137153625488
        },
        {
            "text": "Trichotillomania",
            "probability": 0.03784313634524875,
            "start_logit": 3.6804370880126953,
            "end_logit": 1.2296911478042603
        },
        {
            "text": "Trichotillomania (hair pulling disorder, HPD) is characterized by significant psychological distress, childhood",
            "probability": 0.030075500781959762,
            "start_logit": 3.6804370880126953,
            "end_logit": 0.9999524354934692
        },
        {
            "text": "Trichotillomania (hair pulling disorder, HPD) is characterized by significant psychological distress, childhood-onset, and, in adults",
            "probability": 0.021617283010918815,
            "start_logit": 3.6804370880126953,
            "end_logit": 0.6697346568107605
        },
        {
            "text": "stop-signal task (SST)--assessing inhibitory control. Youth with HPD",
            "probability": 0.02061471170132276,
            "start_logit": 2.5267698764801025,
            "end_logit": 1.7759137153625488
        },
        {
            "text": "inhibitory",
            "probability": 0.019181334808743428,
            "start_logit": 3.650750160217285,
            "end_logit": 0.5798661112785339
        },
        {
            "text": "Trichotillomania (hair pulling disorder, HPD)",
            "probability": 0.01736742815310388,
            "start_logit": 3.6804370880126953,
            "end_logit": 0.45083802938461304
        },
        {
            "text": "hair pulling disorder",
            "probability": 0.01666476528190816,
            "start_logit": 1.4393903017044067,
            "end_logit": 2.6505849361419678
        },
        {
            "text": "stop-signal task",
            "probability": 0.013864601416620057,
            "start_logit": 2.5267698764801025,
            "end_logit": 1.3792476654052734
        },
        {
            "text": "SST)--assessing inhibitory control",
            "probability": 0.011296462133704836,
            "start_logit": 0.09027829021215439,
            "end_logit": 3.6108899116516113
        },
        {
            "text": "Trichotillomania (hair pulling",
            "probability": 0.011093450753775424,
            "start_logit": 3.6804370880126953,
            "end_logit": 0.00259643467143178
        },
        {
            "text": "Trichotillomani",
            "probability": 0.0104096606601984,
            "start_logit": 3.6804370880126953,
            "end_logit": -0.06102419272065163
        },
        {
            "text": "stop-signal task (SST",
            "probability": 0.009655721665492072,
            "start_logit": 2.5267698764801025,
            "end_logit": 1.0174593925476074
        },
        {
            "text": "HPD",
            "probability": 0.009506820253815683,
            "start_logit": 1.7527743577957153,
            "end_logit": 1.7759137153625488
        },
        {
            "text": "Trichotillomania (hair pulling disorder, HPD",
            "probability": 0.008965624296112872,
            "start_logit": 3.6804370880126953,
            "end_logit": -0.21036073565483093
        },
        {
            "text": "Hyperactivity. Trichotillomania (hair pulling disorder",
            "probability": 0.007849934771858726,
            "start_logit": 0.6865988969802856,
            "end_logit": 2.6505849361419678
        },
        {
            "text": "-stop-signal task (SST)--assessing inhibitory control",
            "probability": 0.0073008247467782955,
            "start_logit": -0.34622398018836975,
            "end_logit": 3.6108899116516113
        }
    ],
    "58a9c152396a458e50000001_000": [
        {
            "text": "neonatal sepsis (LOS)",
            "probability": 0.33856284184531055,
            "start_logit": 2.7021706104278564,
            "end_logit": 3.1437606811523438
        },
        {
            "text": "late-onset neonatal sepsis (LOS)",
            "probability": 0.17123565826934092,
            "start_logit": 2.0205016136169434,
            "end_logit": 3.1437606811523438
        },
        {
            "text": "preterm infants, and whether deficiencies of these factors were associated with late-onset neonatal sepsis (LOS)",
            "probability": 0.11112976300846582,
            "start_logit": 1.588159441947937,
            "end_logit": 3.1437606811523438
        },
        {
            "text": "neonatal sepsis",
            "probability": 0.10524390770379422,
            "start_logit": 2.7021706104278564,
            "end_logit": 1.9753315448760986
        },
        {
            "text": "LOS)",
            "probability": 0.05747208451537191,
            "start_logit": 0.9287602305412292,
            "end_logit": 3.1437606811523438
        },
        {
            "text": "late-onset neonatal sepsis",
            "probability": 0.053229438045451535,
            "start_logit": 2.0205016136169434,
            "end_logit": 1.9753315448760986
        },
        {
            "text": "preterm infants, and whether deficiencies of these factors were associated with late-onset neonatal sepsis",
            "probability": 0.03454522787397704,
            "start_logit": 1.588159441947937,
            "end_logit": 1.9753315448760986
        },
        {
            "text": "sepsis (LOS)",
            "probability": 0.029207987879727275,
            "start_logit": 0.25190311670303345,
            "end_logit": 3.1437606811523438
        },
        {
            "text": "Lactoferrin",
            "probability": 0.01863674343741345,
            "start_logit": 2.4171149730682373,
            "end_logit": 0.529241681098938
        },
        {
            "text": "preterm infants at risk of late-onset neonatal sepsis",
            "probability": 0.009339140793960978,
            "start_logit": 1.4920599460601807,
            "end_logit": 0.7633758783340454
        },
        {
            "text": "sepsis",
            "probability": 0.00907944523348505,
            "start_logit": 0.25190311670303345,
            "end_logit": 1.9753315448760986
        },
        {
            "text": "neonatal sepsis (LOS",
            "probability": 0.008984831401399248,
            "start_logit": 2.7021706104278564,
            "end_logit": -0.48541128635406494
        },
        {
            "text": "neonatal sepsis (LOS), a bacterial",
            "probability": 0.007830821261564338,
            "start_logit": 2.7021706104278564,
            "end_logit": -0.6228816509246826
        },
        {
            "text": "neonatal sepsis (LOS), a bacterial infection that frequently occurs in preterm infants",
            "probability": 0.007373264998731901,
            "start_logit": 2.7021706104278564,
            "end_logit": -0.6830884218215942
        },
        {
            "text": ")",
            "probability": 0.007059913470775372,
            "start_logit": -1.1681063175201416,
            "end_logit": 3.1437606811523438
        },
        {
            "text": "lactoferrin",
            "probability": 0.0067344587980903824,
            "start_logit": 1.5603255033493042,
            "end_logit": 0.3681335151195526
        },
        {
            "text": "beta-defensins 1 and 2, and alpha-defensin 5",
            "probability": 0.006722931692097982,
            "start_logit": 1.3566697835922241,
            "end_logit": 0.5700761079788208
        },
        {
            "text": "lactoferrin and defensins in preterm breast milk",
            "probability": 0.0067188656349312864,
            "start_logit": 1.5603255033493042,
            "end_logit": 0.3658154010772705
        },
        {
            "text": "neonatal sepsis (LOS), a bacterial infection that frequently occurs in preterm",
            "probability": 0.0055240578802674065,
            "start_logit": 2.7021706104278564,
            "end_logit": -0.9718363285064697
        },
        {
            "text": "alpha-defensin 5",
            "probability": 0.005368616255843543,
            "start_logit": 1.1317156553268433,
            "end_logit": 0.5700761079788208
        }
    ],
    "58a9c152396a458e50000001_001": [
        {
            "text": "six",
            "probability": 0.20156055935159536,
            "start_logit": 5.24174690246582,
            "end_logit": 4.580578327178955
        },
        {
            "text": "six cysteines, which form three",
            "probability": 0.18731807616251822,
            "start_logit": 5.24174690246582,
            "end_logit": 4.507296562194824
        },
        {
            "text": "Alpha defensins contain six",
            "probability": 0.16441412259521326,
            "start_logit": 5.038045406341553,
            "end_logit": 4.580578327178955
        },
        {
            "text": "Alpha defensins contain six cysteines, which form three",
            "probability": 0.15279644607832849,
            "start_logit": 5.038045406341553,
            "end_logit": 4.507296562194824
        },
        {
            "text": "alpha defensins",
            "probability": 0.09464763454056564,
            "start_logit": 5.492252826690674,
            "end_logit": 3.574143409729004
        },
        {
            "text": "three",
            "probability": 0.09314147807853575,
            "start_logit": 4.543058395385742,
            "end_logit": 4.507296562194824
        },
        {
            "text": "Alpha defensins",
            "probability": 0.028999879933606598,
            "start_logit": 5.038045406341553,
            "end_logit": 2.8454816341400146
        },
        {
            "text": "six cysteines",
            "probability": 0.018491138957592693,
            "start_logit": 5.24174690246582,
            "end_logit": 2.1917800903320312
        },
        {
            "text": "Alpha defensins contain six cysteines",
            "probability": 0.015083329780780872,
            "start_logit": 5.038045406341553,
            "end_logit": 2.1917800903320312
        },
        {
            "text": "alpha defensin. Human alpha defensins",
            "probability": 0.009170877578368158,
            "start_logit": 3.1581249237060547,
            "end_logit": 3.574143409729004
        },
        {
            "text": "six cysteines,",
            "probability": 0.005955009132981842,
            "start_logit": 5.24174690246582,
            "end_logit": 1.0587211847305298
        },
        {
            "text": "cysteines, which form three",
            "probability": 0.005798947775280238,
            "start_logit": 1.7666152715682983,
            "end_logit": 4.507296562194824
        },
        {
            "text": "Alpha defensins contain six cysteines,",
            "probability": 0.004857535644847087,
            "start_logit": 5.038045406341553,
            "end_logit": 1.0587211847305298
        },
        {
            "text": "six cysteines, which form three well defined disulfide bridges",
            "probability": 0.003240791080532566,
            "start_logit": 5.24174690246582,
            "end_logit": 0.45030590891838074
        },
        {
            "text": "defensins contain six",
            "probability": 0.0027363373394255616,
            "start_logit": 0.9422773122787476,
            "end_logit": 4.580578327178955
        },
        {
            "text": "Alpha defensins contain six cysteines, which form three well defined disulfide bridges",
            "probability": 0.002643532165887183,
            "start_logit": 5.038045406341553,
            "end_logit": 0.45030590891838074
        },
        {
            "text": "alpha defensin.",
            "probability": 0.0026195659681415517,
            "start_logit": 3.1581249237060547,
            "end_logit": 2.3211190700531006
        },
        {
            "text": "defensins contain six cysteines, which form three",
            "probability": 0.002542984836923171,
            "start_logit": 0.9422773122787476,
            "end_logit": 4.507296562194824
        },
        {
            "text": "alpha defensins are a class of antimicrobial peptides with additional antiviral activity",
            "probability": 0.002370311767103347,
            "start_logit": 5.492252826690674,
            "end_logit": -0.11299598217010498
        },
        {
            "text": "three well defined disulfide bridges",
            "probability": 0.0016114412317722589,
            "start_logit": 4.543058395385742,
            "end_logit": 0.45030590891838074
        }
    ],
    "58a9c152396a458e50000001_002": [
        {
            "text": "Human papillomavirus",
            "probability": 0.5862654189556741,
            "start_logit": 4.365622520446777,
            "end_logit": 5.107722282409668
        },
        {
            "text": "human papillomavirus 16 L2 to block infection. UNLABELLED: Human papillomavirus",
            "probability": 0.17738623378826152,
            "start_logit": 3.1701793670654297,
            "end_logit": 5.107722282409668
        },
        {
            "text": "Human papillomavirus (HPV",
            "probability": 0.05973179699945178,
            "start_logit": 4.365622520446777,
            "end_logit": 2.8238141536712646
        },
        {
            "text": "papillomavirus 16 L2 to block infection. UNLABELLED: Human papillomavirus",
            "probability": 0.02642354932973469,
            "start_logit": 1.2661055326461792,
            "end_logit": 5.107722282409668
        },
        {
            "text": "human papillomavirus 16 L2",
            "probability": 0.018404286304254256,
            "start_logit": 3.1701793670654297,
            "end_logit": 2.8419764041900635
        },
        {
            "text": "human papillomavirus 16 L2 to block infection. UNLABELLED: Human papillomavirus (HPV",
            "probability": 0.018073040238347805,
            "start_logit": 3.1701793670654297,
            "end_logit": 2.8238141536712646
        },
        {
            "text": "papillomavirus",
            "probability": 0.015048767298942306,
            "start_logit": 0.7031459808349609,
            "end_logit": 5.107722282409668
        },
        {
            "text": "human papillomavirus 16",
            "probability": 0.014957250139516433,
            "start_logit": 3.1701793670654297,
            "end_logit": 2.6345889568328857
        },
        {
            "text": "Human papillomavirus (HPV)",
            "probability": 0.01332322524278845,
            "start_logit": 4.365622520446777,
            "end_logit": 1.3234584331512451
        },
        {
            "text": "Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2",
            "probability": 0.011110475607886163,
            "start_logit": 2.6654841899871826,
            "end_logit": 2.8419764041900635
        },
        {
            "text": "Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16",
            "probability": 0.009029535842296437,
            "start_logit": 2.6654841899871826,
            "end_logit": 2.6345889568328857
        },
        {
            "text": "16 L2 to block infection. UNLABELLED: Human papillomavirus",
            "probability": 0.008509315086335328,
            "start_logit": 0.1330113559961319,
            "end_logit": 5.107722282409668
        },
        {
            "text": "L2 to block infection. UNLABELLED: Human papillomavirus",
            "probability": 0.0077005006803601075,
            "start_logit": 0.033135250210762024,
            "end_logit": 5.107722282409668
        },
        {
            "text": "\u03b1-defensin 5",
            "probability": 0.007371787974868863,
            "start_logit": 3.138974905014038,
            "end_logit": 1.9582575559616089
        },
        {
            "text": "Human papillomavirus (HPV) is a significant oncogenic virus, but the innate immune response to HPV",
            "probability": 0.006640412672921011,
            "start_logit": 4.365622520446777,
            "end_logit": 0.6271237730979919
        },
        {
            "text": "virus",
            "probability": 0.0045351800297536785,
            "start_logit": -0.4962853193283081,
            "end_logit": 5.107722282409668
        },
        {
            "text": "L2",
            "probability": 0.004248040688238479,
            "start_logit": 2.4271340370178223,
            "end_logit": 2.118896007537842
        },
        {
            "text": "human papillomavirus 16 L2 to block infection. UNLABELLED: Human papillomavirus (HPV)",
            "probability": 0.004031206124933707,
            "start_logit": 3.1701793670654297,
            "end_logit": 1.3234584331512451
        },
        {
            "text": "minor capsid protein L2",
            "probability": 0.0037793766438708196,
            "start_logit": 2.3102352619171143,
            "end_logit": 2.118896007537842
        },
        {
            "text": "L2 by host cyclophilin B and furin",
            "probability": 0.00343060035156437,
            "start_logit": 2.4271340370178223,
            "end_logit": 1.905173420906067
        }
    ],
    "58a9c152396a458e50000001_003": [
        {
            "text": "\u03b1-defensin 5",
            "probability": 0.2694118743415767,
            "start_logit": 4.984185695648193,
            "end_logit": 4.304443359375
        },
        {
            "text": "defensin 5",
            "probability": 0.2645574911382263,
            "start_logit": 4.349453926086426,
            "end_logit": 4.920992374420166
        },
        {
            "text": "defensin 5. Human \u03b1-defensin 5",
            "probability": 0.14280921382883527,
            "start_logit": 4.349453926086426,
            "end_logit": 4.304443359375
        },
        {
            "text": "human defensin 5",
            "probability": 0.08895029626494368,
            "start_logit": 3.2594730854034424,
            "end_logit": 4.920992374420166
        },
        {
            "text": "human defensin 5. Human \u03b1-defensin 5",
            "probability": 0.04801573308238531,
            "start_logit": 3.2594730854034424,
            "end_logit": 4.304443359375
        },
        {
            "text": "\u03b1-defensin 5 (HD5",
            "probability": 0.046085497967446314,
            "start_logit": 4.984185695648193,
            "end_logit": 2.5387003421783447
        },
        {
            "text": "defensin 5. Human \u03b1-defensin 5 (HD5",
            "probability": 0.024428892563573695,
            "start_logit": 4.349453926086426,
            "end_logit": 2.5387003421783447
        },
        {
            "text": "defensin 5 (HD5",
            "probability": 0.022365396437108942,
            "start_logit": 4.261202335357666,
            "end_logit": 2.5387003421783447
        },
        {
            "text": "\u03b1-defensin 5 (HD5)",
            "probability": 0.014131220686780762,
            "start_logit": 4.984185695648193,
            "end_logit": 1.35658860206604
        },
        {
            "text": "\u03b1-defensin",
            "probability": 0.011951912793689448,
            "start_logit": 4.984185695648193,
            "end_logit": 1.1890933513641357
        },
        {
            "text": "defensin 5.",
            "probability": 0.010700487602625954,
            "start_logit": 4.349453926086426,
            "end_logit": 1.7132230997085571
        },
        {
            "text": "human defensin 5. Human \u03b1-defensin 5 (HD5",
            "probability": 0.008213553967440031,
            "start_logit": 3.2594730854034424,
            "end_logit": 2.5387003421783447
        },
        {
            "text": "defensin 5. Human \u03b1-defensin 5 (HD5)",
            "probability": 0.007490644284528843,
            "start_logit": 4.349453926086426,
            "end_logit": 1.35658860206604
        },
        {
            "text": "\u03b1-defensin 5 (HD5) is a 32",
            "probability": 0.007484400226050802,
            "start_logit": 4.984185695648193,
            "end_logit": 0.72102290391922
        },
        {
            "text": "defensin 5 (HD5)",
            "probability": 0.0068579133727355406,
            "start_logit": 4.261202335357666,
            "end_logit": 1.35658860206604
        },
        {
            "text": "defensin 5. Human \u03b1-defensin",
            "probability": 0.006335441873113391,
            "start_logit": 4.349453926086426,
            "end_logit": 1.1890933513641357
        },
        {
            "text": "defensin",
            "probability": 0.005800290321294556,
            "start_logit": 4.261202335357666,
            "end_logit": 1.1890933513641357
        },
        {
            "text": "Human \u03b1-defensin 5",
            "probability": 0.00551876480121062,
            "start_logit": 1.0960984230041504,
            "end_logit": 4.304443359375
        },
        {
            "text": "\u03b1-defensin 5 (HD5) is a 32-residue cysteine",
            "probability": 0.004923661146398673,
            "start_logit": 4.984185695648193,
            "end_logit": 0.30225440859794617
        },
        {
            "text": "defensin 5. Human \u03b1-defensin 5 (HD5) is a 32",
            "probability": 0.003967313300034914,
            "start_logit": 4.349453926086426,
            "end_logit": 0.72102290391922
        }
    ],
    "58a9c152396a458e50000001_004": [
        {
            "text": "the",
            "probability": 0.9917525013392489,
            "start_logit": 7.458860874176025,
            "end_logit": 7.364586353302002
        },
        {
            "text": "\u03b1-defensin 5",
            "probability": 0.004382430978426081,
            "start_logit": 5.544372081756592,
            "end_logit": 3.8572051525115967
        },
        {
            "text": "\u03b1-defensin 5 (HD5",
            "probability": 0.0007218134039895941,
            "start_logit": 5.544372081756592,
            "end_logit": 2.0536129474639893
        },
        {
            "text": "\u03b1-defensin 5 (HD5)",
            "probability": 0.0005216392743631745,
            "start_logit": 5.544372081756592,
            "end_logit": 1.7288225889205933
        },
        {
            "text": "\u03b1-defensin",
            "probability": 0.00035184813523857943,
            "start_logit": 5.544372081756592,
            "end_logit": 1.3350459337234497
        },
        {
            "text": "defensins. These results support the notion that HD5, naturally present at very high concentrations in the",
            "probability": 0.0003213188888068842,
            "start_logit": -0.5759339332580566,
            "end_logit": 7.364586353302002
        },
        {
            "text": "the mucosa of the small intestine, could indeed control the very early steps of CDI by killing C. difficile",
            "probability": 0.0002982092579529125,
            "start_logit": 7.458860874176025,
            "end_logit": -0.7448470592498779
        },
        {
            "text": "HD5, naturally present at very high concentrations in the",
            "probability": 0.0002633924308530015,
            "start_logit": -0.7747229337692261,
            "end_logit": 7.364586353302002
        },
        {
            "text": "the mucosa of the small intestine",
            "probability": 0.00025183958540471354,
            "start_logit": 7.458860874176025,
            "end_logit": -0.9138501882553101
        },
        {
            "text": "defensin 5",
            "probability": 0.00019463371606453584,
            "start_logit": 2.4301326274871826,
            "end_logit": 3.8572051525115967
        },
        {
            "text": "Clostridium difficile",
            "probability": 0.0001773642534435339,
            "start_logit": 4.338821887969971,
            "end_logit": 1.8556020259857178
        },
        {
            "text": "the mucosa of the small intestine, could indeed control the very early steps of CDI",
            "probability": 0.0001652114141823723,
            "start_logit": 7.458860874176025,
            "end_logit": -1.335416555404663
        },
        {
            "text": "the mucosa of the small intestine,",
            "probability": 0.0001551162702686688,
            "start_logit": 7.458860874176025,
            "end_logit": -1.3984675407409668
        },
        {
            "text": "Human \u03b1-defensin 5",
            "probability": 0.00010234308672930858,
            "start_logit": 1.787343978881836,
            "end_logit": 3.8572051525115967
        },
        {
            "text": "Clostridium difficile infection",
            "probability": 8.854526489314443e-05,
            "start_logit": 4.338821887969971,
            "end_logit": 1.1609103679656982
        },
        {
            "text": "susceptible to both defensins. These results support the notion that HD5, naturally present at very high concentrations in the",
            "probability": 7.858463611253467e-05,
            "start_logit": -1.9841917753219604,
            "end_logit": 7.364586353302002
        },
        {
            "text": "\u03b1-",
            "probability": 6.672944291412219e-05,
            "start_logit": 5.544372081756592,
            "end_logit": -0.3275074362754822
        },
        {
            "text": "\u03b1-defensin 5 (HD5), the most abundant enteric antimicrobial peptide",
            "probability": 3.976296258933405e-05,
            "start_logit": 5.544372081756592,
            "end_logit": -0.8452178239822388
        },
        {
            "text": "Clostridium difficile infection (CDI)",
            "probability": 3.4658285381495005e-05,
            "start_logit": 4.338821887969971,
            "end_logit": 0.22293329238891602
        },
        {
            "text": "defensin 5 (HD5",
            "probability": 3.205737313725873e-05,
            "start_logit": 2.4301326274871826,
            "end_logit": 2.0536129474639893
        }
    ],
    "58a9c152396a458e50000001_005": [
        {
            "text": "the",
            "probability": 0.9979827368494578,
            "start_logit": 7.400549411773682,
            "end_logit": 7.237917423248291
        },
        {
            "text": "\u03b1-defensin 5",
            "probability": 0.0006321293051835408,
            "start_logit": 3.6460440158843994,
            "end_logit": 3.628025531768799
        },
        {
            "text": "HD5 and non-fatty acylated linear analogs enter the",
            "probability": 0.0003270808598546817,
            "start_logit": -0.6227344274520874,
            "end_logit": 7.237917423248291
        },
        {
            "text": "non-fatty acylated linear analogs. Our results show that HD5 and non-fatty acylated linear analogs enter the",
            "probability": 0.00017853040694648455,
            "start_logit": -1.2281829118728638,
            "end_logit": 7.237917423248291
        },
        {
            "text": "the bacterial cytoplasm",
            "probability": 0.00015683935526118829,
            "start_logit": 7.400549411773682,
            "end_logit": -1.520351767539978
        },
        {
            "text": "non-fatty acylated linear analogs enter the",
            "probability": 0.00010435776406473248,
            "start_logit": -1.765116810798645,
            "end_logit": 7.237917423248291
        },
        {
            "text": "-fatty acylated linear analogs. Our results show that HD5 and non-fatty acylated linear analogs enter the",
            "probability": 9.137158756203562e-05,
            "start_logit": -1.8980072736740112,
            "end_logit": 7.237917423248291
        },
        {
            "text": "defensin 5",
            "probability": 8.275922997436998e-05,
            "start_logit": 1.612885594367981,
            "end_logit": 3.628025531768799
        },
        {
            "text": "fatty acylated linear analogs. Our results show that HD5 and non-fatty acylated linear analogs enter the",
            "probability": 7.668115859346985e-05,
            "start_logit": -2.0732858180999756,
            "end_logit": 7.237917423248291
        },
        {
            "text": "-fatty acylated linear analogs enter the",
            "probability": 7.543369220100063e-05,
            "start_logit": -2.0896878242492676,
            "end_logit": 7.237917423248291
        },
        {
            "text": "linear analogs. Our results show that HD5 and non-fatty acylated linear analogs enter the",
            "probability": 6.572436957730594e-05,
            "start_logit": -2.2274720668792725,
            "end_logit": 7.237917423248291
        },
        {
            "text": "defensin HD5",
            "probability": 4.8567096990860226e-05,
            "start_logit": 2.941474676132202,
            "end_logit": 1.7664471864700317
        },
        {
            "text": "\u03b1-defensin 5 (HD5)",
            "probability": 3.9519164822762595e-05,
            "start_logit": 3.6460440158843994,
            "end_logit": 0.8557173013687134
        },
        {
            "text": "defensin",
            "probability": 3.6330499613333404e-05,
            "start_logit": 2.941474676132202,
            "end_logit": 1.4761584997177124
        },
        {
            "text": "N-terminal fatty acylation results in enhanced antimicrobial activity of the linear analogs. Human \u03b1-defensin 5",
            "probability": 2.5438192448528748e-05,
            "start_logit": 0.43320173025131226,
            "end_logit": 3.628025531768799
        },
        {
            "text": "\u03b1-defensin 5 (HD5",
            "probability": 2.0978634679362375e-05,
            "start_logit": 3.6460440158843994,
            "end_logit": 0.2224360853433609
        },
        {
            "text": "\u03b1-defensin",
            "probability": 2.096093833080456e-05,
            "start_logit": 3.6460440158843994,
            "end_logit": 0.22159218788146973
        },
        {
            "text": "Human \u03b1-defensin 5",
            "probability": 1.2210246414320064e-05,
            "start_logit": -0.300774484872818,
            "end_logit": 3.628025531768799
        },
        {
            "text": "\u03b1-defensin 5 (HD5) exhibits broad spectrum antimicrobial activity",
            "probability": 1.1815602247087935e-05,
            "start_logit": 3.6460440158843994,
            "end_logit": -0.3516475558280945
        },
        {
            "text": "human \u03b1-defensin 5",
            "probability": 1.0535045776432019e-05,
            "start_logit": 0.7260227203369141,
            "end_logit": 2.453660249710083
        }
    ],
    "58a9c152396a458e50000001_006": [
        {
            "text": "Crohn's disease",
            "probability": 0.42094899225389876,
            "start_logit": 5.662599563598633,
            "end_logit": 3.634273052215576
        },
        {
            "text": "\u03b1-defensins",
            "probability": 0.23978043685011824,
            "start_logit": 4.723142623901367,
            "end_logit": 4.010941982269287
        },
        {
            "text": "enteric \u03b1-defensins",
            "probability": 0.11524609539643314,
            "start_logit": 3.9904887676239014,
            "end_logit": 4.010941982269287
        },
        {
            "text": "\u03b1-defensins by NOD2 in the Paneth cell lineage. Human enteric \u03b1-defensins",
            "probability": 0.03279266221196041,
            "start_logit": 2.733623743057251,
            "end_logit": 4.010941982269287
        },
        {
            "text": "\u03b1-defensins (HD5 and HD6",
            "probability": 0.02884008629367922,
            "start_logit": 4.723142623901367,
            "end_logit": 1.8929846286773682
        },
        {
            "text": "Human enteric \u03b1-defensins",
            "probability": 0.028521396736206704,
            "start_logit": 2.594073534011841,
            "end_logit": 4.010941982269287
        },
        {
            "text": "enteric \u03b1-defensins by NOD2 in the Paneth cell lineage. Human enteric \u03b1-defensins",
            "probability": 0.021045266138052517,
            "start_logit": 2.2900946140289307,
            "end_logit": 4.010941982269287
        },
        {
            "text": "\u03b1-defensins (HD5",
            "probability": 0.017147422363172078,
            "start_logit": 4.723142623901367,
            "end_logit": 1.3730661869049072
        },
        {
            "text": "enteric \u03b1-defensins (HD5 and HD6",
            "probability": 0.013861461676793507,
            "start_logit": 3.9904887676239014,
            "end_logit": 1.8929846286773682
        },
        {
            "text": "Crohn's disease (CD",
            "probability": 0.010423086341365906,
            "start_logit": 5.662599563598633,
            "end_logit": -0.06421542912721634
        },
        {
            "text": "Crohn's disease (CD), with decreased expression being more pronounced in the presence of NOD2 mutations",
            "probability": 0.01011860158557707,
            "start_logit": 5.662599563598633,
            "end_logit": -0.09386314451694489
        },
        {
            "text": "Crohn's disease (CD), with decreased expression being more pronounced in the presence of NOD2",
            "probability": 0.010087331413841055,
            "start_logit": 5.662599563598633,
            "end_logit": -0.09695829451084137
        },
        {
            "text": "enteric \u03b1-defensins (HD5",
            "probability": 0.00824159593430187,
            "start_logit": 3.9904887676239014,
            "end_logit": 1.3730661869049072
        },
        {
            "text": "\u03b1-defensins (HD5 and HD6), major antimicrobial peptides produced by Paneth cells",
            "probability": 0.007856876802127141,
            "start_logit": 4.723142623901367,
            "end_logit": 0.5926074981689453
        },
        {
            "text": "\u03b1-defensins (HD5 and HD6)",
            "probability": 0.007541661917810058,
            "start_logit": 4.723142623901367,
            "end_logit": 0.5516608953475952
        },
        {
            "text": "human enteric \u03b1-defensins by NOD2 in the Paneth cell lineage. Human enteric \u03b1-defensins",
            "probability": 0.007401802074356376,
            "start_logit": 1.2451424598693848,
            "end_logit": 4.010941982269287
        },
        {
            "text": "Crohn's",
            "probability": 0.006658533876322813,
            "start_logit": 5.662599563598633,
            "end_logit": -0.5123392939567566
        },
        {
            "text": "\u03b1-defensins (HD5 and HD6), major antimicrobial",
            "probability": 0.004814342373244756,
            "start_logit": 4.723142623901367,
            "end_logit": 0.10281778126955032
        },
        {
            "text": "MAPK",
            "probability": 0.004399260493892231,
            "start_logit": 2.5011136531829834,
            "end_logit": 2.2346837520599365
        },
        {
            "text": "\u03b1-defensins (HD5 and HD6), major antimicrobial peptide",
            "probability": 0.004273087266846271,
            "start_logit": 4.723142623901367,
            "end_logit": -0.0164450965821743
        }
    ],
    "5891c90949702f2e01000001_000": [
        {
            "text": "Win32",
            "probability": 0.28081713410673764,
            "start_logit": 1.7872352600097656,
            "end_logit": 2.020876884460449
        },
        {
            "text": "synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.1270718231165904,
            "start_logit": 2.192368507385254,
            "end_logit": 0.8227924108505249
        },
        {
            "text": "synonymous codon usage analysis and clustering by means of self-organizing map. UNLABELLED: INteractive Codon usage Analysis",
            "probability": 0.08562859936020302,
            "start_logit": 2.192368507385254,
            "end_logit": 0.42805927991867065
        },
        {
            "text": "AVAILABILITY: INCA is available for the Win32",
            "probability": 0.05838875970011858,
            "start_logit": 0.216654971241951,
            "end_logit": 2.020876884460449
        },
        {
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map",
            "probability": 0.046838280106739766,
            "start_logit": 1.1943168640136719,
            "end_logit": 0.8227924108505249
        },
        {
            "text": "synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.04253171292389697,
            "start_logit": 2.192368507385254,
            "end_logit": -0.271710067987442
        },
        {
            "text": "INteractive Codon usage Analysis (INCA",
            "probability": 0.04219991982771658,
            "start_logit": 1.2376708984375,
            "end_logit": 0.6751558780670166
        },
        {
            "text": "INCA",
            "probability": 0.03570135165698088,
            "start_logit": 1.0704411268234253,
            "end_logit": 0.6751558780670166
        },
        {
            "text": "INCA is available for the Win32",
            "probability": 0.034931189223849676,
            "start_logit": -0.2970883250236511,
            "end_logit": 2.020876884460449
        },
        {
            "text": "synonymous codon usage analysis and clustering by means of self-organizing map. UNLABELLED: INteractive Codon usage",
            "probability": 0.03373580265441337,
            "start_logit": 2.192368507385254,
            "end_logit": -0.5034003853797913
        },
        {
            "text": "INteractive Codon usage Analysis",
            "probability": 0.03296089052641101,
            "start_logit": 1.2376708984375,
            "end_logit": 0.42805927991867065
        },
        {
            "text": "synonymous codon usage",
            "probability": 0.028481006156553426,
            "start_logit": 1.8986040353775024,
            "end_logit": -0.37895816564559937
        },
        {
            "text": "32",
            "probability": 0.027005819200631376,
            "start_logit": -0.5544160604476929,
            "end_logit": 2.020876884460449
        },
        {
            "text": "synonymous",
            "probability": 0.023356590126824783,
            "start_logit": 2.192368507385254,
            "end_logit": -0.8710808753967285
        },
        {
            "text": "Win",
            "probability": 0.021619364476105702,
            "start_logit": 1.7872352600097656,
            "end_logit": -0.5432373881340027
        },
        {
            "text": "synonymous codon usage in whole genomes. In addition to computing codon frequencies and several usage indices, such as 'codon bias",
            "probability": 0.020578973513561565,
            "start_logit": 1.8986040353775024,
            "end_logit": -0.7039257287979126
        },
        {
            "text": "INCA: synonymous codon usage analysis and clustering by means of self-organizing map.",
            "probability": 0.01567705754501638,
            "start_logit": 1.1943168640136719,
            "end_logit": -0.271710067987442
        },
        {
            "text": "INteractive Codon usage Analysis (INCA) provides an array of features useful in analysis of synonymous codon usage",
            "probability": 0.014706716254589088,
            "start_logit": 1.2376708984375,
            "end_logit": -0.37895816564559937
        },
        {
            "text": "inca",
            "probability": 0.014314987124561215,
            "start_logit": 0.9350051879882812,
            "end_logit": -0.10328969359397888
        },
        {
            "text": "codons. AVAILABILITY: INCA is available for the Win32",
            "probability": 0.013454022398498487,
            "start_logit": -1.2511903047561646,
            "end_logit": 2.020876884460449
        }
    ],
    "58a2ced760087bc10a000004_000": [
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD",
            "probability": 0.4532425878721049,
            "start_logit": 6.510031223297119,
            "end_logit": 5.442033290863037
        },
        {
            "text": "attention-deficit/hyperactivity disorder",
            "probability": 0.45316392596056804,
            "start_logit": 6.510031223297119,
            "end_logit": 5.441859722137451
        },
        {
            "text": "ADHD",
            "probability": 0.0437073361307331,
            "start_logit": 4.171119689941406,
            "end_logit": 5.442033290863037
        },
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD); linkage to chromosome 5p13",
            "probability": 0.01881671602042555,
            "start_logit": 6.510031223297119,
            "end_logit": 2.2603514194488525
        },
        {
            "text": "attention-deficit/hyperactivity",
            "probability": 0.0173413561145987,
            "start_logit": 6.510031223297119,
            "end_logit": 2.1786999702453613
        },
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD); linkage",
            "probability": 0.003470864833789049,
            "start_logit": 6.510031223297119,
            "end_logit": 0.5700095891952515
        },
        {
            "text": "ADHD); linkage to chromosome 5p13",
            "probability": 0.0018145438094033677,
            "start_logit": 4.171119689941406,
            "end_logit": 2.2603514194488525
        },
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD)",
            "probability": 0.001565903693622361,
            "start_logit": 6.510031223297119,
            "end_logit": -0.2259311079978943
        },
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD); linkage to chromosome 5p",
            "probability": 0.001062929899438282,
            "start_logit": 6.510031223297119,
            "end_logit": -0.6133650541305542
        },
        {
            "text": "attention-deficit/",
            "probability": 0.0008979671132696615,
            "start_logit": 6.510031223297119,
            "end_logit": -0.7820160388946533
        },
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD);",
            "probability": 0.0006633302275865262,
            "start_logit": 6.510031223297119,
            "end_logit": -1.084876537322998
        },
        {
            "text": "dopamine transporter 1; DAT1",
            "probability": 0.0006501972041632063,
            "start_logit": 1.946745753288269,
            "end_logit": 3.458411693572998
        },
        {
            "text": "attention-deficit/hyperactivity disorder (",
            "probability": 0.0006329894383643854,
            "start_logit": 6.510031223297119,
            "end_logit": -1.1316957473754883
        },
        {
            "text": "attention-deficit/hyperactivity disorder (ADHD); linkage to chromosome 5p13 was detected in all of the respective studies.",
            "probability": 0.00062239244888305,
            "start_logit": 6.510031223297119,
            "end_logit": -1.1485786437988281
        },
        {
            "text": "DAT1",
            "probability": 0.0005479057742961993,
            "start_logit": 1.7755733728408813,
            "end_logit": 3.458411693572998
        },
        {
            "text": "hyperactivity disorder (ADHD",
            "probability": 0.0004535765772825406,
            "start_logit": -0.3969874382019043,
            "end_logit": 5.442033290863037
        },
        {
            "text": "hyperactivity disorder",
            "probability": 0.00045349785740591794,
            "start_logit": -0.3969874382019043,
            "end_logit": 5.441859722137451
        },
        {
            "text": "ADHD); linkage",
            "probability": 0.0003347043283531116,
            "start_logit": 4.171119689941406,
            "end_logit": 0.5700095891952515
        },
        {
            "text": "solute carrier 6A3 (SLC6A3; dopamine transporter 1; DAT1",
            "probability": 0.0002874650250264099,
            "start_logit": 1.1305712461471558,
            "end_logit": 3.458411693572998
        },
        {
            "text": "chromosome 5p13",
            "probability": 0.00026980967068548337,
            "start_logit": 2.265247106552124,
            "end_logit": 2.2603514194488525
        }
    ],
    "58a2ced760087bc10a000004_001": [
        {
            "text": "15",
            "probability": 0.4074313903317105,
            "start_logit": 3.023470640182495,
            "end_logit": 3.4717586040496826
        },
        {
            "text": "VNTR",
            "probability": 0.1297824856271977,
            "start_logit": 2.1054999828338623,
            "end_logit": 3.2457165718078613
        },
        {
            "text": "VNTR)",
            "probability": 0.09462481152568553,
            "start_logit": 2.1054999828338623,
            "end_logit": 2.929776430130005
        },
        {
            "text": "variable number of tandem repeat (VNTR",
            "probability": 0.07584325893915131,
            "start_logit": 1.56830894947052,
            "end_logit": 3.2457165718078613
        },
        {
            "text": "variable number of tandem repeat (VNTR)",
            "probability": 0.05529755458087012,
            "start_logit": 1.56830894947052,
            "end_logit": 2.929776430130005
        },
        {
            "text": "DAT1 gene and psychiatric disorders. The present study aimed to determine the distribution of the variable number of tandem repeat (VNTR",
            "probability": 0.02714087147139341,
            "start_logit": 0.5406808853149414,
            "end_logit": 3.2457165718078613
        },
        {
            "text": "variable number of tandem repeat",
            "probability": 0.02420498778971171,
            "start_logit": 1.56830894947052,
            "end_logit": 2.1036064624786377
        },
        {
            "text": "VNTR polymorphism in 12 Indian populations. The dopamine transporter (DAT1",
            "probability": 0.021751525551376227,
            "start_logit": 1.1178104877471924,
            "end_logit": 2.447230100631714
        },
        {
            "text": "DAT1 consists of 15",
            "probability": 0.020244336336110887,
            "start_logit": 0.021473156288266182,
            "end_logit": 3.4717586040496826
        },
        {
            "text": "DAT1 gene and psychiatric disorders. The present study aimed to determine the distribution of the variable number of tandem repeat (VNTR)",
            "probability": 0.0197884933025605,
            "start_logit": 0.5406808853149414,
            "end_logit": 2.929776430130005
        },
        {
            "text": "DAT1",
            "probability": 0.018068167406548288,
            "start_logit": 0.9322782754898071,
            "end_logit": 2.447230100631714
        },
        {
            "text": "number of tandem repeat (VNTR",
            "probability": 0.017269463333662187,
            "start_logit": 0.0885799378156662,
            "end_logit": 3.2457165718078613
        },
        {
            "text": "15 exons spanning 60 kb on chromosome 5p15.32",
            "probability": 0.016202941229509618,
            "start_logit": 3.023470640182495,
            "end_logit": 0.24707883596420288
        },
        {
            "text": "15 exons spanning 60 kb on chromosome 5p15.",
            "probability": 0.015367410666284402,
            "start_logit": 3.023470640182495,
            "end_logit": 0.1941351294517517
        },
        {
            "text": "number of tandem repeat (VNTR)",
            "probability": 0.012591219109422487,
            "start_logit": 0.0885799378156662,
            "end_logit": 2.929776430130005
        },
        {
            "text": "re-uptake of dopamine from the synapse into a neuron. The gene encoding DAT1 consists of 15",
            "probability": 0.009183670954342771,
            "start_logit": -0.7689749002456665,
            "end_logit": 3.4717586040496826
        },
        {
            "text": "VNTR) polymorphism in the 3' untranslated region of DAT1",
            "probability": 0.009174216934239816,
            "start_logit": 2.1054999828338623,
            "end_logit": 0.5962537527084351
        },
        {
            "text": "15 exons spanning 60",
            "probability": 0.009163868898863982,
            "start_logit": 3.023470640182495,
            "end_logit": -0.3228454887866974
        },
        {
            "text": "DAT1 gene and psychiatric disorders. The present study aimed to determine the distribution of the variable number of tandem repeat",
            "probability": 0.008661870174833546,
            "start_logit": 0.5406808853149414,
            "end_logit": 2.1036064624786377
        },
        {
            "text": "psychiatric disorders. The present study aimed to determine the distribution of the variable number of tandem repeat (VNTR",
            "probability": 0.008207455836525213,
            "start_logit": -0.6553168892860413,
            "end_logit": 3.2457165718078613
        }
    ],
    "58a2ced760087bc10a000004_002": [
        {
            "text": "attention deficit hyperactivity disorder (ADHD",
            "probability": 0.5238174098659069,
            "start_logit": 7.4661173820495605,
            "end_logit": 6.287428855895996
        },
        {
            "text": "attention deficit hyperactivity disorder",
            "probability": 0.41742993363882674,
            "start_logit": 7.4661173820495605,
            "end_logit": 6.0604023933410645
        },
        {
            "text": "ADHD",
            "probability": 0.04146855765494716,
            "start_logit": 4.929909706115723,
            "end_logit": 6.287428855895996
        },
        {
            "text": "attention deficit hyperactivity",
            "probability": 0.011085721936261993,
            "start_logit": 7.4661173820495605,
            "end_logit": 2.431943655014038
        },
        {
            "text": "attention deficit hyperactivity disorder (ADHD) striatal dopamine transporter",
            "probability": 0.0024305087210709894,
            "start_logit": 7.4661173820495605,
            "end_logit": 0.9143862724304199
        },
        {
            "text": "attention deficit hyperactivity disorder (ADHD) striatal dopamine transporter (DAT",
            "probability": 0.0005904372436657971,
            "start_logit": 7.4661173820495605,
            "end_logit": -0.5006062388420105
        },
        {
            "text": "attention deficit",
            "probability": 0.0004202410649943931,
            "start_logit": 7.4661173820495605,
            "end_logit": -0.8406410813331604
        },
        {
            "text": "attention deficit hyperactivity disorder (AD",
            "probability": 0.00041701769863750006,
            "start_logit": 7.4661173820495605,
            "end_logit": -0.8483409285545349
        },
        {
            "text": "attention deficit hyperactivity disorder (ADHD) striatal",
            "probability": 0.0003922121666321206,
            "start_logit": 7.4661173820495605,
            "end_logit": -0.9096666574478149
        },
        {
            "text": "deficit hyperactivity disorder (ADHD",
            "probability": 0.0002943614633672815,
            "start_logit": -0.017972586676478386,
            "end_logit": 6.287428855895996
        },
        {
            "text": "attention",
            "probability": 0.00028855807163509294,
            "start_logit": 7.4661173820495605,
            "end_logit": -1.2165732383728027
        },
        {
            "text": "deficit hyperactivity disorder",
            "probability": 0.0002345765600854835,
            "start_logit": -0.017972586676478386,
            "end_logit": 6.0604023933410645
        },
        {
            "text": "ADHD) striatal dopamine transporter",
            "probability": 0.0001924137860488172,
            "start_logit": 4.929909706115723,
            "end_logit": 0.9143862724304199
        },
        {
            "text": "hyperactivity disorder (ADHD",
            "probability": 0.00016994354982941443,
            "start_logit": -0.5673147439956665,
            "end_logit": 6.287428855895996
        },
        {
            "text": "HD",
            "probability": 0.00016221590706085517,
            "start_logit": -0.613852858543396,
            "end_logit": 6.287428855895996
        },
        {
            "text": "10-repeat allele. In 29 adults with attention deficit hyperactivity disorder (ADHD",
            "probability": 0.00014094834122609177,
            "start_logit": -0.754387617111206,
            "end_logit": 6.287428855895996
        },
        {
            "text": "hyperactivity disorder",
            "probability": 0.0001354279628578956,
            "start_logit": -0.5673147439956665,
            "end_logit": 6.0604023933410645
        },
        {
            "text": "10-repeat allele. In 29 adults with attention deficit hyperactivity disorder",
            "probability": 0.00011232168999417518,
            "start_logit": -0.754387617111206,
            "end_logit": 6.0604023933410645
        },
        {
            "text": "29 adults with attention deficit hyperactivity disorder (ADHD",
            "probability": 0.00010866971141247361,
            "start_logit": -1.0144679546356201,
            "end_logit": 6.287428855895996
        },
        {
            "text": "Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD",
            "probability": 0.00010852296553908489,
            "start_logit": 0.6068008542060852,
            "end_logit": 4.664808750152588
        }
    ]
}
